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Lay summary  
 
Commonly known as ‘the flu’, influenza is an infectious disease caused by viruses. 
Three types of influenza viruses infect people; A, B, and C. Influenza A virus (IAV) 
poses the most threat to human populations as it has the potential to cause pandemic 
outbreaks which can spread to millions of people worldwide. Vaccines are developed 
annually to treat influenza virus during ‘flu season’, which typically occurs during the 
winter months. Unfortunately, vaccines are not always successful as the influenza 
virus can change between seasons. Therefore, as a secondary line of defence to treat 
influenza, antiviral drugs are administered. Currently only two classes of antivirals 
have been licensed in the US and Europe for use against influenza virus in humans; 
one class has been rendered ineffective and another is beginning to lose effectiveness. 
Thus, it is necessary to investigate new antivirals for IAV infection.  
 
Like all viruses, IAV uses cells to produce more virus. In this thesis, a set of inhibitors, 
called selective inhibitors of nuclear export (SINE) that target a human cell pathway 
dependent on the CRM1 protein, were assessed as potential influenza antivirals. 
CRM1 facilitates the transport of proteins from the nucleus to the cytoplasm for normal 
cell functions. IAV also uses CRM1 to move its genome from the nucleus to the 
cytoplasm to allow production of new virus particles. SINE compound, KPT-335 was 
effective against many influenza viruses with little toxic effect on cells. To determine 
if IAV would become resistant to KPT-335, resistant viruses were developed in cells 
and the virus was sequenced to determine any changes that occurred. This revealed 
that KPT-335 resistance occurred by a single mutation in one of the virus proteins 
 v 
(NP). However, the resistant viruses did not grow as well in cells and were susceptible 
to an immune factor found in humans (MxA), that recognises and defends the body 
against viruses. Altogether the results of this study demonstrate that KPT-335 could 
















Influenza A virus (IAV) is a global health threat, causing seasonal epidemics and 
potential pandemics leading to morbidity, death and economic losses. Currently, there 
are two main classes of licensed antivirals against IAV available in the US and Europe; 
adamantanes and neuraminidase inhibitors, both of which are hindered by the 
generation of resistant virus variants. The viral polymerase has a high error rate leading 
to mutations that allow the virus to overcome selection pressures directed at its own 
genome from conventional antivirals. The prospect of inhibiting host proteins that the 
virus exploits to facilitate its replication is of increasing interest as an antiviral strategy 
as the emergence of resistance has been predicted to be slower when targeting a host 
cellular factor.  
 
IAV utilizes the host nuclear export protein CRM1 to transport viral 
ribonucleoproteins (vRNPs) from the nucleus to the cytoplasm of an infected cell, a 
critical late stage of the influenza lifecycle. Leptomycin B (LMB), a Streptomyces 
metabolite, has been previously shown to target this pathway, resulting in reduced viral 
propagation; however, LMB’s potent cytotoxicity has limited its use as a therapeutic 
agent. This thesis examined two novel selective inhibitors of nuclear export (SINE), 
KPT-335 and KPT-185, with less cytotoxicity. In vitro, KPT-335 inhibited replication 
of human and animal IAV strains in a dose-dependent manner with minimal 
cytotoxicity. To assess the resistance potential of KPT-335, IAV viruses were serially 
passaged in the presence of a sub-optimal concentration of the compound and assayed 
for the development of resistance. Resistance to KPT-335 became evident at 8-10 
 vii 
rounds of passage. Sequencing analysis of independently derived resistant virus clones 
identified 4 single amino acid changes on a surface exposed patch of the viral 
nucleoprotein (NP). Introduction of these amino acid changes, into otherwise wild type 
viruses by reverse genetics, confirmed that changes Q311R and N309T conferred a 
drug-resistant phenotype. However, these substitutions came at a fitness cost to virus 
replication. The molecular basis for resistance was unclear but Q311R and N309T NP-
mutant viruses produced increased levels of M1 during infection as well as producing 
virus particles with increased M1:NP ratios. Furthermore, the KPT-335-resistance 
mutations were surprisingly similar to NP sequence polymorphisms previously 
associated with susceptibility to the innate defence protein MxA. Consistent with this, 
viruses harbouring the Q311R mutation displayed increased susceptibility to MxA 
inhibition compared to wild-type virus. Altogether this study confirms that SINEs have 
the potential to be successful therapeutic agents against IAV replication and that 
although resistance could be generated, it may be difficult for the virus to overcome 
both drug selection pressures and the human innate immune response restrictions by 
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Chapter 1 Introduction 
 
1.1 Influenza A virus classification and hosts 
 
Influenza viruses, belonging to the Orthomyxoviridae family, have a negative sense 
single-stranded eight segmented RNA genome and are classified into four genera: A-
D (Hause et al., 2013). Influenza A virus (IAV) poses the greatest threat to society as 
it can cause severe, widespread and uncontrolled disease in both humans and livestock. 
The primary host of IAV is waterfowl belonging to the Anseriformes and 
Charadriiformes (Webster et al., 1992), although wild birds and domestic poultry are 
also important reservoirs of infection. Avian IAV replication takes place in the gut 
epithelium of birds where the disease is largely asymptomatic. It can then spread via 
the faecal-oral route to other vertebrate hosts where it manifests as a respiratory illness 
(Webster et al., 1978). The virus undergoes adaption after crossing the species barrier 
to infect a varied collection of hosts, including humans, cats, dogs, horses, cattle, seals, 
whales, mink, camel and penguins (reviewed in Joseph et al., 2016). Human IAV 
typically targets epithelial cells of the respiratory tract and is transmitted via airborne 
droplets and/or fomite contact (reviewed in Killingley et al., 2013).  
 
IAV are further categorised into subtypes based on the glycoproteins presented on the 
virus surface; hemagglutinin (HA) and neuraminidase (NA). There are currently 18 
identified types of HA and 11 identified types of NA. Each IAV strain contains one 
subtype each of HA and NA, all of which have been isolated from aquatic birds apart 
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from two chiropteran-specific subtypes of HA (H17, 18) and NA (N10, 11), found 
only in bat isolates (Tong et al., 2012; 2013). To date, only H1, H2 and H3 subtypes 
are confirmed to infect and transmit between humans. H5, H6, H7, H9 and H10 
subtypes are rarely found in humans and are generally transmitted via direct contact 
from domesticated birds with limited transmission between humans (Schrauwen and 
Fouchier, 2014). However, infections in humans caused by H5N1, H5N6 and H7N9 
viruses have increased in recent years, with mortality rates reaching 30-50 % (WHO, 
2017). This highlights the need for control and preventative measures such as antivirals 
and vaccines to effectively protect the population against emerging viruses.    
 
1.2 Influenza A virion structure 
 
1.2.1 Virion shape   
IAV can be described as a pleomorphic virus as infections do not produce single well-
defined virion sizes. Lab-adapted IAV strains classically produce ‘spherical’ virions 
that have a diameter of ~120 nm (Harris et al., 2006; Yamaguchi et al., 2008) (Fig. 
1.1.A). Spherical strains also often produce elongated virions which are <250 nm long 
(Calder et al., 2010; Harris et al., 2006; Wasilewski et al., 2012; Yamaguchi et al., 
2008) and are termed bacilliforms (Vijayakrishnan et al., 2013). Clinical isolates of 
IAV contain not only spherical and bacilliform virions but also produce very long 
particles known as filaments (Fig. 1.1.D). A filamentous virion is typically >250 nm 
in length although some can reach up to 30 µm (Cox et al., 1980; Roberts et al., 1998). 
A recent study where filaments were selected for during intranasal passage of a highly 
lab-adapted spherical strain in guinea pigs (Seladi-Schulman et al., 2013), highlighted 
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the relevance of filamentous particles in nature. Additionally, filaments have shown to 
be advantageous for transmission between co-housed ferrets and guinea pigs 
(Campbell et al., 2014; Lakdawala et al., 2011).  
 
1.2.2 Virion composition  
The IAV virion is an enveloped particle that derives its lipid bilayer from the plasma 
membrane of the host cell (Palese and Shaw, 2007). The viral envelope is composed 
of three viral proteins; HA, NA and M2 as well as the incorporation of some host cell 
proteins. The two main viral glycoproteins, HA and NA are found at the surface of 
influenza virus particles comprising 80 % and 17 % of the envelope protein 
composition, respectively (Webster et al., 1998). M2 is a minor component of the viral 
envelope with ~20 molecules per virion (Nayak et al., 2009). Additionally, host cell 
proteins have been reported to be incorporated into the virus envelope including two 
members of the tetraspanin family: CD9 and CD81 (Shaw et al., 2008 ;Hutchinson et 
al., 2014). The glycoproteins display a fringe like appearance as shown by electron 
microscopy and/or tomography of spherical and filamentous viruses (Fig. 1.1.C). On 
filamentous structures, the glycoproteins are orderly dispersed, suggesting an arranged 
interaction with the matrix layer beneath (Wasilewski et al., 2012). The M1 protein 
oligomerizes to form the matrix layer, which is bound to an internal surface of the viral 
membrane. The organisation of the M1 helical matrix influences virion morphology 
(Calder et al., 2010). Lattices of multimerized M1 form a rigid cylindrical helix along 
the length of a filamentous virion whereas in spherical virions, M1 forms a less ordered 
structure (Calder et al., 2010). Under the matrix layer lies the viral genome which 





Fig. 1.1 Structure of IAV. (A) Cartoon of a spherical influenza A virion. Cartoon 
drawn by Prof. Paul Digard. (B) Filamentous virions are lost after laboratory passage. 
(i) Two passages of the clinical isolate A/Rockefeller Institute/1/1957 (H2N2), 
presenting a visible filamentous morphology. However, this morphology was lost after 
12 passages as shown in (ii). (Originally published in The Journal of Experimental 
Medicine. 112:945–952. (C) Electron tomograms bacilliform and filamentous influenza 
virions. Electron tomograms of virion ‘slices’ (left panels) and segmented images 
(right panels). Viral glycoproteins are shown in green, membrane and matrix proteins 
are shown in purple and the genome is highlighted in brown (Vijayakrishnan et al., 
2013). (D) Schematic of budding and released filamentous, bacilliforms and spherical 
virions. Images B, C and D taken and adapted from Dadonaite et al., 2016. 
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viral polymerase proteins; PB2, PB1 PA and multiple nucleoprotein (NP) molecules 
(Neumann et al., 2009; Portela and Digard, 2002). The vRNA-polymerase-NP subunit 
is collectively known as a viral ribonucleoprotein (vRNP) complex. Small amounts of 
NS1 and NS2 are incorporated into spherical virions along with the vRNP complexes 
(Hutchinson et al., 2014). The presence of NS1 and NS2 in filamentous viruses has 
not yet been examined.  
 
1.2.3 The vRNP complex 
The structure of the vRNP complex is shown in Figure 1.2. NP binds with high affinity 
to the vRNA phosphate backbone, thereby leaving the RNA bases exposed for base 
pairing or genome replication (Baudin et al., 1994; Compans et al, 1972; Scholtissek 
et al., 1971). The vRNA genomic ends are not bound to NP but fold back and base 
pair to form a partially double stranded structure which is bound together by PB1, PB2 
and PA; the polymerase complex (Fodor, 2013; Hsu et al., 1987). The rest of the vRNA 
is coated by NP monomers (Compans et al., 1972). Electron microscopy has revealed 
that that internal vRNPs are twisted and that the antiparallel double helix of vRNPs 
complexes is maintained by interaction with NP (Wu et al., 2009; Compans et al., 
1972, Jennings et al., 1983). The vRNA forms a loop at the end opposite the 
polymerase bound end.  
 
1.2.4 The IAV genome and gene products  
The IAV genome is 13.5 kB in size and consists of 8 segments of negative sense viral 
RNA (vRNA). The vRNA segments share a similar structure. They contain a long 






Fig. 1.2. The IAV vRNP complex and polymerase trimer structure. (A) Model of a 
vRNP complex. The vRNA is bound by its 5’ and 3 termini by a trimeric RNA 
polymerase and the remaining exposed vRNA is coated by multiple NP monomers. 
The complex is twisted into an antiparallel double helix. (B) Front and (C) side view 
of IAV RNA polymerase structure (Protein DATA Bank; 4WSB). PB1, PB2 and PA are 
coloured in purple, pink and green, respectively. The PB2 cap-binding domain (PB2-
cap), PB2 627-domain (PB2-627), PA endonuclease domain (PA-endo) and PA C-
terminal domain (PA-C) are indicated. The 5′ and 3′ termini of a vRNA are shown in 





 (UTRs). Each segment encodes at least one protein but some can encode more than 
one protein. Individual vRNAs contain one major open reading frame (ORF) which is 
translated into a single protein following faithful transcription of mRNA. IAV employs 
mRNA splicing, ribosomal frame-shifting and alternative translation initiation 
mechanisms to encode further proteins from the same vRNA segment (details of each 
mechanism are described in section 1.3.3.2 mRNA processing, transport and translation). 
The 8 segments encode at least 19 recognised proteins, 14 of which have known 
functions (Table 1.1). IAV gene products are displayed in Fig.1.3 and the roles for the 
characterised polypeptides and their corresponding mechanism of expression are 
detailed in Table 1.1. 
 
1.3 Influenza A virus replication and lifecycle  
 
IAV has evolved many mechanisms to facilitate its ability to invade and hijack host 
cell machinery for successful propagation. Unlike most negative strand RNA viruses, 
which transcribe RNA in the host cytoplasm, influenza virus genome transcription and 
replication takes place in the nucleus (Jackson et al., 1982). The life cycle can be 
divided into the following stages: entry into the host, viral uncoating, import of vRNPs 
into the nucleus, transcription and replication/mRNA processing, protein synthesis and 
processing, export of vRNPs into the cytoplasm and assembly and budding at the 
cellular plasma membrane. Each stage of the viral replication cycle is briefly 
described, with more emphasis on the RNP nuclear export stage to compliment the 
topic of this thesis. 
 
 8 
Fig. 1.3 Influenza A virus gene products. Major structural and/or functional 
domains are indicated along with nucleocytoplasmic trafficking motifs. PB2-S1 
excluded as functional domains are unknown. See table 1.1. for mechanism in 





Table 1.1 IAV proteins*  










Main function(s) No. Name 
1 PB2 PB2 Main ORF 759 Part of heterotrimeric polymerase 
which binds to 5’ cap from host 
RNA during ‘cap snatching’ (Blass 
et al., 1982) 
PB2-S1 Spliced mRNA 508 Inhibits RIG-I signalling 
(Yamayoshi et al., 2015) 
2 PB1 PB1 Main ORF 757 Part of the heterotrimeric 
polymerase which drives 
elongation of mRNA (Braam et al., 
1983) 
PB1-F2 Alternative AUG site 87 Virulence factor (Chen et al., 
2001) 
PB1-N40 Alternative AUG site  718 Unknown (Wise et al., 2009) 
3 PA PA Main ORF 716 Part of the heterotrimeric 
polymerase with endonuclease 
activity involved in ‘cap snatching’ 
(Dias et al., 2009) 
PA-X Ribosomal frameshift 152 Endonuclease activity involved in 
host cell shut-off (Jagger et al., 
2012) 
PA-N155 Alternative AUG site 562 Unknown (Muramoto et al., 2013) 
PA-N182 Alternative AUG site 535 Unknown (Muramoto et al., 2013) 
4 HA HA Main ORF  Mediates receptor binding, virus 
entry and budding  
5 NP NP Main ORF 498 Encapsidation of vRNA to form 
vRNP complexes  
6 NA NA Main ORF 454 Possesses sialidase activity which 
mediates release of progeny virus 
and facilities virus attachment  
7 M M1 Main ORF 252 Major structural protein involved in 
viral budding and assembly  
M2 Spliced mRNA  97 Acts as proton ion channel; during 
virus entry and required for 
membrane scission at the stage of 
budding  
M42 Spliced mRNA and 
alternative AUG site 
99 Variant of M2 (Wise et al., 2012) 
8 NS NS1 Main ORF 230 IFN antagonist (Hale et al., 2008) 
NS2 (NEP) Spliced mRNA 121 Involved in nuclear export of 
vRNPs (O'Neill et al., 1998) 
NS3 Spliced mRNA 187 Unknown (Selman et al., 2012) 




IAV enters the host cell by attaching to sialic acid on the cell surface via the HA 
glycoprotein (Gottschhalk, 1959). Host sialic acids are associated with underlying 
galactose by α2,3 or α2,6 linkages. Human HA subtypes bind to α2,6-linked sialic acid 
while avian HA subtypes bind to α2,3 receptors. One amino acid mutation in HA can 
change receptor binding specificity significantly; accordingly, HA is an important 
factor regarding host tropism (Edinger et al., 2014; Hamilton et al., 2012). Once bound 
to the sialic acids, virions are internalised by dynamin-dependent clathrin-mediated 
endocytosis (Eierhoff et al., 2010). However, micropinocytosis has been suggested as 
the main route for the non-selective uptake of filamentous virions (Rossman et al, 
2010). Before fusion of the host and viral membranes, the HA undergoes post-
translation processing. HA is synthesised as an inactive precursor (HA0). HA0 is then 
cleaved by cellular proteases into two functional subunits: HA1 and HA2. HA1 
initiates endocytosis, while HA2 primes the virus to fuse its membrane with the 
cellular endosomal membrane (Hamilton et al., 2012). Acidification of the late 
endosome triggers the cleaved HA2 to undergo a pH-dependent conformational 
change. This allows insertion of the fusion peptide, which lies at the N-terminus of 
HA2, into the endosome membrane. Subsequently, several HA molecules cluster to 
form a fusogenic unit, which undergoes a further conformational change to bring the 
two opposing membranes together (reviewed in Hamilton et al., 2012). The M2 ion 
channel then acidifies the viral core to allow M1 to dissociate from vRNPs for their 




1.3.2 Nuclear import 
Once released from the late endosomes, vRNPs are transported from the cytoplasm to 
the nucleus. vRNPs are too large to passively diffuse through the nuclear pore complex 
(NPC) and therefore are actively transported using a signal-dependent nuclear import 
pathway; importin-α-importin-ß. The exposed nuclear localisation sequences (NLS) 
on NP molecules associate with importin-α, which in turn associates with importin-ß 
(O'Neill et al., 1995). A non-classical NLS (not arginine or lysine rich) is found within 
the first 13 amino acids of NP (Fig. 1.3) and is essential for vRNP import and virus 
replication (Cros et al., 2005). Once bound to importin-α, RAN-GTP binds to 
importin-ß at the NPC to allow for RAN GTPase to dissociate the importin-α-vRNP 
complex, thereby allowing vRNP release into the nucleus, where viral transcription 
and genome replication take place (Fig. 1.4; (2)). 
 
1.3.3 Transcription, translation and genome replication  
1.3.3.1 Transcription  
After translocation into the nucleus, each of the eight vRNPs of the IAV genome are 
transcribed to produce mRNA; known as transcription. Transcription is primed by a 
process called ‘cap-snatching’, which involves the binding and cleavage of 10-13 
nucleotide RNA fragments containing a 5’ 7-methylguanosine cap (m7GpppXm) from 
host precursor mRNA (pre-mRNA) (Bouloy et al., 1978; Plotch et al., 1979; Plotch et 
al, 1981). The host pre-mRNA 5’ cap binds to the polymerase complex via the PB2 
subunit (Blass et al., 1982) and the cap is cleaved via the interaction with the PA 
endonuclease domain (Hara et al., 2006). The PB1 subunit catalyses RNA elongation 
by reading vRNA as a template from the 3’ to 5’ direction (Braam et al., 1983). The 
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mRNA is then polyadenylated by reiterative copying of a poly U sequence motif near 
the conserved 5’ end of the vRNA template (Poon et al., 1999; Robertson et al., 1981). 
The viral mRNA therefore resembles a host mRNA with a 5’ cap and a 3’ poly(A) tail. 
Viral mRNA then assembles into messenger RNPs (mRNPs) and utilises cellular host 
cell machinery for export (see later) and translation for protein expression (Fig. 1.4; 
(3)). 
 
1.3.3.2 Genome replication  
In contrast to transcription, genome replication involves a non-capped, non-poly(A) 
positive-sense full length copy of vRNA. First, the vRNA is replicated to 
complimentary RNA (cRNA) which acts as an intermediate template. Second, the 
cRNA is copied into vRNA.  Genome replication requires newly synthesised NP and 
polymerase proteins to stop the degradation of cRNA (Vreede et al., 2004). Both 
cRNA and vRNA contain a triphosphate nucleotide at the 5’end suggesting that 
transcript initiation for genome replication is primer independent (McCauley et al., 
1983). Additionally, genome replication can be initiated in trans by polymerase 
complexes that are unbound from the template vRNP complex (Jorba et al., 2014) 
(Fig. 1.4; (4)).  
 
As described, the polymerase has two distinct functions and therefore must regulate 
the frequency in which it generates mRNA versus the replication process. However, 
the mechanism by which the polymerase switches between these two activities is not 
fully understood. Previous studies show that during the early stages of infection there  
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Fig. 1.4. Schematic of the IAV life-cycle. IAV attaches to host cell sialic acid 
receptors via the virus surface glycoprotein HA and subsequently enters via clathrin-
mediated endocytosis (or micropinocytosis). HA is cleaved by cellular proteases to 
allow fusion between the viral envelope and the endosomal membrane (1). 
Acidification of the endosome opens the M2 ion channel to allow uncoating of RNP 
complexes and for pH-dependent HA fusion to allow for the release of vRNPs (2). 
vRNPs are translocated to the nucleus where the viral RNA-dependent RNA 
polymerase transcribes and replicates the –vRNA (3+4). Viral mRNAs are exported 
to the cytoplasm for translation. Viral proteins that are required in transcription and 
replication are translocated back to nucleus. Progeny vRNPs are exported to the 
cytoplasm (5) where the vRNPs are transported via cellular Rab11 vesicles (6) and 
packaged for release from the host cell (7) (Figure is taken from Eisfeld et al, 2014). 
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are higher amounts of mRNA compared to cRNA (Taylor et al., 1977; Robb et 
al.,2009) and at later stages of infection similar amounts of mRNA and cRNA are 
observed alongside vRNA. One switching model suggests that both mRNA and cRNA 
are produced early in infection, but the unprotected cRNA is exposed to host nucleases 
and is degraded, however the polyadenylated and capped mRNA is protected (Vreede 
et al., 2007; Vreede et al., 2004). At later stages, the polymerase and NP have been 
made and protect the cRNA from degradation. It has also been suggested that NS2 
may interact with the polymerase complex which may play a role in the polymerase 
switching from transcription to replication (Robb et al., 2009). 
 
1.3.3.3 mRNA processing, transport and translation  
The viral mRNAs are thought to be recognised similarly to host mRNA; thus, after 
transcription they are (partially) spliced, exported and translated in a similar process 
to the cellular mRNA (Amorim et al., 2011; Read et al., 2010; Bier et al., 2011; Hao 
et al., 2008). Post-transcription modification processes take place such as IAV utilising 
the host cell splicing machinery to splice M and NS viral transcripts to alternative 
mRNAs; M1/M2/M42 and NS1/NS/NS3 respectively. Additionally, PB1-F2 and PB1-
N40 can be expressed by translation of segment 2 (PB1) mRNA, which has several 
start codons downstream of the conventional AUG, thus initiating alternative 
translation events (Chen et al., 2001 Wise et al., 2009). The current mechanism by 
which influenza mRNA nuclear export takes place is not fully understood. However, 
it has been established that the main host protein involved in export of cellular mRNA 
is the nuclear export factor 1 (NXF1) (Read & Digard, 2010; Larsen et al., 2014). Once 
exported to the cytoplasm, viral mRNAs are translated by cellular ribosomes. At this 
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stage, most viruses produce viral proteins by translation downstream of the primary 
ORF, however some viruses can express PA-X following a ribosomal frameshift in 
which segment 3 (PA) mRNA is translated from the +1 reading frame (Jagger et al., 
2012). The protein components of the vRNP complex are then imported back into the 
nucleus where newly synthesised vRNPs assemble.  
 
1.3.4 RNP nuclear export 
In late stages of infection, newly synthesised vRNPs are transported from the nucleus 
to the cytoplasm for packaging of progeny virus particles. IAV utilises the cellular host 
protein chromosomal maintenance 1 (CRM1) (also known as exportin 1 (XPO1)) to 
mediate nucleocytoplasmic transport of vRNPs (Elton et al., 2001; Watanabe et al., 
2001). Cellular CRM1 recognises proteins that contain a leucine-rich nuclear export 
signal (NES) domain (reviewed in Dong et al., 2009). CRM1 interacts with the NES 
motif within cargo proteins and, in association with RAN GTPases, the cargo its 
transported from the nucleus across the NPC. The RAN GTPase-activating protein 
(RANGAP) within the cytoplasmic side of the NPC, hydrolyses RAN-GTP to RAN-
GDP to facilitate the dissociation of the CRM1-protein-RAN-GTP complex and 
release the cargo protein into the cytoplasm. RAN-GDP translocates back to the 
nucleus and the GDP is exchanged for GTP by RAN guanine nucleotide exchange 
factor (RANGEF) for subsequent rounds of nuclear-cytoplasmic transport of proteins 
(reviewed in Hutten et al., 2007). The energy required for CRM1 export is generated 
by high RanGTP concentration gradient in the nucleus, which drives the transport of 
cargo proteins to the cytoplasm (Monecke et al., 2009).  
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In the presence of leptomycin B (LMB), a specific CRM1 inhibitor, vRNPs are 
retained in the nucleus of infected cells (Elton et al., 2001; Ma et al., 2001; Watanabe 
et al., 2001), therefore indicating that the CRM1 pathway is essential for vRNP nuclear 
export. Influenza infection lacking M1 and NS2 proteins results in inefficient export 
of NP (Bui et al., 2000; Martin and Helenius, 1991, Neumann et al., 2000), signifying 
their involvement during the nuclear export process. Mutating the NES domain of the 
M1 protein results in impaired nuclear export of vRNPs; however the M1 NES is not 
sensitive to LMB treatment suggesting M1 does not directly interact with CRM1 
(Sakaguchi et al., 2003). NS2 can directly interact with CRM1 via its two NES 
domains (Huang et al., 2012; Neumann et al., 2000; O'Neill et al., 1998). Although 
there is a strong link to suggest a CRM1-NS2 interaction, at present there is no 
evidence to indicate that NS2 directly interacts with vRNPs. M1, however, has been 
described to directly interact with NS2 via its NLS motif (Yasuda et al., 1993; Akarsu 
et al., 2003; Shimizu et al., 2011). Consequently, it has been suggested that M1 forms 
a bridge between the vRNPs and NS2. Thus, a daisy chain model has been proposed 
as follows; vRNP-M1-NS2-CRM1 for export of the viral genome during late stages of 
infection. However, NP can undergo nuclear export in the absence of other viral 
proteins in both infected and transfected cells (Elton et al., 2001; Watanabe et al., 
2001). Thus, suggesting the possibility of M1 and NS2 independent vRNP export. 
Additionally, NP has three NES motifs, one of which directly interacts with CRM1 
(Elton et al., 2001). NP has also been shown to bind directly to CRM1 in two further 
studies (Chutiwitoonchai et al., 2014; Kakisaka et al., 2015). Nevertheless, the exact 





Fig. 1.5 Model for vRNP nuclear export. During late stages of infection, newly 
synthesized vRNPs are transported from nucleus to the cytoplasm for packaging into 
new virions. vRNPs localise with chromatin at the nuclear membrane and associates 
with CRM1. Phosphorylation may trigger signal transduction necessary to release 
vRNPs from chromatin. vRNPs are thought to be exported via a ‘daisy chain’ complex 
in which viral NS2 (labelled as NEP), containing a NES recognised by CRM1, acts as 
an adaptor between CRM1 and M1-vRNP. At the cytoplasmic side of NPC, RAN-GTP 
is hydrolysed by RANGAP to release vRNPs into the cytoplasm. Cellular Yb-1 protein 
is thought to be transported with vRNPs. M1 remains associated with vRNPs whereas 








1.3.4.1 Other cellular factors involved in vRNP export  
Some nuclear vRNPs are associated with cellular chromatin, also at the nuclear 
periphery of infected cells, implying that vRNPs bound to chromatin could be an 
intermediate nuclear export step (Chase et al., 2011). Chromatin is also associated with 
regulator of chromosome condensation 1 (RCC1), a guanine-nucleotide releasing 
factor that promotes exchange of RAN-bound GDP by GTP; vRNPs have also been 
shown to form complexes with RCC1. As well as vRNPs, M1 is associated with 
chromatin (Chase et al., 2011; Kurokawa et al., 1990). This evidence would support 
the hypothesis that M1 triggers vRNP release from chromatin before undergoing 
nuclear export. A cellular host protein involved in transcription and translation, Y-
box-binding protein (YB-1) (Wolffe, 1998) is imported into the nucleus and 
accumulates with vRNPs, M1 and NS2 after LMB treatment suggesting that YB-1 is 
also associated with vRNP export (Kawaguchi et al, 2012). Cellular kinase activity 
affects nuclear export as treatment with protein kinase C inhibitors (Bui et al., 2000), 
a RAF-MEK-ERK mitogen-activated protein kinase (MAPK) inhibitor (Pleschka et 
al., 2001), a receptor of tyrosine kinase inhibitor (Kumar et al., 2011), and a 
serum/glucocorticoid regulated kinase 1 inhibitor (Alamares-Sapuay et al., 2013) 
impairs RNP nuclear export, suggesting phosphorylation of a viral or cellular factor is 
necessary for the nuclear export process. Additionally, vRNP export is enhanced by 
HA-mediated activation of MAPK signalling pathway when HA reaches the plasma 
membrane (Marjuki et al., 2006; 2007), indicating an indirect role for HA promoting 
vRNP export.  
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1.3.5 Assembly and budding  
Once released into the cytoplasm, vRNPs are transported through the cytoplasm to the 
host cell plasma membrane which forms the virus envelope thus, releasing progeny 
virus particles to infect neighbouring cells. vRNPs associate with the cellular 
microtubule network by access to the Rab11-dependent vesicle-trafficking pathway to 
transport through the cytoplasm (Eisfeld et al., 2011; Amorim et al., 2011; Eisfeld et 
al., 2014; Momose et al., 2011).  The vRNPs are thought to ‘piggyback’ on recycling 
endosomes (RE) to transport through the cytoplasm via an interaction between cellular 
Rab11 and viral PB2 (Amorim et al., 2011). In the cytoplasm, all 8 RNA segments 
must be packaged into a virion particle. There are two methods that have been 
hypothesised to explain packaging of the viral genomic segments into virion particles; 
randomly and specifically. The later model is favoured as packaging signals have been 
identified in non-coding and coding 5’ and 3’ regions of vRNA (Fujii et al., 2005; Fujii 
et al., 2003; Liang et al., 2005; Watanabe et al., 2003). Additionally, an electron 
microscopy study produced further evidence for the selective packaging model by 
establishing that influenza virions contain 8 vRNP segments in a 7+1 formation; 1 
central vRNP and 7 others in a surrounding circle (Noda et al., 2006). 
 
Virus budding is initiated by insertion of HA and NA into the plasma membrane. The 
glycoproteins target cholesterol and sphingolipid enchiridion regions of the plasma 
membrane known as lipid rafts, which are thought to serve as platform for the 
concentration of proteins (Brown et al., 1992; Simons and Toomre, 2000). The M1 
protein possibly crosslinks with the cytoplasmic tails of HA and NA to help mediate 
incorporation into the budding virion (Jin et al., 1997). M1 also binds to the M2 ion 
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channel protein by binding via the M2 cytoplasmic tail (McCown et al., 2006). M2 
performs membrane scission by localising its cytoplasmic tail to the plasma membrane 
and changing the membrane curvature, thus inducing the budding process (Rossman 
et al., 2010). The enzymatic activity of NA, on the surface of the plasma membrane as 
well as the particle, initiates cleavage of the sialic acid receptors to allow release of 
the newly formed virion from the host cell (Palese et al., 1974). 
  
1.3.6. Involvement of the innate immune system during IAV replication 
IAV enters through the oral or nasal passages to the mucosal layer that covers the 
respiratory epithelium; the host’s initial defence barrier to IAV infection. If successful 
at surpassing the mucous layer, the virus invades the respiratory cells via sialic acid 
receptors (as described in section 1.3.1 Entry). After successful replication, the virus 
can spread to both immune and non-immune cells. The vRNA present in infected cells 
is detected by pattern recognition receptors (PRRs). IAV is recognised by at least three 
classes of PRRs; Toll-like receptors (TLR) (TLR3; dsRNA, TLR7 and 8; ssRNA), 
retinoic acid-inducible gene I (RIG-I) (5’triphosphate RNA) and NOD-like receptors 
(nucleotide-binding oligomerization domain-like receptors) (various stimuli) 
(reviewed in Iwasaki and Pillai, 2014). RIG-I and NOD-like receptors recognise the 
virus within the cytoplasm of cells whereas TLR3 and TLR7 detect vRNA in 
endosomes (reviewed in Iwasaki and Pillai, 2014). Each receptor triggers individual 
signalling pathways for upregulation of innate immune factors as shown in Figure 1.6. 
Generally, once the virus is recognised by a PRR, the host cells can secret Type I 
interferons (IFN-I), chemokines, pro-inflammatory cytokines and eicosanoids 




Fig. 1.6. Innate immune recognition during IAV infection. (A) Infected cells are 
phagocytosed by macrophages for recognition of double-stranded RNA (dsRNA) by 
Toll-like receptor 3 (TLR3), which leads to the induction of the expression of NF-κB-
dependent pro-inflammatory cytokines and of IFN-I and ISGs downstream of IFN-
regulatory factor 3 (IRF3) (B) Incoming genomic single-stranded RNA (ssRNA) that 
is contained within the virion is released via the degradation of the viral membrane 
and capsid within acidified endosomes, and ssRNA is recognized by TLR7 in 
plasmacytoid dendritic cells (pDCs). TLR7 signalling induces NF-κB-dependent 
genes from the NF-κB endosome, and IRF7 activation from the IRF7 endosome. (C) 
Within infected cells, vRNA in the cytosol is recognized by RIG-I, which, through the 
activation of mitochondrial antiviral signalling protein(MAVS), leads to the induction of 
pro-inflammatory cytokines and IFN-I. M2 ion channel activity in the Golgi stimulates 
formation of the NOD-, LRR- and pyrin domain-containing 3 (NLRP3) inflammasome, 
which results in caspase 1 activation and the release of the cytokines IL-1β and IL-
18. (Image and figure legend taken and adapted from Iwasaki and Pillai, 2014).  
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produced by non-immune or immune cells such as macrophages and dendritic cells 
(DCS), stimulates the expression of hundreds of genes known as IFN-stimulated genes 
(ISGs) in neighbouring cells, including myxovirus (Mx) proteins, protein kinase R 
(PKR), 2’-5’-oligoadenylate synthetase (OAS) and interferon-induced transmembrane 
protein 1 (IFITM) proteins, which mediate antiviral activity (reviewed in Iwasaki and 
Pillai, 2014). Chemokines can recruit additional immune cells to site of infection such 
as monocytes, natural killer (NK) cells and neutrophils (Hwang et al., 2012). Pro-
inflammatory cytokines and eicosanoids induce local and systemic inflammation and 
are connected to the adaptive immune response (reviewed in Dennis et al., 2015). The 
regulation of adaptive immunity to IAV is out of the scope of this study and therefore 
is not discussed in detail.  
 
 
1.4 The impact of influenza A virus on human health 
 
IAV is a successful, persistent and unpredictable human pathogen. Transmission of 
influenza virus through aerosol causes acute febrile disease in humans, which can 
present as a severe infection in individuals with underlying medical conditions (such 
as cardiopulmonary disease), infants/young children and the elderly. These high-risk 
individuals are more likely to obtain complications such as pneumonia and bronchitis, 
which can result in hospitalisation and even death. IAV is a major burden on the global 
population, increasing mortality and morbidity rates and causing significant economic 
losses. It has been estimated that ~20 % of children and ~5 % of adults present with 
symptomatic influenza A and B virus infection every year (Turner et al., 2003). 
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According to the World Health Organisation (WHO), approximately 1 billion people 
are infected and 250,000 to 500,000 people die annually from an influenza infection 
(WHO, 2016). 
 
1.4.1 Seasonal epidemics 
Influenza epidemics occur annually during the winter months; November-April in the 
Northern hemisphere and May-October in the Southern hemisphere (influenza 
epidemics in tropical regions are not well defined). The current circulating strains that 
infect humans during seasonal epidemics include IAVs H1N1pdm09 and H3N2 and 
influenza B virus (FLUBV) from Victoria and Yamagata lineages. Epidemics can 
present when point mutations occur in the epitope region of the viral surface antigens 
(HA and NA) which is known as antigenic drift. The novel antigenic virus variants can 
evade immune recognition leading to seasonal outbreaks. Antigenic drift occurs due 
to the lack of the viral RNA polymerase ‘proof reading’ function, which for most 
smaller RNA viruses, results in unavoidable virus variance. This error prone activity 
of IAV poses a problem for both seasonal vaccines and antiviral therapy (as discussed 
in section; 1.5 Strategies to combat human influenza infections). Additionally, epidemics 
can occur if the seasonal vaccine efficacy is suboptimal (reviewed in Paules et 
al.,2018). A reduction in vaccine effectiveness can result in limited heard immunity 
within a population. A sufficient heard immunity reduces the spread of disease where 
a high proportion of the population are immune to the disease, particularly through 
vaccination. A person’s prior exposure to influenza, vaccine history, age and co-
existing conditions can affect vaccine effectiveness as well as vaccine mismatches, 
where the circulating influenza strains differ from those in the vaccine formulations.  
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Table 1.2 Influenza A virus pandemics* 
*Information adapted from the WHO pandemic influenza website (WHO, 2016).  
 
1.4.2 Pandemics  
An influenza pandemic occurs when a novel IAV subtype emerges suddenly by 
antigenic shift. The segmented nature of the IAV genome facilitates the reassortment 
during coinfection with both human and non-human viruses. Antigenic shift can occur 
when genes encoding at least the HA glycoprotein are to ‘reassort’ their genetic 
material to form a ‘new’ virus. The new reassortant virus is antigenically different 
from preceding human viruses.  However, the novelty alone is insufficient for the 
emergence of a pandemic influenza virus. The virus must adapt to successfully 
replicate in humans, transmit within from person to person and a susceptible 
population is also required (reviewed in Nicholson et al., 2003).  
 
Five confirmed pandemic outbreaks have occurred in humans since the 20th century 
(each of which are summarised in table 1.2). The most famous influenza pandemic 
outbreak was the 1918 “Spanish flu” in which at least 40 million people died; 
estimated to be around 3-6 % of the world population at the time. Unlike most 
influenza outbreaks, which affect young, elderly and immunosuppressed, the 1918 
Name Year Subtype Source 
Spanish flu 1918 H1N1 Avian (?) 
Asian flu 1957 H2N2 Avian  
Hong Kong flu 1968 H3N2 Avian  
Russian flu 1977 H1N1 Laboratory (?) 
Swine flu 2009 H1N1 Swine 
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pandemic predominately caused morbidity in otherwise healthy young adults. Thus, it 
is the most aggressive IAV outbreak to date (Worobey et al., 2014). All subsequent 
human pandemic strains are caused by viruses derived from this pandemic strain and 
variants continue to be endemic in humans (Taubenberger and Morens, 2006). The 
first pandemic of the 21st century was caused by a swine origin H1N1 virus in 2009 
(H1N1pdm09) in which the virus spread over 215 countries (Nelson et al., 2015) with 
an estimate of ~284,500 deaths in the US (Nguyen et al., 2013). The virus mostly only 
produced mild infections in humans but spread well within the population. The HA, 
NP and NS proteins were derived from an H1N1 strain circulating in pigs in North 
America (Taubenberger and Morens, 2006). The NA and M segments were originally 
derived from an avian virus that adapted in pigs in Europe and Asia (Scoltissek et al., 
1983) and finally the PB2, PB1 and PA proteins came from a linage of swine flu that 
had a reassortment of avian, swine and human origin viruses (Garten et al., 2009). The 
H1N1pdm09 strain has replaced the 1977 Russian H1N1 virus and is still currently 
circulating in humans. 
 
1.5 Strategies to combat human influenza infections  
 
1.5.1 Vaccination 
Vaccination is the primary strategy to combat human influenza infections. The main 
goals of influenza vaccine administration are to provide protection against influenza 
infection and disease symptoms and to prevent transmission within a population (Salk 
and Salk, 1977; Pronker et al., 2012). Vaccines elicit an adaptive immune response by 
administering viral antigens. The main antigen that elicits this immune response is the 
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HA glycoprotein (NA can also elicit an immune response but to a lesser degree). In 
the UK, the seasonal immunisation programme offers protection to individuals who 
are most at risk of serious illness or death should they develop an influenza infection. 
At risk individuals include patients >65 years, pregnant women, health care workers, 
immunosuppressed individuals and patients with underlying health condition such as 
long-term heart or respiratory disease (http://www.nhs.uk/Conditions/vaccinations-
/Pages/who-should-have-flu-vaccine.aspx). 
 
Currently, three types of influenza vaccine are recommended by the WHO for human 
use; inactivated virus, recombinant viral HA and  live-attenuated virus (Belshe et al., 
2007; Cox et al., 2008; Pronker et al., 2012). Any type of seasonal influenza vaccine 
contains antigens from at least three circulating influenza strains: two IAV subtypes: 
H1N1_pdm09, H3N2 and a FLUBV strain from the Victoria-like or Yamagata-like 
lineage (Pronker et al., 2012). The composition of the 2016-2017 trivalent vaccine was 
recommended to contain an A/California/7/2009 (H1N1) pdm09-like virus, an 
A/Hong Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like virus 
(Victoria lineage) (The Green Book, 2008). Additionally, quadrivalent vaccines were 
recommended to contain a fourth FLUBV virus, B/Phuket/3073/2013-like virus 
(Yamagata lineage). The most common type of vaccine is the inactivated influenza 
vaccine (IIV). IIV are administrated intramuscularly and produce neutralising 
antibodies that target HA epitopes, thus eliciting a protective humoral immune 
response (Belongia et al., 2009; Osterholm et al., 2011). IIVs can be classed as whole 
virus vaccines or split vaccines (Belshe et al., 2007). The influenza whole virus 
vaccines were first developed by growing influenza virus in embryonated hen eggs 
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which was purified and chemically inactivated with formaldehyde (reviewed in Wong 
and Webby, 2013). Split vaccines contain a non-ionic detergent treatment step, which 
exposes all viral proteins upon dissociation of the virion (Duxbury et al., 1968). 
Currently, most influenza vaccines in Europe and the US are egg-grown, 
formaldehyde-inactivated and treated with non-ionic detergent. Another type of IIV 
are vaccines that contain subunits of purified HA or HA/NA proteins without any other 
viral components (Cox et al., 2008). These subunits can be generated using 
baculovirus expression systems or recombinant DNA technologies to allow production 
of large quantities of HA and NA (Baxter et al., 2011). Live-attenuated vaccines 
(LAIV) were first developed in the 1960s by serial passaging IAV in eggs at sub-
optimal temperature conditions thus resulting in temperature sensitive, cold-adapted 
and attenuated stains (Mills, 1969). The variants grew at 25 ˚C but not at temperatures 
>35 ˚C, which is similar to the lower respiratory tract and therefore when 
administrated, virus replication was restricted to the upper respiratory tract and 
induced local protective immune responses (Belshe et al., 2007; De Villiers et al., 
2009). LAIV have been available in the US since 2003 and are administered 
intranasally to mimic the natural route of infection which can come with certain risks 
and benefits in comparison to the IIV. In the UK in 2014, the Joint Committee on 
Vaccination and Immunisation (JCVI) recommended administration of a universal 
childhood vaccine programme with a newly licensed LAIV. The childhood LAIV 
programme recommends that all children between the ages of 2-4 years receive a live 
attenuated nasal vaccine (Fluenz Tetra). LAIV can elicit a more rapid and efficient 
innate and adaptive immune response (Belshe et al., 2007), provide cross-reactive T-
cell-mediated protection against multiple influenza viruses (Gorse et al., 1996; Pica 
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and Palese, 2013) and provide a longer lasting immune response (Couch et al., 1997). 
However, due to the inherent risk of immunising with live viruses, LAIV are not 
recommended for immunosuppressed, asthmatic patients (Greenhawt, 2014), and 
children under two years of age (Belshe et al., 2007).  
 
1.5.2 Antivirals  
Annual vaccines have successfully reduced the impact of seasonal influenza 
epidemics; however, they are not without their significant restrictions. The most 
obvious limitation of the annual vaccination is that they only prevent the spread of 
infection and offer no therapeutic benefit. Additionally, the unpredictable antigenic 
changes of the viral surface glycoproteins in circulating IAV strains can render the 
seasonal vaccine ineffective. Furthermore, developing a vaccine to a newly emerging 
strain is a time-consuming process and thus vaccination programs are of limited use in 
preventing the initial spread of infection from a new pandemic strain. Consequently, 
antiviral drugs are critical as a short-term resource to regulate and prevent transmission 
and illness caused by both seasonal and pandemic influenza viruses. The necessity for 
antiviral therapy was clearly demonstrated with the emergence of the recent 
H1N1pdm09 strain in which the antiviral drug, oseltamivir was heavily used while a 
vaccine was under development (Miller et al., 2013). To date, only two classes of 
antiviral have been approved by the FDA in the US and Public Health England (PHE) 
in the UK as a treatment for influenza infections; M2 ion channel blockers and 
neuraminidase inhibitors (NAIs). 
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1.5.2.1 M2 ion channel blockers 
Amantadine was the first drug used against influenza infection in the 1960s as a 
prophylactic against Asian IAV infection (Davies, 1964). Amantadine (Symmetrel) 
and rimantadine (Flumadine), both belonging to the drug class: adamantanes, were 
first approved in 1976 for use as a prophylactic and therapeutic agent against IAV 
infection. Adamantanes block the action of the viral M2 ion channel which is 
responsible the conductance of protons to acidify the viral interior, thereby facilitating 
the dissociation of the matrix protein from vRNPs – required for unpacking of the viral 
genome (Helenius et al., 1992). Adamantanes bind to M2 and inhibit its proton 
conduction mechanism, either directly or allosterically, and subsequently preventing 
the uncoating of the virion and inhibiting vRNP release/viral replication  (Hay et al., 
1985; Cady et al., 2011; Schnell and Chou, 2008; Stouffer et al., 2008). Adamantanes 
possess no inhibitory effect against FLUBV, as they do not contain M2 but a 
homologue protein, that although shares functional homology with IAV M2, differs in 
sequence. In past seasons, the emergence of adamantane resistance in IAV strains has 
become prevalent. 99 % of H3N2 and H1N1pdm09 viruses are resistant to both 
amantadine and rimantadine (according to surveillance data provided by CDC, 
Atlanta, GA). Since 2006 the CDC has recommended the cessation of adamantanes as 
treatment against current circulating strains of IAV. Development of novel M2 ion 
channel blockers are underway; however the new compounds were still inactive 




1.5.2.2 Neuraminidase (NA) inhibitors 
Development of neuraminidase inhibitors (NAIs) commenced in the late 1960s with 
the synthetic compound Neu5Ac2en (DANA) (Edmond et al., 1966); although the 
compound exhibited low specificity and potency. The three-dimensional crystal 
structure exposing the catalytic sites of NA was resolved in the 1980s (Varghese et al., 
1983), which facilitated the design of current NAIs (Colman, 1994). To date, there are 
three FDA-approved NAIs for treatment against IAV infection; oseltamivir (Tamiflu) 
and zanamivir (Relenza) and newly licensed peramivir (Rapivab) (Alame et al., 2016). 
NA is required to help release progeny virus particles by digesting the HA receptors 
from the cell membrane (Palese et al., 1974) and can also help the spread of infection 
by facilitating movement though the respiratory tract by digesting neuraminic acid in 
respiratory mucus (Calfee et al., 1998). NAIs competitively inhibit the viral NA 
sialidase activity, thus consequently blocking the release of newly synthesised virions. 
Unlike adamantanes, NAIs are effective against both IAV and FLUBV strains, as the 
NA active site is highly conserved across all influenza viruses. Oseltamivir is the most 
commonly administered NAI due to the ease of oral delivery, whereas zanamivir is 
usually administered via inhalation and peramivir is delivered intravenously (IV), thus 
providing an alternative route of delivery for patients unable to inhale and/or take 
medication orally. In recent years, there has been a debate on the effectiveness of NAIs 
as an antiviral treatment. The 2014 Cochrane Collaboration study (Jefferson et al., 
2014) and the 2015 Multiparty Group for Advice on Science (MUGAS) report 
(Dobson, 2015) reviewed randomized placebo-controlled trials with patients receiving 
NAI treatment within a 48 h onset of ‘flu-like’ symptoms. The Cochrane and MUGAS 
studies concluded that oseltamivir decreased ‘flu like’ symptoms on average 16.8 h 
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(95% confidence interval (CI) 8.4-25.1) and described the reduction as “small”. 
Additionally, Jefferson et al., stated that there was insufficient evidence for NAI 
effectiveness against influenza infection complications such a pneumonia and that 
oseltamivir increases the risk of adverse effects such as nausea and vomiting.  
However, the lack of clinical trials including the severely ill and hospitalised patients 
reduced the reliability of the analyses of NAI efficacy presented in both studies as the 
success of treatment outcomes was not well represented. Thus, the European Centre 
for Disease Prevention and Control (ECDC) expert panel concluded in 2016 that they 
still endorsed the current policy on the use of NAI as a treatment for influenza virus 
infection along with support from the WHO (ECDC, 2016).  
 
1.5.2.3 Other antivirals  
In addition to the WHO-approved influenza antivirals, other therapeutic agents are 
approved and available in other countries. Laninamivir, also a NAI, is approved for 
treatment in Japan, but is still currently in clinical trials in the US (Kashiwagi et al, 
2016). Arbidol, a membrane fusion inhibitor that acts by binding to the HA2 subunit 
and preventing the conformational change required for membrane fusion (Leneva et 
al., 2009), is currently only licensed for use in Russia and China. An influenza 
polymerase inhibitor Favipiravir (T-705) has been approved for use in Japan and is 
currently undergoing Phase III clinical trials in US and Europe (Furuta et al., 2013). 
Other potential virus-acting therapeutic agents are undergoing clinical trials. These 
include PA endonuclease inhibitors; AL-794 and S-033188 and a small molecule 
inhibitor of PB2 cap-binding; VX-787 currently undergoing phase II human trials in 
Belgium (Table 1.3). In addition, human monoclonal antibodies (HuMAbs) prepared 
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from vaccinated donors and/or patients with viral infections could have therapeutic 
use, with several HuMAbs displaying broad neutralising activities against a range of 
HA subtypes (Table 1.3). Finally, a small number of host-targeting potential IAV 
drugs are also currently being evaluated clinically (Table 1.3) and are discussed in 
detail in section 1.5.4.2 Targeting cellular host factors  
 
1.5.3 Antiviral resistance  
 
The emergence of antiviral drug resistance in IAV has been a growing problem in the 
past few years, with many circulating strains accumulating drug-resistant mutations. 
The ability of influenza viruses to overcome certain selection pressures such as drug 
inhibition is most likely due a viral error-prone RdRp which introduces mutations and 
thus produces a high abundance of viral variants. The inappropriate use of antivirals 
within hospitals and clinics, such as misdiagnosis or overuse, has also be speculated 
to contribute to the rapid increase in resistance observed over the past few decades. 
 
1.5.3.1 Genetic barriers to resistance and fitness cost 
The number and type of mutations necessary to generate resistance differ dependant 
on the antiviral class and target; which is referred to as the genetic barrier to resistance 
(Gotte, 2012).  Some older classes of antivirals have been described to have a low 
genetic barrier, in which the viruses only require one or two mutations to gain 
resistance such as the first generation HIV antivirals, RT inhibitors (Perno et al., 2008). 
The genetic barrier will affect the rate at which resistance to a drug will occur. For 
example, if one resistance pathway only requires one mutation and another pathway 
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require multiple mutations, the former would likely occur more often. Thus, the ideal 
antiviral drug would have a high genetic barrier so resistance would not arise easily. 
 
Established resistance mutations are often not maintained in a population after drug 
treatment has ceased. This is usually because of the fitness costs associated with the 
drug-resistance mutations. When under a selection pressure, the mutations would 
produce a benefit (becoming resistant) but carry a cost as a result of the fitness gain in 
a drug dependant environment. Examples of these cost/benefit trade-offs include 
thymidine kinase mutations in HSV to gain resistance to acyclovir, resulting in 
decreased enzyme production (Piret and Boivin, 2014) and resistance to thymine 
analogue HIV inhibitors by removal of chain-terminating function, which results in 
lower replication titres (Hu et al., 2006). However, these trade-offs are not always 
present. In the case with the influenza H1N1 2009 strain, containing oseltamivir 
resistance mutation H274Y had little to no cost to virus fitness (Renzette et al., 2014; 
Hauge et al., 2009) (as discussed in more detail below).  
 
1.5.3.1 Adamantine resistance  
Early resistance to adamantanes was revealed in the 1990s, where during clinical use, 
amantadine and rimantadine resistant strains emerged in 30 % of patients after 2-3 
days of treatment (Hayden,1992). Furthermore, in the late 1980s, it was determined 
that drug-resistant virus variants did not lose pathogenicity and could still transmit 
efficiently between individuals (Belshe et al, 1988). After 50 decades of effective use 
of adamantanes, global drug resistance has increased drastically. In the US, the 
frequency of adamantane resistance at the end of the 2003-2004 influenza season was 
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1.9 %. This increased to 14.5 % between 2004-2005 and at the beginning of 2006, 92 
% of circulating H3N2 strains were adamantane-resistant (Bright, 2006). The 
mutations for IAV to escape the M2 ion channel blocker have been well characterised. 
Mutations identified to cause adamantane resistance  (L26F, V27A, A30T/V, S31N, 
G34E and L38F) are found within the M2 transmembrane domain (Cheung et al., 
2006; Hayden, 1992). The S31N substitution renders viruses highly resistant, with >97 
% of strains harbouring this mutation (Bright et al, 2006; Deyde et al., 2007; Frederick 
and Hayden, 2006). Mutations within the M2 transmembrane domain that line the 
channel pore (V27A, A30T/V and G34E) lead to an increase in M2 pore size and 
hydrophilicity, whereas mutations in the tetramer helix-helix packaging region (L26F, 
L38F and S31N) destabilise the helix assembly, therefore narrowing the M2 pore size 
(reviewed in Hussain et al., 2017). Currently, > 99 % of circulating influenza strains 
are thought to be resistant to adamantanes, which has subsequently led the CDC to 
change their recommendation for the use of adamantanes as treatment against IAV 
infection. Thus, NAIs have been made the antiviral treatment of choice for influenza 
infection.  
 
1.5.3.2 NAI resistance   
Due to the rapid emergence of adamantane-resistant virus variants, preclinical in vitro 
resistance studies were performed to determine the prevalence of NAI-resistant IAV 
strains. Drug-resistant mutations E119G/A/D/V and R292K were found in NA after in 
vitro passage with NAIs and in patients treated with both oseltamivir and zanamivir 
(McKimm-Breschkin, 2000). Additionally, two drug resistant viruses containing the 
mutation H274Y in NA, were isolated from healthy volunteers that were infected with 
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IAV and administered oseltamivir (Gubareva et al., 2001). In 1999, a global 
Neuraminidase Inhibitor Susceptibility Network (NISN) was established to monitor 
the clinical IAV resistance to NAIs (Zambon and Hayden, 2001). The first few reports 
from 1999 to 2006, determined that IAV strains remained relatively susceptible to 
NAIs, with the expectation of a few rare cases of resistant variants (Monto et al., 2006). 
However, between 2007-2008, oseltamivir resistance presented in seasonal H1N1 
viruses with a 7 % increase of strains containing the drug-resistant escape mutation 
H274Y (Sheu et al., 2008). By the 2008-2009 season, >90 % of circulating H1N1 
viruses were resistant to oseltamivir; however all strains were still sensitive to 
zanamivir and all H3N2 viruses were still susceptible to oseltamivir and zanamivir 
(Baranovich et al., 2010; Matsuzaki et al., 2010). The emergence of the novel 
pandemic H1N1 2009 strain replaced the pre-pandemic oseltamivir-resistant H1N1 
subtype. Global analyses of clinical isolates from April 2009 to January 2010 
demonstrated that almost all post-pandemic strains were susceptible to NAIs (Dapat 
et al., 2013; Okomo-Adhiambo et al., 2010). IAV continues to be largely susceptible 
to NAIs with >98 % of pandemic H1N1 and H3N2 strains sensitive to NAIs (Hurt et 
al., 2016).  
 
1.5.4 Methods of preventing antiviral resistance 
The establishment of the M2 escape mutation S31N in IAV has rendered adamantanes 
ineffective as an anti-influenza treatment after ~50 years of use. Luckily, the majority 
of circulating H1N1 and H3N2 subtypes are still sensitive to NAIs. However, if the 
same timeline of viral adamantane resistance was applied to NAIs, first approved for 
clinical use in 1990s, circulating strains could be resistant to NAIs by 2030. 
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Consequently, investigation into new strategies for the control of viral drug resistance 
are essential. Proper diagnosis of respiratory illness will reduce the use of 
unnecessary/over-use of prescription of antivirals and potentially decrease the 
prevalence and speed of resistant strain emergence. Physicians often fail to correctly 
diagnosis influenza infection or associate ‘flu-like’ symptoms with another respiratory 
illness. In 2006, a study concluded that most children that were either hospitalized or  
 
1.5.4.1 Combination therapy 
The emergence of drug-resistant virus variants can be reduced with treatment of two 
or more drugs that target the virus and/or a cellular host factor, in which the mechanism 
of inhibition differs. This combination therapy presents the virus with two or more 
genetic barriers to adapt to and overcome and therefore may reduce the likelihood that 
a drug-resistant strain will develop. Additionally, the use of combination therapy 
clinically may allow physicians to reduce the doses of individual drugs necessary for 
potent antiviral activity thereby reducing dose-related side effects. Combination 
treatment to avoid the selection of resistant viruses has been a successful strategy for 
antiretroviral therapy (ART) against HIV (Lohse et al., 2007; Taiwo et al., 2010). 
 
Since the mid to late 1990s it has been known that simultaneous treatment with three 
antivirals against HIV blocks viral replication and decreases the probability of 
resistance by effectively establishing a chemicogenetic barrier. The multiple HIV 
therapy can keep viral plasma loads below detectable levels, prevent the likelihood of 
resistant viral variants and allow successful management of HIV-infected patients 
(Gulick, 2002; Raboud et al.,  2002). Additionally, treatment with pegylated interferon  
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 Table 1.3 Summary of influenza antivirals currently licenced or in clinical trials* 







Class Name Development stage  
Virus 
targeting 
M2 ion channel blockers Amantadine Licensed in 1976 - no 
longer recommended  
Rimantadine Licensed in 1976 - no 
longer recommended  
NA inhibitors  Oseltamivir 
carboxylate 
Approved in US and UK 
(1999) 
Zanamivir Approved in US and UK 
(1999) 
Laninamivir Approved in Japan (2010)  
Peramivir  Approved in Japan, Korea 
and US (2016) 
Nucleoside analogues 
for RNA-dependent RNA 
polymerase 
Favipiravir Approved in Japan (2014) 
and in phase III in US and 
Europe  
Ribavirin  Phase II as a combination 
therapy in US 
Membrane fusion 
inhibitors  
Arbidol  Approved in Russia (2005) 
Small molecules that 
inhibit PB2 cap-binding  
JNJ-63623872 
aka VX-787 
Phase IIb in Belgium  
PA endonuclease 
inhibitors  
Al-794 Phase I in UK 
S-033188 Phase III in Japan  
Monoclonal HA 
antibodies  
CR261 Phase I in Holland  
CR8020 Phase II in Holland  
MEDI8852 Phase II in US   
MHAA4549A Phase II in UK   
VIS410 Phase II in UK  
Host 
targeting  
Attachment  Fludase 
(DAS181) 
Phase II in US 
Attachment  Nitazoxanide  Phase II in US  
Nuclear export inhibitors KPT-335) Phase I in Australia  
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(IFN) in combination with ribavirin has been used as a therapy for severe hepatitis C 
infections and respiratory syncytial virus infection (Cacoub et al., 2005).  
 
Exploiting combination antivirals is not a novel pharmacological rationale to control 
influenza virus infection. Many investigations study the activity of drug combinations 
against influenza virus in vitro and in vivo. The effects of the interactions of two or 
more drugs can be defined as synergistic, additive or antagonistic; depending on if the  
combined effect exceeds, equals or is less than the overall sum of the antiviral effects 
of each drug, respectively. Synergistic drug combinations are more advantageous, as 
the drugs can enhance each other’s mechanism of action and therefore may result in a 
dose reduction, a decrease in cellular toxicity/side effects and permit greater cost-
effectiveness. Synergistic interactions between combinations of current anti-influenza 
drugs amantadine, oseltamivir and ribavirin have been found to be more efficacious 
prophylatically than monotherapy in vitro and in vivo (Nguygen et al., 2012; 
Govorkova et al, 2004; Ilyushina et al., 2008; Ilyushina et al, 2007; Smee et al., 2006). 
Several influenza studies, which tested the compounds in animal models, show 
enhanced antiviral activity when used in combination; the success of influenza 
antiviral combinations are detailed in Table 1.4. However, clinical applications of 
combination therapy against influenza virus are limited, possibly due to the 
development of resistance to the current antiviral class of adamantanes, thus limiting 
the number of other classes of approved antivirals for use. Two randomised clinical 
trials tested the combination of oseltamivir and zanamivir treatment against H3N2 and 
H1N1pdm09 viruses but failed to indicate an additive effect of the combination  
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Table 1.4. Outcome of double drug combinations on influenza virus infection in 





Drug interactions Reference 
Oseltamivir + 
Amantadine 
H1N1 Enhanced protection (Masihi et al., 2007) 
H3N2 Enhanced protection (Masihi et al., 2007) 
H5N1 Greater protection than monotherapy  (Ilyushina et al., 
2007) 
H5N1 Greater protection than monotherapy (Smee et al., 2009) 
Oseltamivir + 
Rimantadine 
H9N2 Greater protection than monotherapy (Leneva et al., 2009) 




H1N1 No added benefit  (Smee et al., 2006) 
FLUBV Synergistic (Smee et al., 2006) 
H5N1 Greater protection than monotherapy (Smee et al., 2009) 
H5N1 Additive at some concentrations  (Ilyushina et al., 
2008) 




H5N1 Greater protection than monotherapy (Smee et al., 2009) 
Peramivir + 
Ribavirin  
H1N1 Additive-synergistic  (Smee et al., 2002) 
Oseltamivir + 
T-705 
H1N1 Strong synergy  (Smee et al., 2010) 
H3N2 Strong synergy  (Smee et al., 2010) 












therapy (Duval et al., 2010; Escuret et al., 2012). In another study, a comparison 
between a triple combination with amantadine, ribavirin and oseltamivir vs oseltamivir 
monotherapy was examined (Kim et al., 2011). Results indicated that the mortality 
rate was lower in patients receiving triple therapy compared to the monotherapy (17 % 
versus 35 %). Notably, two trials comparing zanamivir/oseltamivir combination and 
oseltamivir alone resulted in reduced clinical efficacy, potentially as a result of 
competitive antagonism (Dunning et al., 2014; Duval et al., 2010). Currently, another 
randomised clinical trial is underway, testing a triple combination of amantadine, 
ribavirin and oseltamivir vs oseltamivir alone (Dunning et al., 2014). 
 
1.5.4.2 Targeting cellular host factors  
Targeting cellular factors involved in influenza virus replication signifies a novel 
antiviral strategy that could potentially slow the emergence of viral drug resistance. It 
is hypothesised that the virus would find it more challenging to escape inhibition of 
host-encoded target compared to inhibition of a viral protein (Watanabe and Kawaoka, 
2015). Influenza virus replication takes place in non-immune (respiratory epithelial 
cells) and immune cells (alveolar macrophages and dendritic cells) and relies on 
numerous host cell factors (reviewed in Hale et al., 2010). Many host factors have 
been identified using genome-wide siRNA screening and genomic/proteomic 
bioinformatics approaches; however, development and validation of compounds with 
antiviral properties against novel cellular targets can be a time consuming and 
expensive approach. Nevertheless, if a host targeting antiviral could counteract viral 
drug resistance it could be cost effective in the long-term. One of the major difficulties 
when developing a cellular targeting antiviral is the potential for the compound to 
cause adverse effects on host cells. This difficulty may explain why there are currently 
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no licenced influenza antiviral therapies that inhibit cellular factors. However, the 
severity of the disease may outweigh the consequences of overt toxicity. For example, 
one host-targeting antiviral drug, Maraviroc (a CCR5 chemokine receptor antagonist) 
has been FDA-approved for the treatment of HIV, which presents itself as persistent, 
life threatening disease. Influenza antivirals are often administered to 
immunosuppressed individuals that have acquired influenza virus as a secondary 
infection and thus present with more serious illness than in a healthy individual. 
Accordingly, it is important to take in to consideration the severity of disease and 
determine the benefits and risks of administration of the cellular targeting therapy. 
Nonetheless, the area of cellular drug targets is advancing. Recently, a few potential 
antivirals, that block host factors, have been developed with lower toxicity and are 
currently being tested experimental in vitro/in vivo, with some advancing to human 
clinical trials (Table 1.4). 
 
To date, nitazoxanide (NTZ) is the most successful cell-targeting compound to 
proceed in clinical trials. NTZ was originally developed and licensed for treatment 
against protozoa and helminth infection (White, 2004). It was first identified to have 
antiviral properties during a clinical trial for Cryptosporidium treatment in patients 
with HIV infection (Capparelli and Syed, 2008). Since then, NTZ has been shown to 
inhibit a range of both bacterial and viral infections (reviewed in Rossingnol, 2014). 
For influenza infection, NTZ inhibits replication by impairing HA assembly through 
disruption of HA transportation from the endoplasmic reticulum (ER) to Golgi, thus 
preventing the exit of virus particles from infected cells (Rossingnol et al., 2009). In 
vitro studies have shown broad-spectrum antiviral activity of NTZ (Rossingnol et al., 
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2009) and a synergistic effect when used in combination with oseltamivir (Belardo et 
al., 2015). A recent phase IIb human clinical trial demonstrated reduced influenza 
symptoms by 36 hours (treatment started 48 h after the onset of symptoms) (Haffizulla 
et al., 2014). Currently, four phase II and III trials are underway including a 4-way 
comparison trial of NTZ vs oseltamivir vs NTZ/oseltamivir vs placebo 
(NCT01610245: study identification number obtained from the  https://clinical-
trials.gov/ database). Additionally, there is encouraging in vitro data to suggest that 
serial passage of influenza virus in the presence of NTZ failed to select for drug 
resistance virus variants  (Belardo et al., 2015). 
 
Fludase (DAS18) is another successful cell-targeting compound to proceed to phase II 
clinical studies. Fludase is a recombinant fusion protein containing a sialidase catalytic 
domain, derived from Actinomyces viscosus, fused with a cell surface anchoring 
domain. The compound cleaves sialic acid receptors from the airway epithelium and 
therefore prevents virus attachment (Malakhov et al., 2006). Preclinical in vitro and in 
vivo studies have demonstrated that Fludase possesses potent broad-spectrum antiviral 
efficacy and cell protective properties when administered long term. In 2007, the first 
phase I clinical trial of Fludase was carried out in healthy adults to determine the safety 
and tolerability of the drug. The study concluded in 2009 and revealed that the drug 
was well tolerated at all dosage levels tested (Triana-Baltzer et al., 2009). Since then, 
multiple successful phase I trials have been carried out on healthy adults and on those 
suffering from asthma and bronchiolitis (NCT01113034). Thus far, one phase II study 
has been performed with patients who were otherwise healthy but suffering from IAV 
infection. Fludase was well tolerated with slightly more mild to moderate adverse 
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effects in the treatment than the placebo group (Moss et al., 2012). Further testing of 
Fludase is currently underway to evaluate its safety and tolerability during influenza 
infected individuals that have known chronic health conditions.   
 
Other cellular targeting antiviral compounds, yet to advance to clinical testing, are 
currently under experimental investigation in both in vitro and in vivo, such as 
protease, phospholipase and V-ATPase inhibitors, compounds that target various 
cellular signalling pathways including Raf/MEK/ERK, mechanistic target of 
rapamycin (mTOR) and epidermal growth factor receptor (eGRF) and inhibitors 
against immunomodulatory factors such as cyclooxygenase, angiotensin converting 
enzyme (ACE), angiotensin receptors and AMP activated protein kinase (AMPK) (see 
Table 1.5 for details). A few of these compounds are approved for treatment against 
other diseases; however, thus far none have successfully proceeded to clinical-stage 
trials regarding treatment of influenza virus infection. NTZ and Fludase are the only 
two cellular inhibitors to date that have proceeded to phase II clinical testing against 
IAV. KPT-335 (also known as verdinexor), is a cellular inhibitor that targets host cell 
factor CRM1, which has recently completed an initial phase I clinical trial. 










Drug target Drug name Mechanism of action  Current development stage 
Attachment  Fludase (DAS181) Removes sialic acid receptors 
from respiratory epithelial cells 
thus preventing attachment of 
the virus to the host cell surface  
Successfully inhibits influenza A 
viruses in vivo (Belser et al., 2007) 
Currently in Phase II clinical trials 
(http://www.drugdevelopment-
technology.com) (US) 
Attachment Nitazoxanide  Interferes with assembly of viral 
HA 
Clinical Phase III (US) 
NCT02612922 
Membrane fluidity  Fattiviracin FV-8 Alters the fluidity of the plasma 
membrane thus may restrict 
effect virus entry  
Broad spectrum antiviral activity 




Viramidine  Inosine-5’-monophosphate 
dehydrogense  
Influenza A virus inhibition in vitro and 
in vivo (Sidwell et al., 2005) 
Nuclear export   Verdinexor (KPT-335) Targets host cell export protein 
CRM1 which the virus utilizes 
for nucleocytoplasmic transport 
of vRNPs   
Inhibits various influenza A and B 
strains in vitro (Perwitasari et al., 2014) 
Reduced influenza replication in mice 
and ferrets (Perwitasari et al., 2016) 







Inhibits the host proteases 
ability to splice mRNA which 
determines whether species 
specificity and virulence of the 
virus 
Protease inhibitors have shown to 
block infection at viral entry (reviewed 
in Kido et al., 2017) 
Phospholipase 
inhibitors  
ML395 Inhibits catalyzation of 
phosplipase which plays a role 
in metabolic pathways,  
Broad-spectrum activity against 






Thought to increase internal pH 
of the pre-lysyosome thus 
inhibiting conformational 
transformation of HA 
Parkinson treatments that contain the 
adamantine scaffold shown to have an 
inhibitory effect against influenza A and 
B viruses (Schroeder et al., 1985) 
Raf/MEK/ERK 
pathway 
U0126 Inhibits Raf signalling resulting 
in nuclear retention of vRNPs 
Inhibition of influenza A virus in vitro 
(Pleschka et al., 2001) 
mTOR pathway Rapamycin  Potent immunosuppressive and 
antiproliferative properties 
Treatment lead to protection from 
multiple influenza subtypes (McMichael 
and Haynes, 2013) 
eGFR pathway  PPQ-B May down regulate NF-kB and 
MAPK pathways to inhibit 
replication and inflammatory 
responses 
Suppressed replication of influenza A 
viruses in vitro (Wang et al., 2017) 
Immunomodulator







Reduce levels of LDL-
cholesterol and improve 
inflammatory changes this 
reduce the mortality of 
influenza infection 
Reduced mortality in mouse models 
(reviewed in Fedson, 2009) and 






Targets COX-1 and COX-2 
pathways; modulators of the 
immune response  
Approved as anti-inflammatory drugs 
COX-1 plays a role in controlling 
thermoregulatory response to IAV in 




Statins  Targets HMG-CoA which helps 
modulate the immune response  
Approved as cardio-protective drugs. 
Possibly help control immune system 
cytokine overexpression during IAV 
infection (Mehrbod et al., 2014) 
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1.6 Selective inhibitors of nuclear export (SINEs) 
 
1.6.1 CRM1, the major nuclear export receptor 
NPCs mediate the exchange of macromolecules between the nucleus and the 
cytoplasm. NPCs permit the passive diffusion of small molecules (<~40 kDa), while 
larger cargos (greater than 40 kDa) are selectively transported by signal-mediated 
pathways, driven by the RANGTP/GDP cycle (reviewed in Beck and Hurt, 2017). 
There are currently 7 members of the karyopherin superfamily of importin and 
exportin nucleocytoplasmic transport receptors.  CRM1 is the most versatile cellular 
export protein that lies within the NPC and facilitates the nuclear export of  >240 
proteins and RNA molecules (reviewed in Wente and Roul, 2010). CRM1 interacts 
with a NES domain on the nuclear-cytoplasmic shuttling cargo (Matsuyama et al., 
2006). The initial understanding that CRM1 mediated nuclear export of proteins was 
significantly influenced by studies with the HIV-1 REV protein (Pollard and Malim, 
1998). REV recognised and stimulated export of unspliced/ partially spliced mRNA 
and was one of the first proteins identified to contain a NES domain (Fischer et al., 
1995). Investigations of the REV NES motif subsequently led to the identification of 
the CRM1 pathway. 
 
1.6.1.2 CRM1 structure and LMB binding 
The CRM1 structure is conserved between species including yeast, fungi, mice and 
humans (Fung and Chook, 2014). The 120 kDa ring-shaped protein is composed of 21 
tandem HEAT repeats and contains a pair of anti-parallel helices A and B that form 
the outer and inner surfaces (Dickmanns et al., 2015). The highest sequence identity 
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between CRM1 and other karyopherin superfamily members has been shown in the 
first 3 HEAT repeats and the CRIME domain (Fig. 1.7.A), thus indicating their 
functional importance (Fornerod et al., 1997; Monecke et al., 2014). The NES binding 
groove is located between HEAT proteins 11 and 12 (Dong et al., 2009; Monecke et 
al., 2009). CRM1 binds to cargoes at the outer surfaces anchoring to five key 
hydrophobic residues (Φ1–Φ5) in the NES region (Fig. 1.7.B). The cysteine residue 
528 (yellow circle) is the major target for CRM1 inhibitors. LMB was the first 
compound identified as the potent CRM1 inhibitor. LMB is a 540 Da polyketide which 
contains an α,β-unsaturated δ-lactone ring (Fig. 1.8.A). Structure analysis has revealed 
that LMB bind to the NES domain by occupying 4 of the 5 hydrophobic pockets 
leaving Φ4 vacant (Fig. 1.7.C). The α,β-unsaturated δ-lactone ring covalently binds to 
Cys528 of human CRM1 through a Michael reaction. The hydrolysis of the lactone 
ring (catalysed by CRM1) renders the binding irreversible, thus responsible LMB’s 
cytotoxic effects. 
 
1.6.2. Karyopharm therapeutics  
Karyopharm Therapeutics is a clinical-stage US-based pharmaceutical company that 
have developed first-in-class novel selective inhibitors of nuclear export (SINE). The 
discovery and development of the novel compounds was performed using an in silico 
molecular modelling system to screen a virtual library containing compounds 
predicted to bind to the NES groove of the human CRM1 protein (Dong et al., 2009). 
The compounds were further validated and confirmed to disrupt binding between 






Figure 1.7. Structure of CRM1 and inhibitors binding via the NES-binding cleft. 
(A) The structure of CRM1 (grey) showing the CRIME-domain (green), the acidic loop 
(blue), the C-terminal helix (HEAT helix 21B (red)) and the NES-binding cleft (orange) 
(B) The 5 interacting residues (hydrophobic pockets) of the NES region indicated by 
circles. The yellow circle indicates the position of Cys-528 in human CRM1. LMB (C) 
and KPT-185 (D) molecules binding to the NES region of CRM1. Figure taken and 











cargo binding site, which blocks CRM1-mediated transport for ~12-24 h (London et 
al., 2014). SINE’s transient binding properties have been designed to reduce potential 
adverse toxic side effects that can be caused by the cellular inhibitors.  
 
SINE inhibitors contain a trifluoromethly pheyl triazole scaffold (Fig. 1.8.C.D) and 
have been crystallized in complex with CRM1 (Lamalobella et al., 2012; Tai et al., 
2014). The crystal structure analysis revealed that they occupy three of the five 
hydrophobic pockets (24) leaving 0 and 1 sites vacant (Fig. 1.7.D). The 
Michael acceptors (an isopropyl acrylate) are not hydrolysed when bound to CRM1, 
thus bind in a reversible fashion to NES which may explain their reduced side effects 
in contrast to the irreversible cytotoxic inhibitor, LMB. 
 
Karyopharm originally developed SINEs as therapeutic cancer agents as they retain 
tumour suppressor proteins such as p53, forkhead box O (FOXO), retinoblastoma 
protein (RB1) and cyclin dependent kinase inhibitor 1A (CDKN1A), within the 
nucleus of a cell (Das et al., 2015; Parikh et al., 2014; Zhang et al., 2013). 
Accumulation of these proteins allows the functional activation of tumour necrosis 
factor (TNF) proteins thus limiting oncogenesis. CRM1 also exports anti-
inflammatory protein IkB which inhibits nuclear factor kappa-light-chain enhancer of 
activated B cells (NF-kB). NF-kB is associated with cancer metastasis and resistance 
to chemotherapy, therefore nuclear sequestration of IkB by SINEs reduces metastasis 
growth and help overcome chemotherapy resistance (Nair et al., 2017). Currently, 
Karyopharm have five main SINE compounds in their drug development pipeline: 





Figure 1.8. Chemical structures of CRM1 inhibitors; LMB, KPT-185 and KPT-
335. (A) Chemical structure of LMB (C33H48O6, MW = 540.74 g/mol). LMB contains 
α,β-unsaturated δ-lactone, two conjugated dienes, a β-hydroxy-ketone moiety and a 
terminal carboxylate (B, C) Chemical structure of SINEs; KPT-185 (C16H16F3N3O3, 
MW = 355.31 g/mol) and KPT-335 (C18H12F6N6O, MW = 442.325 g/mol). Both 
inhibitors contain a trifluoromethyl phenyl triazole (4-phenyl-5-(trifluoromethyl)-2H-







 (https://www.karyopharm.com/pipeline/). KPT-330 is the most successful SINE to 
date, with >2000 patients administered treatment thus far. The compound is well 
tolerated and many patients are receiving long term therapy to treat multiple myeloma 
and B-cell lymphoma (Kuruvilla et al., 2017; Muz et al., 2017). KPT-350 and KPT-
8601 are second generation SINE compounds and are currently in phase I clinical trials 
for treatment against MM, myelodysplastic syndrome, colorectal cancer, prostate 
cancer, solid tumours and lymphoma (Turner et al., 2016). KPT-335 is the lead 
compound in development for treatment of viruses (www.karopharm.com-
/pipeline/oral-verdinexor-kpt-335/). 
 
1.6.3. KPT-335 as an antiviral agent 
Many viruses exclusively utilise the host protein, CRM1, for nuclear-cytoplasmic 
transport of cargos for virus replication. IAV hijacks the CRM1 pathway to transport 
vRNPs from the nucleus to cytoplasm as shown previously by use of the specific 
CRM1 inhibitor LMB, as well as by other approaches (1.3.4 Nuclear export). The first 
study to report KPT-335’s efficacy against IAV was by Perwitasari et al., (2014). 
KPT-335 inhibited vRNP export and had antiviral activity against both influenza A 
and B virus strains in vitro. Additionally, prophylactic and therapeutic treatment of 
KPT-335 protected mice against influenza disease pathology and reduced viral lung 
loads. A second study, published in 2016, further evaluated in vivo efficacy of KPT-
335 in two animal models of influenza infection: mice and ferrets (Perwitasari et al., 
2016). KPT-335 reduced virus shedding and pro-inflammatory cytokine expression in 
both animal models. Additionally, KPT-335 has also been shown to have antiviral 
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activity against Venezuelan equine encephalitis (VEEV) by retaining the viral capsids 
in the nucleus of the host cell (Lundberg et al., 2016). 
 
The success of KPT-335 in pre-clinical in vitro and in vivo studies warranted its 
development as a novel therapeutic agent against influenza infection. Subsequently, in 
2015, a phase I clinical trial was conducted in healthy human volunteers. The 
randomized, double-blind, placebo controlled, dose-escalating trial was designed to 
evaluate the safety and tolerability of KPT-335 (NCT02431364). KPT-335 was 
generally well tolerated with mild to moderate AE. Karyopharm are continuing clinical 
development of KPT-335 as treatment against IAV (www.karopharm.com/-
pipeline/oral-verdinexor-kpt-335/). The KPT-335 pipeline is demonstrated in Fig. 1.9.
  
Figure. 1.9. KPT-335 therapeutic pipeline 
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The aim of this project was to investigate the potential of two SINE compounds, KPT-
335 (verdinexor) and KPT-185 as novel therapeutic agents against IAV infection. 
Chapter 1 characterises pre-clinical efficacy of the compounds including 
investigations into cytotoxicity, antiviral efficacy and confirmation of the drugs 
mechanism of action. Subsequent chapters investigate the potential for emergence of 
drug-resistant virus variants in vitro. Although determining the potential for drug-
resistant is not a requirement for pre-clinical development of a therapeutic agent, the 
FDA recommend that the drug resistance threshold for novel compounds should be 
considered before proceeding to clinical trials. This work aimed to support the ongoing 
development of KPT-335 as a potential influenza therapeutic agent as well as help 













Chapter 2 Characterising the antiviral activity of 
selective inhibitors of nuclear export against 
influenza A virus in vitro. 
 
2.1 Introduction  
 
CRM1, also known as XPO1, is a eukaryotic protein involved in the nuclear-
cytoplasmic transport of proteins containing leucine-rich sequences termed nuclear 
export signals (NES) (reviewed in Hutten & Kehlenbach, 2007). Influenza viruses 
exploit the cellular CRM1 protein to achieve nuclear export of their viral genome, in 
the form of vRNP complexes, to the cytoplasm for propagation of progeny viruses. 
The current ‘daisy-chain’ model for CRM1-mediated export of vRNPs suggests the 
viral NP within the vRNP complex binds to the M1 protein, which in turns interacts 
with the NS2 protein (also known as the nuclear export protein (NEP)). NS2 contains 
a leucine-rich NES which  is then subsequently recognised by CRM1 (reviewed in 
Eisfeld et al., 2014). In part, the knowledge that influenza viruses utilise this cellular 
pathway comes from use of a natural inhibitor of CRM1, the fungal toxin leptomycin 
B (LMB) (Kudo et al., 1999; Nishi, Yoshida, & Fujiwara, 1994). Influenza virus-
infected cells treated with LMB displayed nuclear retention of vRNPs, indicating that 
their normal nuclear-cytoplasmic transport had been blocked (Elton et al., 2001; Ma, 
Roy, & Whittaker, 2001; Watanabe et al., 2001). Not unexpectedly, LMB is a potent 
cytotoxin, as displayed by numerous studies, which indicate significant potency in 
vitro but poor tolerability in vivo (reviewed by Mutka et al., 2009). LMB’s overt 
 55 
toxicity is thought to be due to the covalent and irreversible nature of its interaction 
with the CRM1, thus hindering its use as a potential therapeutic antiviral agent. 
 
Karyopharm Therapeutics, a clinical-stage US pharmaceutical company, specialise in 
the discovery and development of novel drugs directed against cellular nuclear 
transport. They succeeded in developing CRM1 inhibitors with lower toxicity and 
greater oral bioavailability than LMB, known as Selective Inhibitors of Nuclear Export 
(SINEs). These compounds have been described to inhibit CRM1-mediated nuclear-
cytoplasmic transport by selectively and transiently binding to CRM1’s cargo binding 
site, cysteine residue 529 (Turner and Sullivan, 2008).  Although primarily focused on 
developing anti-cancer agents for veterinary and human applications, Karyopharm 
recognise that SINEs also have potential as antiviral agents and have preliminary data 
indicating that their compounds inhibit influenza A virus (IAV) (Perwitasari et al., 
2014; 2016). 
 
The aim of this section was to test the efficacy and mechanism of action of the 
Karyopharm compounds KPT-185 and KPT-335 (as well as an inactive chiral 
enantiomer control to KPT-185; KPT-301) alongside LMB, which was used as a 
positive control for inhibition of nuclear export. Initially, cytotoxic effects caused by 
the compounds were assessed and subsequently their antiviral efficacy was analysed 
against a human lab-adapted IAV strain and then against a range of both human and 
animal isolates of IAV. The mechanism of action of the compounds was also 
investigated with respect to the intracellular trafficking of IAV.  
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2.2 Results  
 
2.2.1 Antiviral activity of SINEs  
Prior to testing the activity of SINEs against IAV, the cytotoxicity of KPT-185, KPT-
335 and an inactive control (KPT-301) was examined in cell culture. A549 or MDCK 
cells were treated with 2-fold dilutions of the compounds starting from 5 µM and the 
ATP content was measured 24 h later to assess cell viability. The assay determines the 
number of viable cells in culture based in quantification of ATP, which indicates the 
presence of metabolically active cells. Thus, a reduction of ATP in the presence of 
compound would signal a cytotoxic effect of the drug.  KPT-301 displayed a 20-30 % 
reduction in ATP levels at concentrations >1 µM indicating the inactive compound 
was slightly toxic to both A549 and MDCK cells at the higher concentrations tested 
(Fig. 2.1. A.B). Little toxicity was observed at concentrations between 0.15 µM and 1 
µM for both KPT-185 and KPT-335 in A549 and MDCK treated cells (Fig. 2.1. A.B). 
As dose response curves are generally sigmoidal, EC50 values (the half maximal 
effective concentrations) were determined using a non-linear regression model. From 
the dose-response analysis, the concentrations required for 50 % cytotoxicity (CC50 
value) were determined as 2.7 µM and 2.9 µM for KPT-185 and 2.6 µM and 9.8 µM 
for KPT-335 in A549 and MDCK cells, respectively (Table 2.1). All forthcoming 
experiments were carried out with drug concentrations ≤1 µM to ensure that inhibition 
of virus replication observed was not caused by adverse cellular toxicity. 
 
To analyse the efficacy of SINEs against IAV, A549 cells were infected with a 
laboratory-adapted human H1N1 virus, A/PR/8/34 (PR8), at either high (3) or low 
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Fig. 2.1. Efficacy of SINEs against IAV in vitro. (A, B) Cytotoxicity of SINEs. A549 
or MDCK cells were treated with either the vehicle control (DMSO) or SINEs in 2-fold 
dilutions. 24 h post-treatment, cells were assayed for ATP content to determine cell 
viability. Data are the mean ± S.D of two independent assays, each measured in 
triplicate. Curves were fitted using a non-linear regression model. (C, D) Dose-
response efficacy of SINEs against IAV. A549 cells were infected with PR8 virus at 
(C) MOI 3 or (D) MOI 0.01 and treated with increasing concentrations of SINEs. Virus 
supernatant was taken 24 h p.i. and titred by plaque assay. Data are the mean ± SEM 
of three independent experiments. Curves were fitted using a non-linear regression 
model. This analysis assumes a standard slope where the response goes from 10% 




(0.01) multiplicities of infection (MOI) and treated with SINEs, starting at a 
concentration of 0.01 µM and increasing in 0.5-log10 increments to 1 µM. Supernatants 
were collected at 16 h (MOI=3) or 24 h (MOI=0.01) post-infection (p.i.) for viral titre 
determination by plaque assay, as previously described (Turnbull et al., 2016). The 
inactive compound, KPT-301, had little effect on virus replication at concentrations < 
0.3 µM tested in both single and multi-cycle replication assays. At concentrations >1 
µM, KPT-301 appears to reduce viral titre by ~30 % during single cycle infection and 
~10% in a multi-cycle assay. (Fig. 2.1. C, D). 
 
Both KPT-185 and KPT-335 successfully inhibited virus replication in a dose-
dependent manner at both the low and high MOI infection conditions (Fig. 2.1.C.D). 
Under multi cycle replication conditions, KPT-185 and KPT-335 had similar 50 % 
inhibitory concentration (IC50) values of 0.05 µM and 0.06 µM, respectively (Table 
2.1). Under single cycle conditions, an IC50 value of 0.04 µM was determined for KPT-
335 inhibition, which was similar to the value obtained for multi-cycle infections 
(Table 2.1). However, curve fitting for the rather variable KPT-185 data, obtained 
under single cycle conditions, determined an estimate (~) IC50 value of ~0.26 µM, with 
wide 95 % confidence intervals (CI) (Table 2.1).  Thus, these results indicated that the 
SINE compounds effectively inhibited replication in vitro at concentrations below that 
exhibiting cytotoxicity and that KPT-335 was the most potent inhibitory compound 
under both conditions.  
 
To provide a point of comparison with previous work, cytotoxicity and dose-response 
assays were performed in a similar manner to the SINE compounds with the natural 
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 Fig. 2.2. Efficacy of LMB against IAV in vitro. (A) Cytotoxicity of LMB. A549 cells 
were treated with either the vehicle control (DMSO) or LMB in 2-fold dilutions. 24 h 
post-treatment, cells were assayed for ATP content to determine cell viability. Data 
are the mean ± S.E.M of three independent assays, each measured in triplicate. 
Curve was fitted using a non-linear regression model. (B) Dose-response efficacy of 
LMB against IAV. A549 cells were infected with PR8 virus at MOI 0.01 and treated 
with increasing concentrations of LMB. Virus supernatant was taken 24 h p.i. and 
titred by plaque assay. Data are the mean ± SEM of two independent experiments. 
Curve was fitted using non-linear regression model.
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CRM1 inhibitor, LMB (Fig. 2.2). Cell viability was assessed by treating A549 cells 
with 2-fold dilutions of LMB, starting from 30 nM and the ATP content was measured 
24 h later. Substantial cytotoxic effects were observed at concentrations as low as 1 
nM with a 40 % decrease in cell viability compared to the untreated cells. A 60 % 
reduction in cell viability was observed at the highest concentration tested (30 nM) 
(Fig. 2.2.A). A CC50 value of 2 nM (0.02 µM) was determined by non-linear regression 
model analysis (Table 2.1). To determine the concentration at which LMB was 
antiviral, A549 cells were infected with PR8 at a low MOI (0.01) and treated with 
increasing concentrations of LMB, starting at a concentration of 0.03 nM and 
increasing in 0.5-log10 increments to 30 nM. Supernatants were collected at 24 h p.i., 
for viral titre determination by plaque assay. LMB inhibited virus replication in a dose-
dependent manner (Fig. 2.3.B) and had a resulting IC50 value of 6 nM (0.006 µM) 
(Table 2.1). However, at the IC50 concentration, LMB caused around a 30 % loss of 
cell ATP content, suggesting that overt cytotoxic damage to cells may contribute to 
the observed reduction in virus titre. These data confirmed that LMB would likely be 
excessively toxic to be used as an antiviral agent. 
 
The CC50 and IC50 values established from the data presented in Figs. 2.1 and 2.2 along 
with corresponding 95 % CI and R2 values are presented in Table 2.1. All 95% CI 
calculated were small apart from the aforementioned wide range CI obtained for KPT-
185 under single cycle infection conditions. Aside from KPT-185 single cycle 
infection and KPT-335 MDCK cytotoxicity, all R2 values were ≥0.7 indicating that 
the IC50 determinations from curve fitting could be considered reasonably accurate. 
Accordingly, selective indexes (SI) were determined for KPT-185, KPT-335 and 
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 LMB under the single or multicycle infection conditions by calculating the ratio of 
the CC50 values (from A549 cells) to the IC50 values. Also described as the therapeutic 
window, this number represents the comparison of the concentration of compound that 
causes an antiviral effect to the concentration that causes cytotoxicity. Accordingly, is 
preferable to have a wide therapeutic window i.e. a high SI index value. KPT-335 had 
the greatest SI for single cycle infection (SI=65) and KPT-185 had a higher index for 
multi cycle infection (SI=52). Both SINE compounds had a considerably higher SI 
value than LMB which was <1. Overall, these results indicate that the SINE 
compounds effectively inhibited PR8 replication in vitro at concentrations well below 
that exhibiting cytotoxicity, leading to a desirable high SI value much greater than 
their toxic counterpart LMB. 
 
2.2.2 Effect SINEs have on intracellular localisation of viral proteins   
To determine whether SINEs inhibited viral replication at the stage of vRNP nuclear 
export, the intracellular localisation of viral NP was examined by immunofluorescence 
(IF). NP (the main component of the vRNP complex) localisation can act as a marker 
to determine whether the virus genome has undergone nuclear export late post-
infection (Amorim et al., 2011; Martin et al., 1999: Elton et al., 2005). A549 cells 
were mock infected or infected with PR8 at an MOI of 3 and incubated in the absence 
of compound (vehicle control; DMSO) or presence of an inhibitory concentration of 
SINEs (1 µM). LMB (10 nM) was used as a positive control for inhibition of vRNP 
nuclear export (Elton et al., 2001; Ma et al., 2001; Watanabe et al., 2001). At 8 h p.i., 
cells were permeabilized and immunofluorescently stained for viral NP (green) and 
cellular DNA (blue). Mock infected cells, in the absence (DMSO) or presence of drug 
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treatment, showed no NP staining (Fig. 2.3.A), indicating that the compounds did not 
induce any unspecific background noise. NP was not present in all cells analysed, 
indicating a lower than expected infection level for an MOI of 3 infection. This may 
be due to a discrepancy in the original titre of the PR8 stock used to calculate the MOI.  
As expected, in the absence of inhibitors, NP localised predominantly in the cytoplasm 
of infected cells, indicating nuclear export of the replicated viral genome had taken 
place. A similar pattern was observed with the inactive compound, KPT-301. In 
contrast, both KPT-185 and KPT-335 treated infected cells displayed mainly nuclear 
staining of NP. This NP nuclear localisation was comparable to the LMB treated cells, 
thus suggesting both KPT-185 and KPT-335 blocked the export of vRNPs. 
 
To assess the reproducibility of this effect, NP localisation was examined over a range 
(0.01 µM to 1 µM) of compound concentrations. Cells were imaged at random and 
infected cells were scored for whether NP was predominantly localised in the nucleus 
or the cytoplasm. No treatment, DMSO and KPT-301 controls showed <10 % of cells 
with NP nuclear retention, indicating that most had already exported the virus genome 
after the 8 h infection (Fig. 2.3.B). Almost all cells displayed NP nuclear retention at 
the higher concentrations of KPT-185 and KPT-335, as well as the LMB positive 
control. Intermediate amounts of the active drugs resulted in some, but not all, cells 
showing NP nuclear retention. By this measurement the IC50 concentration for NP 
nuclear export for KPT-185 and KPT-335 was ~0.09 µM and ~0.07 µM, respectively, 
comparable to the IC50 values established for single cycle virus replication (~0.26 µM 
and 0.04 µM) and multicycle infection (0.05 µM and 0.6 µM) (Fig. 2.1.A, Table 2.1). 
Overall these data suggest that SINEs block the export of vRNPs during later stages  
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Fig. 2.3. Effect of SINEs on intracellular localisation and accumulation of IAV 
NP. (A) SINEs block nuclear export of NP. A549 cells were mock infected or infected 
with PR8 virus at MOI 3 in the presence of SINEs (1 µM), LMB (10 nM) or the vehicle 
control (DMSO). 8 h p.i. cells were fixed, permeabilised and stained with anti-NP 
(green) as well as a nuclear stain (DAPI; blue) and imaged by confocal microscopy. 
Single optical slices are shown. (B) Quantification of NP nuclear retention after 
SINE/LMB treatment. A549 cells were infected as (A), and treated with increasing 
concentrations of SINEs or LMB (0.01 µM to 1 µM or 1 nM to 10 nM in 0.5 log10 
increments, respectively) and imaged as in (A). Cells with predominantly nuclear NP 
were scored. Counts were taken from three images per drug concentration from two 
independent experiments and are plotted as mean ± S.D..
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of infection: a similar mechanism to previously published reports with LMB (Elton et 
al., 2001; Ma et al., 2001; Watanabe et al., 2001). Previously published work with 
LMB demonstrates conflicting observations to whether CRM1 inhibition leads to 
nuclear retention of other viral proteins that contain a nuclear export signal (NES) 
and/or are involved in RNP nuclear export (Cao et al., 2012; Elton et al., 2001; Huang 
et al., 2012; Ma et al., 2001; Watanabe et al., 2001). To determine whether 
translocation of viral proteins other than NP were affected by treatment with SINEs, 
PB2, M1, NS2 and NS1 protein localisation was examined by IF. The HA and NA 
proteins were not examined due to the lower likelihood that these proteins would 
change in localisation in response to KPT-335 treatment Similar to the previous 
experiment (Fig. 2.3), A549 cells were mock infected or infected with PR8 at an MOI 
of 3 and incubated in the presence of the vehicle control (-drug) or KPT-335 (1 µM). 
At 8 h p.i. cells were fixed, permeabilised and immunofluorescently stained with anti-
NP, PB1, M1, NS2 and NS1. Mock infected cells incubated with the various primary 
antibodies displayed little to no unspecific background staining for any of the proteins 
examined. Cells stained with anti-NP (green) were used as a positive control for drug 
efficacy at the concentration used. As previously observed (Fig. 2.3.), NP was 
predominately localised to the cytoplasm in the absence of KPT-335, whereas in the 
presence of compound it localised to the nucleus of cells, indicating successful 
blockade of nuclear export. PB2, part of the vRNP complex, was examined as an 
example of a polymerase protein. PB2 localisation remained unchanged in the 
presence of KPT-335 with the polypeptide mainly localised to the nucleus of infected 
cells. M1 and NS2, both mediators involved in nuclear export of vRNPs (Eisfeld et 
al., 2014), showed no difference in localisation in the presence of compound,  
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Fig. 2.4. Effect of KPT-335 on localisation of IAV viral proteins. A549 cells were 
infected with PR8 virus at MOI 3 and treated with 1 µM of KPT-335. 8 h p.i. cells were 
fixed, permeabilised and stained with anti-NP (green), PB2 (red), M1 (green), NS2 
(red) or NS1(green) and a nuclear stain DAPI (blue). Images were taken as single 
optical slices. Data are representative of 2 independent experiments.
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displaying a mixed nuclear and cytoplasmic staining pattern similar to that of NP 
without compound. Although NS1 contains a NES, there is limited published evidence 
to suggest its involvement in CRM-mediated transport (Huang et al., 2012; Tynell et 
al.,  2014). Similar to M1 and NS2 localisation, NS1 also displayed unchanged 
nuclear/cytoplasmic location after drug treatment. Thus, of the viral proteins 
examined, only NP localisation was affected by KPT-335 treatment. Although the 
other proteins analysed have been reported to be involved in nuclear export, the 
nuclear/cytoplasmic localisation of M1, NS2 and NS1 and the nuclear localisation of 
PB2 was unaltered after treatment with the compound. This data supports the 
hypothesis that NP is the most suitable viral protein to be used for determination of 
whether the virus genome has undergone nuclear export during late stages of infection. 
 
2.2.3 Time dependent efficacy of KPT-335 
The hypothesis that SINEs act by blocking nuclear export of the viral genome predicts 
that the compounds should act only when added during the first half of the virus 
lifecycle. Accordingly, a time of drug-addition assay was performed, where KPT-335 
was added at various time points during virus infection and NP localisation as well as 
overall virus replication examined. A549 cells were mock infected or infected with 
PR8 at an MOI of 3 and KPT-335 was added before (-1 h), at the time of infection (0 
h) or at varying times post-infection (+1, 2, 4, 6 and 8 h). Mock infected and infected 
but untreated (no drug) cells were included as controls. For IF analysis, the infection 
was stopped at 9 h p.i., while virus supernatant was harvested at 16 h p.i. for titre 
analysis. As expected, mock infected cells showed no NP staining and infected 
untreated cells displayed mostly cytoplasmic staining as observed previously (Fig.  
 68 
 
Fig. 2.5. Time-dependent efficacy of KPT-335. A549 cells were infected or (mock 
infected) with PR8 virus at MOI 3. Drug (0.3 µM) was added before infection (-1 h), 
at the time of infection (0 h) or at 1, 2, 4, 6 and 8 h p.i, as well as a no drug control. 
(A) NP localisation after addition of KPT-335. 9 h p.i. cells were fixed, permeablised 
and stained with anti-NP (green) and a nuclear stain (DAPI; blue). (B) Virus titres after 
addition of KPT-335. Cell supernatants were harvested at 16 h p.i. and virus titres 
determined by plaque assay. Data are the mean ± S.D. of 2 independent experiments.
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2.5.A). NP was retained in the nucleus of infected cells when KPT-335 was added 
before (-1), during (0 h) and up to 4 h p.i.. However, when compound was added at 6 
h or 8 h p.i., NP staining was seen in both the nucleus and the cytoplasm of infected 
cells, similar to the localisation of NP in the no drug-treated control cells. The 
corresponding titre data showed that addition of the drug at any time point prior to and 
including 4 h p.i. led to highly effective suppression of virus replication, whereas drug 
addition at 6 h p.i. was less effective and drug added at 8 h p.i. caused only a minor 
decrease in viral titre (Fig. 2.5.B). Since previous studies indicated that nuclear export 
of replicated vRNPs begins after ~5 h p.i. (Elton et al., 2005; Elton et al., 2001 Martin 
et al., 1991), these data are consistent with the drug acting by inhibiting nuclear export 
of the viral genome. These data further support the conclusion drawn from the NP IF 
analysis in Fig. 2.4., that SINEs were acting at the stage of RNP nuclear export. 
 
2.2.4 Viral gene expression after treatment with SINEs 
Nuclear localisation of NP at later times of infection can reflect a block to nuclear 
export of the viral genome, but can also suggest slower kinetics of virus replication, 
with NP acting as a visual ‘clock’ of virus infection (Elton et al., 2005; Martin et al., 
1991) . To assess whether SINEs were inhibiting viral gene expression, accumulation 
of NP, M1 and NS2 was examined by western blotting. A549 cells were mock infected 
or infected with PR8 at an MOI of 3 and treated with increasing concentrations of 
KPT-335 or left untreated (-). LMB and KPT-301 were included as controls. At 8 h 
p.i., total cell lysates were harvested and blotted for NP, M1, NS2 as well as cellular 
tubulin as a loading control. Mock infected samples did not contain viral proteins, as 
expected (Fig. 2.6). All drug-treated infected samples contained similar amounts of  
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Fig. 2.6. Viral gene expression after SINE treatment in a single cycle growth 
assay. A549 cells were infected (or mock infected) with PR8 virus (MOI 3), treated 
with increasing concentrations of KPT-335/KPT-301, LMB (0.01 µM to 1 µM or 1 nM 
to 10 nM in 0.5 log10 increments, respectively (as depicted with white triangle)) or with 
a DMSO control (-). Cells were harvested at 8 h p.i. and total cell lysates analysed by 
SDS-PAGE and western blotting for viral NP, M1 and NS2 as well as cellular tubulin 
as a loading control.
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NP, M1 and NS2 protein compared to the untreated infected samples as well as 
similar amounts of viral proteins between treatment groups. Thus, as previously 
defined for LMB (Elton et al., 2001), SINEs did not generally inhibit IAV gene 
expression in a single round of replication. 
 
2.2.5 KPT-185 has a lower antiviral efficacy compared to KPT-335 in 
plaque reduction assays 
To assess the efficacy of SINE compounds against IAV infection further, plaque 
reduction assays were performed. Optimisation of this assay was central to future drug 
resistance investigations presented in subsequent chapters. This assay determines drug 
efficacy by observing the compounds’ direct effects on the plaque number and/or the 
plaque size in tissue culture.  MDCK cells were infected with 100 plaque forming 
units (PFU)/ml of PR8. After 1 h incubation with the virus, cells were grown under 
inhibitory concentrations (1 µM) of KPT-185, KPT-335 or KPT-301 or in the presence 
of DMSO. At 48 h p.i., cells were fixed and stained with toluidine blue to visualise 
plaque formation. Consistent with previous results, KPT-301 had no effect on the 
number of plaques when compared to DMSO-treated control (Fig. 2.7.A). Infection in 
the presence of 1 µM of KPT-185 gave around a 50 % reduction in plaque number 
compared to the DMSO-treated cells, while cells treated with KPT-335, at the same 
concentration, almost totally eliminated plaque formation. No obvious difference in 
plaque size was observed for any drug treatment. These results suggested KPT-335 




Fig. 2.7. Efficacy of SINEs by plaque reduction assay. MDCK cells were infected 
with PR8 virus at 100 PFU/well in the presence of increasing concentration of SINEs. 
(A) Plaque reduction assay. 48 h p.i. cells were stained with toluidine blue and 
imaged. (B) Relative plaque numbers. Plaque counts were taken from three 
independent experiments and data plotted as mean ± S.D.. Curves were fitted using 
a non-linear regression model. (C) IC50, 95 % CI and R2 values obtained from the 
curves fitted in (B). 
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To determine the reproducibility of these results, the plaque reduction assays were 
carried out over a range of compound concentrations. Infected cells were treated with 
increasing concentrations of compounds, starting at 0.01 µM and increasing in 0.5- 
log10 increments to 1 µM. As expected, KPT-301 had no effect on plaque number over 
the range of drug concentrations tested (Fig. 2.7.B). As a reduction in plaques was not 
observed a non-linear regression model could not be fitted and thus an IC50 value could 
not predicted for this data set. Unexpectedly, KPT-185 only suppressed plaque number 
at the highest concentration (1 µM), with a ~50 % reduction in plaques compared to 
the DMSO control. An IC50 value of 1.02 µM (with a wide range of uncertainty) was 
determined by fitting the data to a non-linear regression model (Fig. 2.7.C). This was 
contradictory to the dose-response replication data exhibited in Fig. 2.1, which showed 
KPT-185 to be inhibitory at concentrations substantially lower than 1 µM with an IC50 
value of 0.05 µM. In comparison, KPT-335 reduced plaque number by ~60 % at a 
concentration of 0.3 µM and completely inhibited plaque formation at 1 µM with a 
subsequent IC50 value of 0.18 µM; a value more comparable to the tire data in Fig. 
2.1., which gave an IC50 of 0.06 µM. However, for both compounds, measuring drug 
susceptibility by plaque reduction did not appear to be as sensitive an assay as 
measuring the titre of replicated virus from liquid supernatant. Based on the above 
data, the decision was made to remove KPT-185 from further experimentation and 
continue with KPT-335 only.  
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2.2.6 Efficacy of KPT-335 against a panel of human and animal IAV 
strains  
To establish whether KPT-335 had general antiviral potency against a variety of 
influenza strains, the compound was tested against a panel of human and animal 
(equine, avian and swine) isolates of IAV, by measuring the endpoint titres of 
multicycle replication assays. As described previously for PR8 (Fig. 2.1.D), A549 
cells were infected with virus at an MOI of 0.01 and treated with increasing 
concentrations of KPT-335. The compound was tested against a swine (H1N1), two 
duck (H4N6, H5N3) and an equine (H3N8) derived viruses as well as a human isolate 
(H3N2). Sensitivity to a recombinant virus, PR8 MUd, was also analysed as this virus 
would be used in drug-resistant investigations in the subsequent chapter. At 24 h p.i., 
cell supernatants were taken and virus titre determined by plaque assay. Dose-
response curves were fitted to the data (Fig. 2.8) and IC50 values were determined. 
Selective indexes were calculated using the A549 CC50 value obtained from data 
analysis in Fig. 2.1.A. and results are shown in Table 2.2. KPT-335 was found to be 
antiviral against all strains tested, displaying dose-dependent inhibition of virus 
replication, with subsequent IC50 values ranging between 0.004-0.03 µM (Table 2.2). 
Additionally, selective indexes were high for all strains, varying from 87 to 650. Both 
the IC50 values and selective indexes were comparable to the values calculated 
previously for the human lab-adapted strain PR8 (0.04 µM). To quantify the sensitivity 
of KPT-335 between viruses, non-linear regression curves were fitted to the data. 
Results were inconclusive due to the curve fits for some strains (in particular 
A/duck/England/62 and A/equine/Miami/63); thus any differences in drug-sensitivity 
between strains could not be reliably determined. Nevertheless, none of the IC50 values 
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Fig. 2.8. Efficacy of KPT-335 against human and animal IAV strains. A549 cells 
were infected with indicated viruses at MOI 0.01 and treated with increasing 
concentrations of KPT-335 from 0.01 µM. Virus supernatant was taken 24 h p.i. and 
titred by plaque assay. Data are the mean ± S.D. of two independent experiments. 
Curves were fitted using a non-linear regression model.
 
































A/Udorn/72 H3N2 Human 0.02 0.01 to 0.04 0.8 130 
PR8 MUd H1N1 PR8 containing seg7 from Udorn 0.02 0.01 to 0.03 0.9 130 
A/swine/England/453/06 H1N1 Swine (Eurasian)  0.02 0.004 to 0.4 0.6 130 
A/duck/England/62 H4N6 Avian 0.004 0.004 to 0.03 0.5 650 
A/duck/Singapore/5/97 H5N3 Avian 0.03 0.01 to 0.07 0.7 87 
A/equine/Miami/63 H3N8 Equine 0.01 9e-5 to 0.2 0.3 260 
A 
IC50  - the concentration of drug that is required for 50 % virus inhibition  
B 95 % confidence interval (CI) - probability that a value will fall between an upper and lower bound of a probability distribution (0.95) 
C R2 - statistical measure of how close the data are to the fitted regression line 
D 
Selective index (SI) – A549 CC501/IC50 
1 A549 CC50 value2 = 2.6 µM 
2 CC50 - the concentration of drug that is required for 50 % cytotoxicity
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were significantly different even between those strains with better R2 values and 
narrower CI limits for the IC50 estimates. Overall, these results demonstrate a 
relatively broad anti-influenza A virus activity of KPT-335 in vitro. Evidence for 
general activity against IAV was important data to obtain to justify further 






































2.3 Discussion  
 
In this chapter, the antiviral activity of selective inhibitors of nuclear export (SINEs) 
against IAV were characterised in vitro. The company, Karyopharm, developed 
SINEs KPT-185 and KPT-335 to transiently bind to the CRM1 cargo binding site and 
subsequently inhibit export of proteins exploiting this pathway with less cytotoxic 
effects than their fungal toxic counterpart, LMB. Although SINEs were initially 
developed as anti-cancer agents, Karyopharm acquired evidence to suggest SINEs 
inhibited influenza virus infection. Subsequently, in collaboration with Karyopharm, 
tests were carried out to confirm this hypothesis.  
 
The inhibitors, KPT-185 and KPT-335, successfully reduced replication of the 
laboratory-adapted human H1N1 virus (PR8) replication in a dose-dependent manner 
with little toxic effect on a human lung cell line (A549) and as well as on the ‘gold-
standard’ mammalian cell line (MDCK) for growing IAV (Fig. 2.1.A, B). Typically, 
compounds that target a host cell factor are suspected to have greater toxic side effects. 
The low cytotoxicity observed for SINEs may be explained by the mechanism in 
which SINEs transiently bind to CRM1. Although this reversible interaction would 
also block host proteins that utilise the CRM1 export pathway, they would not be 
blocked permanently. The covalent nature of the LMB-CRM1 interaction is likely the 
reason why LMB is so overtly toxic as it would essentially bind indefinitely to CRM1, 
thus affecting host cell export functions in the long term.   
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This study was supported by Karyopharm, who also supported studies in Professor 
Ralph Tripp’s laboratory (USA). The Tripp group has published two papers on this 
subject since 2014. The first paper by Perwitasari et al., (2014) investigated the 
efficacy of the novel SINE compound KPT-335 in vitro. They determined an IC50 
value of 0.02 µM for the human H1N1pdm09 strain, A/California/04/09, which was 
very similar to the KPT-335 multicycle IC50 of 0.04 µM determined for the H1N1 PR8 
strain in this study. The Perwitasari study determined an  KPT-335 CC50 value of 26.8 
µM, which was 10 times greater than the CC50 value determined in this study: 2.6 µM. 
Perwitasari et al., used a Toxilight (Adenylate kinase (AK) enzyme quantification) 
assay to determine cytotoxicity whereas in this study the CellTiter-Glo (ATP 
quantification) was used. An evaluation study of commercial cytotoxicity assays 
indicated that the CellTiter-Glo assay was ~50 % more sensitive than the Toxilight 
assay (Peternel et al., 2009). Additionally, CellTiter-Glo was found to be the most 
reproducible cytotoxicity assay in comparison to other assays tested. These data 
suggest that CellTiter-Glo assay is more a more accurate assay to determine CC50 and 
thus may explain the discrepancy in the CC50 values between the Perwitasari study 
and this one.  
 
The low cytotoxicity and low inhibitory concentration values of the SINEs led to a 
desirable high selective index (Table 2.1). For KPT-335, this was over 15 times higher 
than its toxic counterpart LMB, indicating its potential as a therapeutic agent. KPT-
335’s antiviral activity against a range of human and animal IAV strains confirmed 
that the compound could be used as an effective broad-spectrum antiviral (Fig. 2.8). 
No significant differences were observed between the IC50 values of the range of 
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strains tested which included human, avian, equine, and swine origin. There was a 
slight discrepancy in the Eq/Miami and Dck/Sing strains due to the poor curve fits as 
indicated by the low R2 values.  The avian/equine virus replication was performed in 
a human cell line (A549 cells) and may be suboptimal growth conditions, explaining 
the poor curve fits. The use of a suitable animal cell line (i.e. avian and equine) would 
perhaps have been a better model to measure the drug efficacy against these strains. 
This may also explain why these subtypes were slightly more sensitive to the 
compound at lower concentrations compared to the other strains examined. 
Nevertheless, both viruses displayed reduced overall growth in A549 cells compared 
to PR8 and the other strains examined. These results are supported by previously 
published work (Perwitasari et al., 2014) in which KPT-335 was tested against a wide 
range of IAV strains including human (H1N1, H3N2) and avian (H5N1, H7N3, H7N9) 
viruses as well as, influenza B strains. The authors found little to no differences in 
efficacy of the compound between the strains tested, with an IC50 value range between 
0.01-0.4 µM, comparable to the IC50 values in this study (0.004-0.03 µM). Their data 
support the findings in this chapter suggesting that all IAV strains make use of the 
CRM1 export pathway irrespective of their subtype and origin. If use of the CRM1 
pathway is a general feature of IAV infection, KPT-335 would be a highly desirable 
antiviral candidate especially when considering pandemic outbreaks, where the 
subtypes and host source cannot be predicted.  
 
The Tripp group’s second paper, by Perwitasari et al., (2016), investigated KPT-335 
efficacy further by examining its antiviral activity against IAV infection in two animal 
models; mice and ferrets. The study, which used A/California/04/09 (H1N1 – a 2009 
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pandemic strain), concluded that KPT-355 reduced virus shedding, pro-inflammatory 
cytokines and inflammatory cell infiltration in a mouse model, as well as limiting IAV 
replication, lung pathology and inflammation in ferrets. The Perwitasari et al., data 
provided further evidence for KPT-335’s potential as a successful therapeutic antiviral 
agent against IAV infection. 
 
The mechanism by which the SINE compounds inhibit IAV was hypothesised to be 
the same as LMB, as their development was based on the fungal-derived inhibitor, 
which has been previously shown to block export of vRNPs via CRM1 inhibition 
(Elton et al., 2001; Kudo et al., 1999; Nishi et al., 1994). By IF analysis, both KPT-
185 and KPT-335 were found to inhibit nuclear export of vRNPs as effectively as 
LMB (Fig. 2.3.A). IF examination of infected SINE-treated cells showed 
accumulation of NP in the nucleus, indicating inhibition of virus export, which was 
reproducible in dose-response experiments (Fig. 2.3.B). IC50 values for NP nuclear 
retention efficacy were comparable to the dose-dependent inhibitory concentrations 
calculated for Fig. 2.1.A.B. Further confirmation that the SINE compounds were 
targeting nuclear export of viral proteins was determined by a time of drug-addition 
assay. Virus replication was suppressed (Fig. 2.5.B) and NP export blocked (Fig. 
2.5.A) when KPT-335 was added any time point prior to and including 4 h p.i. 
Previously published work indicates nuclear export of the viral genome takes place 
around 5 h p.i. (Elton et al., 2001), therefore these data support the IF data presented 
in Fig. 2.3., i.e. that the compound was acting at the stage of nuclear export the vRNPs.    
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IF analysis of other viral proteins revealed no difference in the localisation of NS1, 
PB2, M1 or NS2 after treatment with KPT-335. NS1 is known to be involved in 
interaction with mRNA export machinery pathways including NXF1, Tap15 and Rae1 
(Larsen et al., 2014; Satterly et al., 2007; Wang et al., 2015, Pereira et al., 2017), 
however currently there is limited evidence to suggest its direct involvement in 
CRM1-mediated export. All NS1 proteins have a well-conserved leucine rich-NES 
motif (Tynell et al., 2014), therefore it may be hypothesised that NS1 could be directly 
recognised by CRM1 through this domain. However, a FRET analysis conducted by 
Han et al., (2010) revealed that a transiently expressed NS1 protein did not directly 
interact with CRM1. Additionally, Tynell et al., (2014), examined the localisation of 
NS1 during IAV infection after LMB treatment by IF using NP as a positive control 
for nuclear retention. The authors discovered little difference in the localisation of 
NS1 in the untreated and LMB-treated cells with most cells displaying both nuclear 
and cytoplasmic NS1 staining. These data are comparable to the results found in Fig. 
2.5, where KPT-335 did not alter the nuclear/cytoplasmic localisation of NS1. This 
suggests CRM1-inhibition was inefficient at blocking nuclear export of NS1, 
indicating that the export of this protein is possibly independent or only partially 
dependent on CRM1.  
 
Similarly to what was observed for NS1, KPT-335 did not alter PB2’s localisation 
(Fig. 2.5.). However, in contrast to NS1, PB2 staining appeared to be predominantly 
nuclear. There is some evidence to suggest that the bulk of the polymerase proteins in 
the nucleus may not be RNP-associated (Loucaides et al., 2009). If most PB2 
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molecules are not RNP-associated, then any change in the localisation of the minority 
population bound to vRNPs after KPT-335 treatment may not be detected.  
 
M1 and NS2 have been implicated as adaptor proteins involved during CRM1-
mediated export of vRNP complexes. Both M1 and NS2 nuclear/cytoplasmic 
localisation was unaltered after KPT-335 treatment (Fig. 2.5) which is comparable to 
previous studies using LMB, which also found that the intracellular distribution of M1 
was not changed by LMB during infection (Elton et al., 2001; Ma et al., 2001). 
Additionally, Cao et al., (2012), found that the localisation of a GFP-M1-NES 
recombinant protein was also unaltered after LMB treatment. These data and the 
results displayed in this study, suggest M1 is not necessarily exported with RNPs in a 
detectable amount as analysed by IF. A previous study demonstrated that a virus 
lacking the NES1 of NS2 was retained in the nucleus of the cell after treatment with 
LMB, suggesting NES1 within the NS2 protein is necessary for CRM1-dependent 
export (Huang et al., 2012). However, similar to M1, NS2 localisation also remained 
unchanged after treatment with LMB (Ma et al., 2001), suggesting that vRNP nuclear 
export does not involve the bulk of M1 and NS2. The unchanged location of NS2 may 
suggest there is an excess of NS2 in nucleus with only a minor fraction of NS2 required 
for CRM1-export, or that the transport of NS2-RNP complexes is too transitory to be 
examined by IF.  
 
CRM1 generally actively transports molecules over 42 kDa through the nuclear pore 
complex (NPC) (Hutten & Kehlenbach, 2007). Given that M1 and NS2 are 28 kDa 
and 11 kDa in size, respectively (NP = 52kDa), they may export via an CRM1-
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independent pathway, possibly by passive diffusion. Therefore, another potential 
explanation for the unchanged M1 and NS2 localisation may be that a larger 
proportion of these proteins are transported out the nucleus via passive diffusion and, 
as mentioned previously, a smaller proportion of M1 and NS2 are required for CRM1-
mediated export. Arguing against this notion, a previous study by (Zhao et al., 1998) 
found that newly synthesised M1 oligomerizes into both dimers and mulitrimers in 
vivo, therefore exceeding the molecular mass limit (>40 kDa) for passive diffusion. 
Therefore, another explanation for the unchanged M1 location could be that inhibition 
of CRM1 does not stop M1 transport as the compounds do not block M1 and CRM1 
binding, if they are interacting directly, or perhaps M1 may interact with other 
undefined cellular adapters. Consequently, differentiating between M1 and NS2 
transported by CRM1 as part of the vRNP complex or whether they have been 
transported by passive diffusion would not be possible by the IF method presented and 
therefore the effect SINEs had on the localisation of these proteins would be 
undetectable.  
 
Western blotting analysis revealed that inhibition of nuclear export by SINEs did not 
affect viral gene expression (Fig. 2.6), suggesting inhibitors are not slowing virus 
replication kinetics upstream of the nuclear export process under single cycle 
replication conditions. The data were comparable to previously published work for 
LMB, where there were no differences in the level of protein synthesis of HA0, NP or 
M1 between treated and untreated PR8 infected BHK cells (Elton et al., 2001), 
confirming that there is no evidence to suggest CRM1-inhibitors act by altering viral 
protein levels. The direct or indirect effect the natural CRM1 inhibitor, LMB, has on 
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other export functions is undefined, whereas Karyopharm state SINE compounds were 
designed to act specifically by targeting CRM1 with no off-target effects 
(https://www.karopharm.com). Published reports indicate that CRM1 is not utilised 
by influenza mRNAs for export from the nucleus. This has been examined in multiple 
cell lines including MDCK, BHK, 293T and A549 cells (Amorim et al., 2006; Elton 
et al., 2001; Hughes, 2000; Larsen et al., 2014; Read & Digard, 2010; Satterly et al., 
2007; Wang et al., 2015). These data and the data presented in this section supports 
Karyopharm’s claim, as SINEs inability to inhibit protein synthesis suggests the 
compounds directly target CRM1 and other cellular nuclear export pathways, such as 
those used to transport mRNAs, remain unaffected.  
 
Antiviral activity of SINEs analysed by plaque reduction assay revealed that KPT-185 
was less potent against IAV replication compared to KPT-335 (Fig. 2.7). The reduced 
efficacy of KPT-185 may be explained by a possible loss in stability of the compound 
over the longer time-period of this assay (48 h) as the previous multi-cycle and single 
infection assays were carried out over 16-24 h (Fig. 2.1.C (24 h), Fig. 2.2.D (16 h)), 
implying KPT-185’s in vitro effective-life to be <48h. However, no further 
investigation was performed to validate this notion. As stated previously, plaque 
reduction assays performed with a sub-optimal inhibitory concentration were a key 
experimental approach for future investigations into potential drug-resistance of the 
compounds. Therefore, further experimentation in this thesis was conducted with 
KPT-335 only. Furthermore, since the start of this study, Karyopharm Therapeutics 
removed KPT-185 from their pipeline and defined KPT-335 as their lead compound 
in development for the treatment of viral infections, available at 
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https://www.karopharm.com [Accessed on 06/2015]. This information, combined 
with the plaque reduction data, supported the decision to continue only with KPT-335.  
 
The data described in this chapter determine that SINEs inhibit IAV at the stage of 
nuclear export by targeting the cellular CRM1 protein and that SINE KPT-335 was 
effective at inhibiting a broad-range of IAV strains. As previously described in chapter 
1, the emergence of drug-resistant escape variants is a major problem hindering the 
effectiveness of existing antiviral therapies. Therefore, the potential of a drug-resistant 
IAV mutant emerging should be examined in vitro when considering a novel antiviral 
therapy. The next line of investigation was to determine the ability for a KPT-335-
















Chapter 3 Generating an influenza A virus strain 
resistant to the nuclear export inhibitor, KPT-335.  
 
3.1 Introduction  
 
Present anti-influenza virus therapies are hindered by the rapid generation of 
resistance. The lack of a ‘proofreading’ function in the influenza virus polymerase 
results in a high error rate, leading to mutations that allow the virus to overcome 
certain selection pressures and develop resistant variants to current antivirals such as 
amantadine and oseltamivir. Amantadine was the first antiviral shown to inhibit IAV, 
working by blocking ion channel activity of the M2 and it has been used for >30 years. 
This has led to the rapid emergence of drug-resistant viruses that result from by single 
amino acid substitutions within the M2 protein. Consequently, amantadine is no 
longer recommended as antiviral agent (Dong et al., 2015). To combat this problem, 
there is growing interest in the prospect of inhibiting cellular targets as, if the toxicity 
problem can be solved, the generation of resistance will be predicted to be slower 
(Watanabe & Kawaoka, 2015). As described in chapter 2, KPT-335 is a broad-
spectrum nuclear export inhibitor exhibiting relatively low cytotoxicity in vitro. The 
US-based pharmaceutical company, Karyopharm Therapeutics, are aiming to develop 
their clinical stage anti-cancer drug, KPT-335, as a potential antiviral drug.  
 
The US Food and Drug Administration (FDA) recommend that the in vitro selection 
of resistant viruses to a potential antiviral therapy should be examined before 
commencing with clinical studies of infected patients (www.fda.gov, guidance for 
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industry #213, 2013). Although resistance data generated in vitro will not necessarily 
predict the potential for clinical resistance, selection of drug-resistant virus variants 
can provide an insight into whether the genetic threshold for resistance to develop is 
high or low, as well as providing understanding of the proposed mechanism of action 
of the investigational compound. Investigation into the genetic barrier for a given 
target may help determine if single or multiple mutations are required for resistance 
and if the resistance gain will affect viral fitness. Although in vitro resistance 
development may not correlate to a similar pattern clinically, these types of studies 
will help the understanding of the resistance potential of drug, which in turn will help 
select viral traits that should be targeted in order to avoid rapidly developing 
resistance. Therefore, the next step for development of KPT-335 as an antiviral for 
IAV was to determine the compound’s resistance potential.    
 
The aim of this chapter was to test whether viral variants resistant to the CRM1-
inhibitor KPT-335 could be generated upon serial passage of an H1N1 lab-adapted 
IAV in the presence of sub-optimal concentrations of the drug. Potential drug-resistant 
viruses were then characterised phenotypically by plaque reduction assays and IF 
analysis. Genotypic analysis was then carried out by sequencing relevant IAV genes 
to identify any mutational changes. An outline of the experimental strategy used in 































Fig. 3.1. Flow diagram describing the experimental strategy for producing a 





















3.2.1 Serial passage of IAV in the presence of KPT-335 
To assess whether it was possible to develop a KPT-335 resistant IAV strain, multi-
passage experiments were performed. Five independent passages were carried out, 
designated R1-R5, in the presence of either 0.15 µM or 0.3 µM KPT-335. Amantadine 
was used as a positive control (AC) for selection of drug-resistant virus variants since 
resistance is readily produced (Hurt et al., 2016). PR8 is already resistant to 
amantadine, therefore a PR8 reassortant virus which contains an M segment from 
Udorn that confers amantadine susceptibility (as well as a filamentous budding 
phenotype) (Noton et al., 2007) was used for serial passage with amantadine in the 
first 3 serial passage experiments (R1-R3). For reasons that will become apparent, two 
further passage experiments (R4 and R5) were subsequently carried out with WT PR8 
and only KPT-335 as the selective pressure. A549 cells were infected with viruses at 
an MOI of 0.001 in the presence of the vehicle control (DMSO), amantadine or KPT-
335. A very low MOI was used to perform the serial passage under multi-cycle 
infection conditions and reduce the likelihood of the production of DIPs (as discussed 
later). Details of the conditions for each passage experiment are described in Table 
3.1. After 48 h p.i., supernatant was harvested and viral titre determined by plaque 
assay. The progeny viruses were then passaged again under the same conditions for a 
total of 10 (R1-R3) or 9 (R4, R5) passages. As the two blocks of serial passages were 
carried out independently, each set had a matching DMSO control. As expected, virus 
passaged in the presence of DMSO generally replicated well, producing titres that 
fluctuated around 107-108 PFU/ml over the course of the two blocks of experiments 
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DMSO (1) PR8 MUd DMSO - 10 
R1 PR8 MUd KPT-335 0.15 10 
R2 PR8 MUd KPT-335 0.15 10 
R3 PR8 MUd KPT-335 0.3 10 
DMSO (2) PR8  DMSO - 9 
R4 PR8 KPT-335 0.15 9 
R5 PR8 KPT-335 0.3 9 
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(AC/R1-R3 and R4/R5) (Fig. 3.2). Treatment with amantadine initially inhibited virus 
replication to 105 PFU/ml at passages 1 and 2 (P1, 2) but the titre then increased to    
107 PFU/ml at P3 (Fig. 3.2 AC). Apart from a dip in viral tire at P8 (potentially due to 
a technical error) the virus appeared unaffected by amantadine treatment thereafter, 
suggesting that the virus was resistant to the drug (discussed further in section 3.3). 
For the five serial passages carried out with KPT-335, the drug initially suppressed 
viral titre at P1, as expected. For passages performed with 0.15 µM KPT-335 (R1, R2, 
R4), replication was initially knocked down to 105 PFU/ml and for passages 
performed with 0.3 µM drug (R3 and R5), inhibited to 103 PFU/ml. Thereafter, all 
KPT-335 passages produced rises in titre up until P3. However, with the exception of 
R4 (which kept generally high titres up until P10), decreases in titre were then 
observed at P4-5, followed by fluctuating titres that mostly produced a final increase 
in titre from P8 to P9 (R4 and R5) and P10 (R2 and R3). These patterns of rising and 
falling titres were unexpected, but nevertheless suggested the viruses were no longer 
susceptible to KPT-335 by the end of the passage experiments. 
 
3.2.2 Determination of drug-resistant IAV by plaque reduction assay 
To establish at what stage the R1-R5 viruses became resistant to the compound, KPT-
335 drug sensitivity at early (P3), middle (P6) and late passages (P9/10) was assayed 
by plaque reduction experiments. MDCK cells were infected with 100 PFU/ml of 
DMSO-passaged virus or R1-R5 viruses from the multi-passage experiments and 
incubated in the presence of DMSO (-) or KPT-335 at 0.3 µM (+) or 1 µM (++). At 
48 h p.i., cells were fixed and stained with toluidine blue to visualise plaque formation. 
As expected, plaque formation was inhibited by KPT-335 in cells infected with the 
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 Fig. 3.2. Serial passage of IAV in the presence of a sub-optimal inhibitory 
concentration of KPT-335. A549 cells were infected with PR8 MUd or PR8 (MOI = 
0.001) in the presence of 0.3 µM (R3 and R5) or 0.15 µM (R1, R2 and R4) of KPT-
335, as well as the vehicle control (DMSO). 9 or 10 passages were carried out and 
after each, the virus titre (PFU/ml) was determined by plaque assay before setting 
the next passage up. 5 independent serial passages were performed in two blocks, 
named (R1-R3 and R4, R5 respectively) as well as an amantadine control (AC, 30 
µM)
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DMSO (P3 and P6) viruses at both drug concentrations, while all viruses gave 
abundant numbers of plaques in the absence of drug (Fig. 3.3). However, phenotypic 
differences were apparent in the plaque morphology of the R1-R4 pools, with the 
viruses producing noticeably smaller and/or hazier foci of CPE than the control 
passaged virus. R1 and R2 virus pools at P3 formed few plaques in the presence of 0.3 
µM of drug (+) and little to no plaques were observed after treatment with 1 µM (++) 
of KPT-335. Infections with R3-R5 virus pools harvested at P3 displayed little to no 
plaques at either of the drug concentrations tested. Thus, although all virus pools 
replicated to notably higher titres at P3 than P0, this did not correspond with a drug-
resistant phenotype as assessed by plaque reduction assay. At P6, R1-R5 viruses 
remained mostly susceptible to the compound although R1, R2 and R4 presented ~10-
20 plaques under the growth of the lower concentration of compound. No P6 virus 
presented unambiguous plaques at the higher concentration of drug. However, by this 
point all drug-passaged virus pools had a small plaque phenotype in the absence of 
compound, with the R1 population in particular producing poor CPE in comparison 
to the large, clearer plaques demonstrated by the DMSO control virus, suggestive of 
a fitness loss in the absence of the drug. Overall, these data indicated that although the 
P6 viruses had been altered by the selection pressure, they were still susceptible to the 
compound and true drug resistance had not yet developed.  
 
To determine if the concluding P9 (R4 and R5) and P10 (R1-R3) viruses were resistant 
to KPT-335, plaque reduction assays were carried out as before. Once again, DMSO 
(P10) virus plaque formation was inhibited at both concentrations of KPT-335 (Fig. 
3.4). However, the R1-R4 viruses produced abundant plaques in the presence of 0.3  
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Fig. 3.3. Determination of drug-resistant IAV at P3 and P6 by plaque reduction 
assay. MDCK cells were infected with 100 PFU/well of virus harvested at passage 3 
and 6 (P3, P6) for each independent serial passage (R1-R5) as well as the DMSO 
vehicle control (DMSO). Infected cells were grown in the presence of KPT-335 at a 
concentration of 0.3 µM (+) or 1 µM (++) or in the absence of compound (-). 48 h p.i. 
cells were fixed and stained with toluidine blue and imaged. Images representative of 
2 independent experiments.  
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µM of KPT-335, in similar numbers to the corresponding untreated controls. The R3 
population gave smaller plaques in the presence of the compound, while R4 pool 
plaques were not obviously different in size. Curiously however, the R1 and R2 virus 
pools displayed clearer plaques in the presence of 0.3 µM of compound compared to 
the untreated control. R1 and R2 viruses also produced smaller numbers of 
unambiguous plaques in the presence of 1µM of drug, while the R3 and R4 
populations gave a few foci of possible CPE. R5 infected cells did not produce plaques 
in the presence of both 0.3 µM and 1 µM of compound, with a similar phenotype to 
the DMSO control virus.  
 
Overall, these data provided substantial evidence that serially passaged viruses R1-R4 
had become resistant to KPT-335 by passages P9/10, while the variance in numbers 
and morphologies of plaques between the serial passages suggested differences in the 
degree of resistance. Although R5 appeared to be less sensitive to the compound in 
the multi-cycle growth experiment (Fig. 3.2.), by plaque reduction assay this virus 
population did not present a clear resistant phenotype. Additionally, R1, R2 and R4 
resistance was associated with a small plaque phenotype in the absence of compound 
suggesting the gain of resistance had reduced the fitness of these viruses.  
 
3.2.3 NP localisation of drug-resistant IAV after KPT-335 treatment   
As presented in the previous chapter, KPT-335 inhibits IAV replication by blocking 
vRNP nuclear export. To determine if the P10 drug-resistant viruses had escaped this 
repressive mechanism, NP intracellular localisation in the presence and absence of 
compound was analysed. A549 cells were mock infected or infected with P10 R1 or  
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Fig. 3.4. Confirmation of drug-resistant IAV at passages 9 and 10.   MDCK cells 
were infected with 100 PFU/well of virus harvested at passage 10 (R1-R3) or passage 
9 (R4, R5) as well as the DMSO vehicle control. Infected cells were grown in the 
presence of KPT-335 at a conc. of 0.3 µM (+) or 1 µM (++) or in the absence of 
compound (-). 48 h p.i. cells were fixed and stained with toluidine blue and imaged.
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R3 virus stocks or with a DMSO-passaged P10 virus as a control and grown in the 
presence of DMSO only or (0.3 µM or 1 µM) KPT-335. At 8 h p.i., cells were fixed, 
permeabilized and stained immunofluorescently for viral NP (green) and cellular 
DNA (blue). As expected, mock-infected untreated and treated cells did not show NP 
staining while, infection with the DMSO P10 (positive control) virus in the absence 
of compound produced cytoplasmic NP staining (Fig. 3.5), indicating normal export 
of vRNPs had taken place. Complete nuclear retention of DMSO P10 virus NP was 
observed after treatment with 1 µM of KPT-335 and partial retention at 0.3 µM, 
indicating that the drug had inhibited nuclear-cytoplasmic transport the of the viral 
genome. In contrast, for both P10 R1 and R3 virus pools, NP was no longer fully 
retained in the nucleus at 1 µM KPT-335m unlike the control virus (DMSO P10). 
These results support the resistant phenotype displayed by the plaque reduction data 
in Fig. 3.3 and suggests that P10 viruses were no longer inhibited at the stage of 
nuclear export. 
 
3.2.4 Isolation and characterisation of drug-resistant viral clones 
Next, the potential genetic changes responsible for KPT-335 resistance were 
investigated. However, serial passaging an influenza virus under selective pressure 
may well result in a mixed population of genotypes/phenotypes. Consequently, 
sequencing pooled virus supernatants would give a mixed consensus sequence of the 
whole population, which could be difficult to interpret. Accordingly, to isolate drug-
resistant virus clones for sequencing, plaque purification of the P10 R1-R3 viruses 
was performed. As depicted in Fig. 3.6, serial passaged viruses harvested at P10 
(including a DMSO-passaged control virus) were used to infect MDCK cells and  
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Fig. 3.5. Effect of KPT-335 on intracellular localisation of NP after infection with 
P10 viruses. A549 cells were infected with DMSO, R1 or R3 (P10) viral supernatants 
at MOI 3 in the presence (0.3 µM or 1 µM) or absence (DMSO control) of KPT-335. 
8 h p.i. cells were fixed and stained with anti-NP (green) and a nuclear stain (DAPI, 
blue). Images were taken as optical slices through the middle of the cells using a 
Leica fluorescence microscope.
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grown in the presence of KPT-335 (1 µM) under an agarose overlay. 48 h p.i., plaques 
formed in the presence of compound were isolated from the agarose and transferred 
to fresh MDCK cells and grown for a further 24 h in the presence of compound (0.3  
µM). 8 plaques were isolated per serial passage experiment (R1-R3) and subjected to 
further experimentation before genotypic analyses. As an example, Fig. 3.7. displays 
outcomes of the set of experiments carried out to characterise the 8 plaque isolates 
from R3 (P10). Similar sets of experiments were also performed for the R1 and R2 
P10 plaque pick viruses (data not shown). Initially, the 8 viral clones were grown in 
the presence and absence of the compound to determine the difference in titre and 
establish the most phenotypically resistant isolates for sequencing. MDCK cells were 
infected with the isolates in the absence (-drug) or presence (+ drug, 0.3 µM) of KPT-
335. At 24 h p.i., viral titre was determined by plaque assay. In the absence of 
compound, DMSO (P10) virus grew to 108 PFU/ml, whereas the isolates grew to ~107 
PFU/ml (Fig. 3.7.A). This difference in titre may be  due to the isolates containing 
drug dependent adaptations, which as mentioned previously, usually come at a fitness 
cost to the virus. The DMSO (P10) virus in the presence of compound, displayed a 2-
log10 reduction in titre (106 PFU/ml) in the presence of compound compared to the 
untreated control. All R3 plaque isolates grown in the presence of compound displayed 
<1-log10 reduction in titre in comparison to the untreated control, indicating that all 
plaque picks (PP) were partially drug-resistant. Isolates 3, 6 and 7 from P10, 
experiment R3 (re-designated PP1, 2 and 3), displayed the smallest differences in virus 





Fig. 3.6 Isolation of drug-resistant viral clones from serial passage experiments 
R1-R3.  Viral supernatants harvested from serial passage (P10) were used to infect 
MDCK cells at 100 PFU/well. Cells were overlaid with agarose containing 1 µM of 
KPT-335. 48 h p.i. individual plaques were isolated from the agarose using a cut 
pipette tip. 8 plaques were picked from each serial passage experiment; R1, R2 and 
R3. Isolates were grown on fresh MDCK cells in the presence of 0.3 µM of compound. 
24 h p.i. supernatant was harvested for further experiments.
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To test whether the individual plaque picked virus clones were truly resistant, PP1-3 
were tested by a dose response assay similar to those performed in chapter 2 (Fig. 
2.1.D). A549 cells were infected with the isolates (PP1, 2 and 3) and a DMSO PP 
control at an MOI of 0.01 and treated with increasing concentrations of compound. At 
24 h p.i., supernatants were harvested and virus titres were determined by plaque 
assay. As expected, the control DMSO PP was inhibited by the compound in a dose-  
dependent manner (Fig. 3.7.B). In contrast, the three isolates (PP1-PP3) from the 
resistant virus stock were not suppressed by the compound at any of the concentrations 
tested. The drug susceptibility of the three isolates was also checked by plaque 
reduction assay as performed previously. MDCK cells were infected with the DMSO 
PP or the isolates at 100 PFU/ml and were left untreated (0 µM) or treated with (0.3 
µM or 1 µM) of KPT-335. At 48 h p.i., cells were stained with toluidine blue to 
visualise plaques. As previously observed, plaque formation by the DMSO PP was 
inhibited at both 0.3 µM and 1 µM concentrations of the compound (Fig. 3.7.C). All 
three R3 isolates displayed a slightly hazy small plaque phenotype in absence of 
compound but the numbers of plaques formed in the presence of 0.3 µM of drug were 
similar to the numbers observed in the untreated control, indicating resistance to the 
compound at this concentration. However, little to no plaques were observed at the 
higher concentration of 1 µM, similarly to the DMSO virus, suggesting that although 
the isolates were not susceptible to KPT-335 at 0.3 µM, they were not resistant to 
higher concentrations of the compound. The same set of experiments were performed 
for the plaques picked for the P10 R1 and R2 serial passaged experiments, in which 
the outcomes were similar (data not shown). Thus, overall these data indicated the 
successful isolation of drug-dependent viral isolates.    
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 Fig. 3.7. Experimental method to characterise drug-resistant virus isolates for 
sequencing (using R3 as an example). (A) Growth of viral isolates in the presence 
and absence of compound. MDCK cells were infected with isolates (MOI = 0.01) in 
the presence (0.3 µM) or absence (0 µM) of compound. 24 h p.i. virus supernatant 
was titred by plaque assay. The three plaques picks with the smallest difference in 
titre (indicated by numbers) were selected for further experimentation (B, C). (B) 
Dose-response curve with KPT-335. A549 cells were infected with virus isolates (MOI 
= 0.01) and treated with increasing concentrations of KPT-335. 24 h p.i. viral 
supernatant was titred by plaque assay. (C) Plaque reduction assay with selected 
viral isolates.  MDCK cells were infected with 100 PFU/well of PP3, 6, and 8, as well 
as a DMSO vehicle control. Infected cells were treated with KPT-335 at a conc. of 0, 
0.3 µM or 1 µM or with no drug (0 µM). 48 h p.i. cells were stained with toluidine blue 
and imaged.  
104  
As a further phenotypic test of the cloned resistant viruses, NP localisation in the 
presence of compound was assessed by IF assay. Example data are shown for two 
isolates, one from R1 and one from R2. A549 cells were infected with DMSO PP or 
the resistant isolates at an MOI of 3 in the absence (0 µM) or the presence (0.3 µM or 
1 µM) of compound. 8 h p.i. cells were fixed, permeabilised and immunofluorescently  
stained for NP (green) and DAPI (blue). Confocal images were taken at high 
magnification as single optical slices through the middle of the cell. The DMSO PP 
virus and the isolates, in absence of compound, displayed punctate cytoplasmic 
staining, as expected, indicating RNP nuclear export had taken place (Fig. 3.8). In the 
presence of 0.3 µM and 1 µM of KPT-335, the DMSO virus predominantly displayed 
NP staining in the cell nuclei, with stronger staining at 1 µM indicating enhanced 
retention at the higher drug concentration, as previously observed. In addition, NP 
staining concentrated around the edge of the nucleus in a ring-like formation, similar 
to previous reports with LMB (Elton et al., 2005; Elton et al., 2001; Ma et al., 2001). 
For both plaque isolates, NP gave stronger cytoplasmic staining in the presence of 
compound than the DMSO PP, suggesting persistence of RNP nuclear export, 
although some nuclear retention of NP was nevertheless still evident. Interestingly, 
this nuclear NP localisation differed from the ring-like staining displayed by the 
DMSO PP, forming large intranuclear bodies throughout the organelle. 
 
These results indicated that the R1-R3 isolated viral clones were resistant to the KPT-
335 compound, at least to some extent. The dose-response data suggested that the 
isolates were unaffected at any of the drug concentrations, indicating they were fully 




Fig. 3.8. Effect of KPT-335 on intracellular localisation of drug-resistant virus 
isolates. A549 cells were infected with virus isolates (R1, PP3 and R2, PP2), as well 
as a DMSO (PP) control (MOI =3). Infections were carried out in the presence (0.3 
µM, 1 µM) or absence (0 µM) of KPT-335. 8 h p.i. cells were stained with anti-NP 
(green) and a nuclear stain (DAPI; blue). Images were taken as single optical slices 
by confocal microscopy. Data are representative of 2 independent experiments.
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at sub-inhibitory concentrations of the compound (0.3 µM), suggesting there was a 
threshold concentration of drug for resistance. 
 
3.2.5 Sequencing analysis of KPT-335-selected IAV  
Genotypic analysis of drug-resistant variants would be expected to reveal mutational 
changes that may be responsible for a resistant phenotype. To characterise genotypic 
alterations in the KPT-335-selected viruses, Sanger sequencing of the relevant 
influenza genes was performed. Viral RNA was extracted and cDNA obtained by 
reverse transcription reactions carried out with an IAV universal oligonucleotide 
primer (5′-AGCAAAAGCAGG-3′). The post reverse transcriptase (RT) reactions 
(cDNA) were then amplified with terminal primers specific for PA, PB1, PB2, NP, M 
and NS segments as well as with sets of internal primers for PA, PB1 and PB2 to 
amplify the middle regions of these larger genes. The PCR products were purified, 
size checked on a DNA gel and then sequenced commercially (GATC Biotech, 
Constance, Germany). The HA and NA genes were not sequenced because of the 
lower likelihood that these proteins would accumulate functionally important changes 
in response to KPT-335 treatment. The three characterised clonal isolates from each 
of experiments R1-R3 as well as a DMSO PP were sequenced. Pooled R4 and R5 P9 
samples as well as a DMSO P9 control virus were also sequenced. Sequencing of PR8-
WT virus P1 stock was included as a reference sequence (details of the samples 
processed for sequencing are indicated in Table 3.2). 
 
Sequence analysis revealed genotypic changes present in all serial passaged viruses. 
Details of changes in the coding regions are shown in Table 3.3. PR8 MUd (P1) and 
PR8-WT (P1) stocks were used as a reference sequence to compare any amino acid  
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DMSO (1) PP 1 P10 
 
R1 PP 3 P10 
 
R2 PP 3 P10 
 
R3 PP 3 P10 
 
DMSO (2) Pool 1 P9 
 
R4 Pool 1 P9 
 
R5 Pool 1 P9 
 
A Virus population sequenced; the initial virus stock (stock), plaque pick (PP) or pooled virus 
population (pool) 
B The number of stock virus, plaque isolates or pooled virus populations selected for 
sequencing. 













changes found in the serial passaged viruses. Sequence analysis of the DMSO PP (the 
control from the R1-R3 experiments) revealed a few mutational changes (shown in 
blue in Table 3.3), which possibly arose from adaption to infection in A549 cells 
during the serial passage (the PR8 clone used was an MDCK-cell adapted one; de Wit 
et al., 2004). These mutations were also found in some of the R1-R3 plaque isolates. 
However for simplicity, these mutations were excluded from further analysis as they 
were expected to not contribute to the drug-resistant phenotype. For each of the three 
plaque isolates from the R1-R3 passages, amino acid changes were found in all genes 
analysed. Several nucleotide changes resulted in silent mutations and therefore the 
probability of them functionally contributing to the resistant phenotype was expected 
to be low (presented in italics in Table 3.3). Additionally, even though the R1-R3 
isolates had been clonally purified, several mutations contained a heterozygous base 
as established by the analysis of the sequencing chromatograms (traces); these 
changes are depicted in grey in Table 3.3. These sequence polymorphisms could have 
resulted from contamination at the plaque pick stage and/or arisen during subsequent 
amplification steps, but either way, since they had not gone to fixation in the virus 
population, they were discounted from further analysis. Other potential compensatory 
drug resistant mutations that had apparently been fixed but were found in only one or 
two of the three isolated clones are as follows; PB2, F551S (R2+R3), PB1, R363G 
(R3) and NP, A178T (R2). However, for R1-R3, the only nucleotide changes which 
had a strong homozygous base and that were conserved between all three plaque 
isolates within a passage series were discovered in the NP gene. Amino acid changes 
Q311R, N309T and Y296H (highlighted in red in Table 3.3) were found in passages 
R1, R2 and R3, respectively. The presence of these mutations in all three clonal 
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Table 3.4. Sequencing analysis of drug-selected pooled viruses (R4 and R5) 
 
 
 DMSO R4 R5 
PB2   R258K 
PB1    
PA  L470C  




M    
NS    
 
 
Blue text = mutations found in DMSO serial passaged control virus  
Grey text = mixed nucleotide trace   
Italic text = silent mutational change 
Red text = mutations identified all 3 plaque isolates (R1-R3) or mutations with a homozygous 
nucleotide trace in pooled viruses (R4, R5) 
* Udorn M sequence “mutated” to PR8 M sequence for DMSO and R1-R3 all PP (discussed in section 
3.3)
 DMSO R1 R2 R3 
PP 1 1 2 3 1 2 3 1 2 3 








    
PB1   P444 P444  R363G     
PA         A396H  
NP S377N Q311R Q311R 
A178T 
Q311R N309T N309T 
 









  G82R    I152  
NS  Mixed, 
all in 
intron 
     S190 S190  
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isolates proposed a convincing argument that these amino acid changes contributed to 
the drug-resistant phenotype. For R4 and R5, the whole P9 virus population was 
sequenced rather than individual plaque-picked clones, as well as the matching DMSO 
P9 control virus. Therefore, as expected, sequencing analysis was ‘noisier’ with the 
presence of multiple peaks and poorly defined peaks in the trace analysis, leading to 
difficulty in confidently identifying single nucleotide changes at some positions. No 
mutations were found in the DMSO-passaged P10 virus. Five ‘mixed’ sequences were 
discovered in R4 and R5 as presented in grey in Table. 3.4. However, two changes 
with a homozygous nucleotide trace were present in the NP gene: P283S and C333S 
in R4 and R5, respectively. Applying the same logic as above to the sequencing 
analysis to the R4 and R5 virus populations, suggested that these mutations in NP were 
most likely to contribute to possible KPT-335 resistance.  
 
Chromatograms of sections within the NP gene where the five amino acid mutations 
were identified are displayed in Fig. 3.9. All chromatograms where nucleotide changes 
were discovered displayed well defined and sharp peaks with no (or in the case of R4, 
minimal) background interference present at the peak baseline; therefore, mutations 
observed from these trace analyses could be considered as accurate data.  
 
In summary, genotypic analysis of the serially passaged viruses (R1-R5) revealed 
consistent amino acid substitutions within the NP gene. The NP mutations found were 
conserved between the three plaque isolates from each of the R1-R3 serial passages 
and evidently at or near fixation in passages R4 and R5. Mutations found in the other 
genes analysed were either silent, mixed within a virus pool or not conserved between  
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 Fig. 3.9. Sequencing chromatograms of sections within the NP gene sequence 
where 5 amino acid mutations were identified. (A) Chromatogram of NP 
nucleotide sequence between nucleotides 963 to 984. Nucleotide change found in 
R1, A977G translated to amino acid change Q311R (highlighted in pink). Nucleotide 
change found in R2, A971C, translated to N309T (highlighted in turquoise). (B) 
Chromatogram of NP nucleotide sequence between 874 to 895. Nucleotide change 
found in R3, T886C, translated to Y296H (highlighted in yellow). (C) Chromatogram 
of NP nucleotide sequence between 835 to 855. Nucleotide change found in R4, 
C847T, translated to P283S (highlighted in purple). (D) Chromatogram of NP 
nucleotide sequence between 968 to 989. Nucleotide change found in R5, T997A, 
translated to C333S (highlighted in orange). Blue highlighted peaks indicate 
nucleotide difference from WT virus sequence. Nt. = nucleotide. AA = amino acid. 
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the isolates sequenced. Thus, the sequencing data strongly indicated that resistance 
correlated to mutational changes within the NP protein.  
 
3.2.6 Prevalence of KPT-selected NP mutations in human IAV sequences  
To determine if the potential drug-resistant NP mutations were found naturally in other 
human IAV strains, a widespread analysis of full-length segment 5 sequences was 
conducted. Sequences were obtained by a NCBI database search (conducted on 
13/02/17) and gave 18,317 results. The breakdown of subtypes obtained are as 
follows; 8900 (H3N2), 8862 (H1N1), 193 (H5N1), 119 (H7N9), 91 (H5N6) with 
remaining sequences other subtypes. Sequences from unknown origins were removed 
from analysis and any identical sequences were collapsed. An R script was written 
and provided by Dr Sam Lycett (The University of Edinburgh) and modified by Carina 
Conceição (PhD student within the Digard group), which separated all sequences into 
groups of 500 for alignment analysis using FASTA software. Analysis revealed that 
the KPT-335-selected NP mutations; Q311R, N309T, Y296H, P283S and C333S (Fig. 
3.10.B) were not prevalent in the NP protein (data kindly examined by Rute Pinto 
(PhD student within the Digard group). Additionally, the most predominant amino 
acid at the NP position of interest was identical to that in the PR8 WT strain.  At 
positions 311 and 296, 99.9 % of sequences had a glutamine (Q) or tyrosine (Y) 
respectively, with only 0.005 % of sequences displaying either the KPT-335-induced 
mutant arginine (R) or histidine (H), respectively. At position 333, no sequences were 
found with a serine (S). At position 283, 57.7 % of sequences matched the PR8 WT 
proline (P), with 42.3 % containing other amino acids. However, only 0.005 % had 
the potentially drug-resistant serine (S). Interestingly, 309 was the only amino acid  
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Fig. 3.10. Prevalence of NP mutations in human IAV sequences. All human full-
length NP IAV sequences were downloaded from the NCBI database (18,317) 
Sequences were then separated into segments of 500 using an Rscript programme 
written by Dr Sam Lycett. The 500 sequence segments were aligned using MEGA6 
and stored as a FASTA file. 10 separate alignments were carried out to determine if 
the motif had a ‘WT’ AA or the ‘mutant’ AA at the 5 different NP positions. Results 
from the alignments were analysed using excel functions to determine the number of 
sequences which had an ‘X’ AA at the NP position of interest (performed by Rute 
Pinto). (A) Bar graph indicating % prevalence of a WT, mutant or another AA at the 
NP positon specified. (B) Table showing the % prevalence values of the AA found at 
each NP position. 
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position where a significant number of virus sequences contained the polymorphism 
of interest. 92.4 % of sequences had a PR8 WT asparagine (N) while 7.6 % matched 
the mutation to threonine (T). Further analysis revealed that most sequences with a T 
at 309 were pre-2009 pandemic with ~10 % sequences containing a T before and <3 
% containing a T post pandemic 2009 in comparison to the ~11 % with an N pre-
pandemic and 75 % post-pandemic (data not shown). These results indicated that the 
potential drug-resistant mutations were not present in the majority of the previously 
sequenced human IAV strains, suggesting that other ongoing selective pressures on 
IAV do not normally select for these potential NP KPT-335-resistant mutations. 
 
3.2.7 Location of drug-selected mutations within the NP protein  
To determine where the drug-selected mutations were located within the NP protein, 
the mutations were mapped onto a linear depiction of the polypeptide together with 
known intracellular trafficking signals, as well as onto a crystal structure of the 
trimeric form of the NP protein molecule (Fig. 3.11). The NP protein is 498 amino 
acids in length and contains at least two nuclear localization signals (NLS) (Neumann 
et al., 1997; Wang & Palese, 1997), a cytoplasmic accumulation sequences (CAS) 
(Digard et al., 1999) and three nuclear export signals (NES1, NES2, NES3) (Yu et al., 
2012), one of which (NES3) is required for CRM1-mediated nuclear export (Fig. 
3.11.A). P283S, Y296H, N309T, Q311R and C333S all appeared in the middle to the 
C terminal region of the NP polypeptide and as the amino acid numbers suggest, in 
close proximity to each other. Although not found within the reported CRM1-
dependent NES site (NES3; 248-274), they all appear just downstream of this region. 
Additionally, the C333S mutation from the non-phenotypically resistant virus  
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Fig. 3.11. Drug-selected mutations mapped to the structure of NP. (A) NP protein 
sequence diagram indicating the two nuclear localisation sequences (NLS), a 
cytoplasmic accumulation signal (CAS) and three nuclear export signal (NES1-3) in 
relation to the 5 mutations. (B) Ribbon structure of the monomer form of NP with 
amino acids changes mapped in colour. Using Pymol software and the 3.2Å crystal 
structure sequence from (Ye et al., 2006), NP mutations at positions 283, 296, 309, 
311 and 333 were mapped on the structure of the protein. (C) Surface structure of 
NP with 4 (283, 296, 309 and 311) out of 5 mutations visibly mapped to the surface 
of the trimer form of the protein. 
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(as shown in R5 (P9) plaque reduction data in Fig. 3.4) was found within the CAS 
motif associated with cytoplasmic retention of RNPs possibly by tethering NP to the 
actin cytoskeleton (Digard et al., 1999). Mutations were mapped on a trimeric form of 
a 3.2Å resolution NP crystal structure obtained from the Protein Data Bank (PDB) 
under code 2IQH.pdb (published by Ye et al., 2006) and the protein structure was 
annotated using PyMol software. An NP monomer is composed of a head domain, a 
body domain and a tail loop as depicted in Fig. 3.11.B. Mapping of the NP mutant 
amino acids onto the monomer crystal structure demonstrated that all five mutations 
located to a similar region on the body domain (Fig. 3.11.B). Surface visualisation of 
the trimeric structure revealed that four of the five mutations were located on the 
surface of the NP molecule (Fig. 3.11.C). P283S (purple), Y296H (yellow), N309T 
(turquoise) and Q311R (pink) all clustered together at the side of the NP body. C333S 
(orange), although close to the other four amino acids was not surface exposed.  
 
Thus, all five of the NP mutations were close to each other within the tertiary structure 
of the protein, although not located within a known NES reported to be involved in 
CRM1-dependent nuclear export. Importantly, four of the five mutated amino acids 
were surface exposed on the NP protein, suggesting that if these mutations were 
responsible for the drug-resistant phenotype, the escape mechanism could involve a 






3.3 Discussion  
 
In this chapter, the generation of a KPT-335-resistant IAV was described. 
Investigating the likelihood of the emergence of drug resistant virus variants is an 
important pre-clinical step for potential antiviral therapies. Although in vitro 
investigations will not necessarily predict the probability of clinical resistance, it can 
determine if the genetic barrier for drug resistance would be low or high. Additionally, 
sequencing of a CRM1-inhibitor resistant virus would be expected to reveal causative 
mutations within the IAV genome and subsequently expand our knowledge of the 
CRM1-dependent nuclear export process with regards to influenza virus infection. 
Therefore, phenotypic and genotypic analyses for potential KPT-resistant variants 
were performed in cell culture.  
 
KPT-335 resistance was gained by serially passaging H1N1 laboratory strains PR8 
MUd and PR8 in A549 cells in the presence of KPT-335, resulting in a selection of 
isolates showing decreased susceptibility to KPT-335 after 9-10 passages (Fig. 3.2). 
An amantadine serial passage experiment was initially used as a positive control for 
the selection of drug-resistant variants. It is widely known from both in vitro and in 
vivo studies that the M2 ion channel blocker can easily elicit a variety of drug resistant 
mutations such as L26F, V27A, A30T/V, S31N, G34E and L38F within the M2 gene 
of H1N1 viruses (reviewed in Hussain et al., 2017). Therefore, serial passage of an 
amantadine sensitive virus, such as PR8 MUd, would be expected to result in a drug-
resistant variant after few passages in the presence of the compound. Results presented 
in Fig. 3.2, displayed an increase in virus titre after 3 passages in the presence of 
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amantadine, suggesting resistance had occurred. However, subsequent sequencing of 
the M gene revealed that instead of P10 PR8 MUd isolates from the R1-R3 serial 
passage experiments gaining a specific amantadine resistance mutation, they actually 
gained a PR8 segment 7 (which already encodes an amantadine-resistant M2) in place 
of the expected Udorn segment 7 (Table 3.3). A similar replacement of segment 7 had 
also occurred in the KPT-335-passaged viruses. Sequencing of the PR8 MUd stock 
and P1 viruses revealed that these viruses contained Udorn segment 7, indicating the 
original stock was indeed PR8 MUd (data not shown). This suggests that the 
transformation of the Udorn segment 7 to PR8 segment 7 occurred during the serial 
passage. PR8 MUd passage experiments were carried out independently from the PR8 
passage experiments, which therefore reduced the risk of samples being contaminated 
with PR8 during the passaging itself. Therefore, it was hypothesised that the initial 
stock of PR8 MUd contained a low amount of contaminating PR8 virus. This could 
also be checked by examining the plaque morphology i.e. a mixed population would 
contain both small (PR8 MUd) and larger (PR8) plaques. Additionally, sequencing the 
viruses harvested at the various passage points would help determine when the 
transformation from PR8 MUd to PR8 occurred. To prevent this type of problem 
occurring in future serial passage experiments with PR8, a single virus clone was 
isolated to ensure a purified stock before starting the R4 and R5 serial passage 
experiments.  
 
Perwitasari et al., (2016) investigated the effect of KPT-335 against IAV in two in vivo 
models, as discussed in more detail in chapter 2. They also investigated the potential 
for drug resistance in vitro. The authors serially passaged A/WSN/33 (H1N1) in A549 
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cells in the absence and presence of KPT-335. In contrast to this study, they found that 
WSN was still susceptible to KPT-335 even after 10 passages in the presence of the 
compound. A possible explanation for the discrepancies in results between Perwitasari 
et al., (2016) and this study may due to the difference in the experimental procedures 
performed. The serial passage experiment performed by the Perwitasari and colleagues 
was carried out under selection of 0.2 µM KPT-335, which is a not dissimilar 
concentration to those assessed in this study (0.15 µM and 0.3 µM). However, to test 
the susceptibility of the virus harvested at various passages, they used 5 µM KPT-335. 
Here, it was found that a concentration of 1 µM of drug could completely inhibit WT 
virus replication (chapter 2, Fig. 2.1), thus suggesting that 5 µM would be too harsh a 
test and may miss smaller differences in susceptibility to the compound that might be 
biologically important. Ideally, the KPT-335 serial-passaged virus would benefit from 
being tested against a sub-optimal drug concentration. Additionally, the authors did 
not determine virus titre between passages, thus leading to unknown MOIs and 
possibly increasing the chances of defective inferring particle (DIPs) generation. A 
DIP influenza virus particle has a large deletion in the central region in one of the eight 
RNAs and they have been shown to develop upon successive high multiplicity 
passages of IAV (Magnus, 1954). The presence of many DIPs may interfere with the 
development of drug resistance as they can affect WT virus function through 
competitive inhibition during infection (Pathak & Nagy, 2009). Therefore, 
determining virus quantification between passages to ensure subsequent rounds of 
passages are performed at low multiplicity, such as performed in this study, would be 
expected to reduce the presence of DIPs.  
 
120  
Notable fluctuations in virus titre were observed over the course of all three PR8 MUd 
serial passage experiments (R1, R2 and R3) (Fig. 3.2). To determine whether this was 
an artefact of the likely contamination with a virus bearing PR8 segment 7, a further 
two passages were carried out with a plaque-purified PR8 virus (R4 and R5). However, 
these experiments also gave a similar pattern of fluctuating virus titre over the course 
of 9 passages. Initially, it was hypothesised that the observed variations in titre could 
be caused by the production of DIPs (despite controlling the MOI of each passage 
step), which would interfere with the function of the susceptible WT virus through 
competitive inhibition. An increase in DIPs can interfere with virus replication and 
therefore lead to decreases in virus titre. To determine if an increase in DIPs correlated 
with the decrease in viral titre observed at P3 and/or P6-7, the particle to PFU ratio 
was estimated by qPCR quantification of segment 7 to derive genome copy: PFU ratios 
(data not shown). However, these data were inconclusive and did not indicate any 
convincing differences in the proportion of infectious particles at the passages 
examined. Although it cannot be ruled out that DIPs did not cause this fluctuation in 
titre, it can be hypothesised that the low MOI conditions would have reduced this 
possibility.  
 
Examination of KPT-335 sensitivity of the serial passaged viruses, showed that P3 and 
P6 viruses were all still largely susceptible to the compound as determined by plaque 
reduction assay (Fig. 3.3). These results seemed to contradict the increase in titre 
observed during the multi-passage experiments, which suggested that the viruses were 
already less susceptible to the compound at these sampling points (Fig. 3.2). Although 
R1 and R2 did not display a resistant phenotype at P6 (Fig.3.3), they did display a 
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smaller, less cytopathic plaque phenotype in the absence of drug, similar to the 
resistant phenotype observed at P10 for these viruses (Fig. 3.4). Thus indicating, that 
the viruses had phenotypically changed at these early passages and suggesting that 
KPT-335-resistance may come at a fitness cost to the virus. Further sequencing 
analysis of P3 and P6 viruses would determine if the potential drug-resistant mutations 
(Table 3.3) were present at these early passages, but this work was not carried out 
because of other priorities. 
 
The plaque reduction data clearly revealed that R1-R3 (P10) and R4 (P9) viruses were 
no longer susceptible to the compound at 0.3 µM, indicating a drug-resistant 
phenotype. R1 and R2 isolates displayed a larger plaque phenotype in the presence of 
drug (Fig. 3.4) indicating these two populations were possibly now dependent on the 
drug and were the most drug-resistant isolates. All viruses were still largely inhibited 
at 1 µM, suggesting there was a threshold for KPT-335 resistance. The R5 pool of 
virus did not display a resistant phenotype by plaque reduction assay. Nevertheless, 
sequencing analysis did reveal a fixed mutational change (C333S) in the NP gene of 
R5 (P9) virus. IF analysis of P10 viruses (R1 and R3) supported the resistant phenotype 
observed in the plaque reduction assay data by showing that the drug no longer 
completely retained NP in the nucleus of the infected cells. Additionally, analysis of 
NP nuclear export by IF directly indicated that the serial passaged viruses have 
somehow escaped CRM1 inhibition. 
 
Identifying resistance mutations by DNA sequence analysis of the relevant portions of 
the virus genome can be useful in predicting clinical outcomes and supporting the 
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proposed mechanism of action of the compound. It was evident that sequencing of R1-
R3 isolates displayed a cleaner trace analysis than the P9 viruses for R4 and R5. 
Ideally, it would have been beneficial to also plaque purify R4 and R5 for sequencing 
but as a drug-resistant phenotype was observed and mutations present for R1-R3 this 
was not followed up. Many of the mutations discovered were discounted to simplify 
downstream analyses (as detailed in the next chapter). All nucleotide changes that 
translated to a silent mutation and those presenting heterozygous (mixed) nucleotide 
traces were not analysed further. The three mutations found in only 1 or 2 of the 3 
isolates for R1-R3 (PB2; F551S, PB1; R363G and NP; A178T) were perhaps 
compensatory drug-resistant mutations and are discussed further in the subsequent 
chapter. The mutations discovered in all three isolates and in the P10 viruses 
containing homozygous nucleotide traces (Table 3.3:3.4 Fig. 3.9) were found in the 
NP gene suggesting that this protein was the major determinant of potential drug-
resistance and therefore subsequent analysis was performed with the mutations found 
in this protein.  
 
Widespread analysis of available IAV sequences revealed that none of the NP 
mutations were especially prevalent in human IAV strains (Fig. 3.10). In fact, 311R, 
296H and 283S appeared in only one sequence and 333S was present in none of the 
available sequences. 309 was the only amino acid that had a notable number of 
sequences containing the mutation T (7 %). Interestingly, further analysis revealed that 
the T309 was mostly present in pre- 2009 pandemic strains (data not shown). These 
results of the IAV sequence screen suggests viruses containing the NP mutations are 
not naturally selected for in a biological setting. This would be advantageous if KPT-
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335 was developed for use as a clinical antiviral as it suggests the compound would be 
effective against current circulating strains. Additionally, if KPT-335-resistance 
occurred in a clinical setting, the drug-resistant mutations found in this study, would 
result in a less fit virus as also shown by the plaque reduction data for R1 and R2 (Fig. 
3.3; 3.4). These mutations would potentially make the virus unstable and therefore 
their ability to replicate and/or transmit within a population would likely be hindered. 
A literature search for IAV publications including these NP amino acid mutations was 
also conducted. Details of this search are presented in chapter 5 (Table 5.1).  
 
NP, a key component of the vRNP complex, is a major determinant for vRNP import 
and export. Thus far, two nuclear localisations signals (NLS) and a cytoplasmic 
accumulation signal (CAS) have been identified for their involvement in vRNP 
transport. As mentioned previously, proteins containing a nuclear export signal (NES), 
are involved in export of proteins via cellular CRM1. Currently NS2 (NEP), with 
contains a NES motif, has been deemed the main mediator responsible for directing 
export of vRNPs. However, primary evidence suggested that exogenous NP can shuttle 
between the nucleus and cytoplasm (Whittaker et al., 1996). Additionally, Neumann 
et al., (1997) found that the N terminal 38 amino acids of NP were capable of 
transporting RNPs from the nucleus to the cytoplasm. Since then, (Yu et al., 2012), 
identified three novel NES motifs within the NP protein, two of which were CRM1-
independent NES1 [24-49] and NES2 [183-197], and one CRM1-dependent NES3 
[248-274]. The authors found that these motifs were sufficient to direct a GFP-NP-
fusion protein from the nucleus to cytoplasm. The potential CRM1-inhibitor resistant 
mutations found in this study were present downstream of the CRM1-dependent NES 
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region, suggesting the potential of another unidentified NES motif. Although the Yu 
et al., study does not exclusively define that this NES motif could not be involved in 
CRM1-mediated export, it does suggest the hypothesis that vRNPs are unlikely to 
transport via this NES region alone. Interestingly, the fact that Yu et al., identified two 
NES that were CRM1 independent suggests the possibility that other export pathway 
may also be involved in the nuclear export of NP. 
 
The NP structure presented in Fig. 3.11.C displays an H5N1 NP protein that was 
crystallised as a trimer. The NP crystal structure reveals two regions; a head domain 
and a tail loop region. On the core of the protein, within the head domain, lies a groove 
comprised of a largely positively charged surface region which forms ionic bonds with 
the negatively charged backbones of viral cRNA and vRNA. On the opposite side of 
this binding groove lies a flexible tail loop formed by residues 392-407 (H1N1). The 
four potential drug-resistant mutations were surface exposed on NP opposite the RNA 
binding cleft. The surface location of Q311R, N309T, Y296H and P283S suggests 
drug resistance may have occurred by changing NP’s ability to bind directly to another 
protein involved in the nuclear export process such as CRM1, M1, NS2 or another 
unknown mediator. As mentioned previously, there is evidence to suggest that NP can 
bind directly to CRM1. An additional study has shown that overexpression of CRM1 
biased transfected NP towards cytoplasmic accumulation and in vitro-binding assays 
determined that these two proteins interact (Elton et al., 2001; Elton et al., 2005). Two 
subsequent studies confirmed NP-CRM1 interactions in the absence of other IAV 
proteins (Chutiwitooncahi et al., 2014; Kakisaka et al., 2015). Thus, direct interaction 
of NP with CRM1 may also take place during export of vRNPs. It is currently 
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hypothesised that nuclear export of vRNPs is mediated by the vRNP-M1-NS2-CRM1 
complex. Currently there is no evidence to suggest that NP directly binds to NS2, 
however studies have indicated that M1 can interact with the vRNP complexes. It has 
been reported that an M1 NES motif can interact with vRNPs to promote export of the 
virus (Sakaguchi et al., 2003). Additionally, another study discovered that the C-
terminal domain of M1 bound to both RNPs and NP alone (Baudin et al., 2001). 
Furthermore, by using recombinant proteins in vitro, Noton et al., (2007) found that 
the middle domain of M1 was responsible for binding to NP, in the absence of a RNA 
interaction. Thus, although there are some discrepancies as to which M1 domain 
interacts with NP, it is clear that M1 can directly interact with NP in some manner. 
These data suggest that the NP mutations found in this study could possibly alter 
interactions with M1; however, a M1-binding region on NP has not yet been defined. 
Overall the surface exposure of these mutations suggested that the amino acid changes 
in NP allowed the virus to escape inhibition of CRM1-dependent export by altering an 
interaction with another protein. Based on current literature, the most likely interaction 
with NP would be hypothesised to be with CRM1 and/or M1.  However, these 
mutations could also enhance interaction and/or disrupt binding to other proteins 
involved such as NS2 and/or an unknown mediator or potentially reveal that NP can 
interact with a novel cellular export pathway.  
 
The data described in this chapter demonstrated that KPT-335-resistant IAVs could be 
developed after 9-10 passages in the presence of a suboptimal concentration of the 
compound. Sequencing analysis of potential drug-resistant viruses revealed the most 
likely mutations contributing to the resistant phenotype were found within the NP gene 
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and interestingly, four of the five NP-mutants were surface exposed. The next line of 
investigation was to confirm if these amino acid changes contributed to the resistant 
phenotype by generating recombinant viruses harbouring the mutations. Chapter 4 will 
describe the generation of NP-mutant viruses and testing their susceptibility to KPT-
335 as well as utilising the recombinant viruses for further investigation into a 



































Chapter 4 Investigating the genetic basis of 
resistance of influenza A virus to a selective inhibitor 
of nuclear export, KPT-335 
 
4.1 Introduction  
 
As described in chapter 3, the ability of IAV to develop resistance to the nuclear export 
inhibitor, KPT-335, was determined by serial passage of the virus in the presence of 
the compound. Analysing the coding sequences of the viral proteins thought to be 
potentially involved in the nuclear export process (PB2, PB1, PA, NP, M and NS) lead 
to the discovery of five amino acid changes within the NP gene. The changes Q311R, 
N309T, Y296H, P283S and C333S were found after 9 or more passages in five 
independent experiments. Reverse genetics allows for the introduction of a desired 
amino acid change into a wild-type (WT) virus for analysis of its phenotypic effect 
(Fodor et al., 1999). In this chapter, site-directed mutagenesis was used (on plasmid-
borne copies of segment 5) to introduce the NP mutations into the genetic background 
of a PR8 virus, a standard H1N1 laboratory strain. Determining if the NP amino acid 
substitutions reduced the virus’ susceptibility to KPT-335 would test whether the 
changes identified in the passaged viruses were responsible for resistance. Further 
phenotypic analysis with the NP-mutant viruses could also help broaden knowledge 
of the biology of IAV genome nuclear export. Additionally, investigations into the 
mechanism of drug-resistance could eventually help the selection of alternative 
therapies if resistance was to occur and/or provide information into the development 
of novel antivirals. 
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The aim of this chapter was to firstly generate recombinant IAVs containing the 
potential KPT-335 resistant NP-mutations discovered in chapter 3. Initially, the mutant 
viruses were tested for their susceptibility to KPT-335 and the fungal-derived inhibitor 
LMB. Further investigations into a potential mechanism of resistance were performed 
by examining the phenotypic changes of the recombinant viruses compared to the WT 
PR8 virus. These analyses included examination of plaque size and viral protein 
localisation in the absence and presence of KPT-335, as well as investigating 

















4.2 Results  
 
4.2.1 Generation of recombinant viruses harbouring the potential KPT-
335-resistant NP-mutations 
As presented in chapter 3, sequencing analyses of the KPT-335 serial passaged viruses 
revealed mutations within the IAV NP gene. Although other genotypic changes were 
discovered, the NP mutations: Q311R, N309T, Y296H, P283S and C333S, were 
regarded as the most significant, as these substitutions were conserved between clonal 
isolates from passages R1-R3 and the consensus sequences from pools R4 and R5. 
Therefore, to simplify phenotypic investigations, the experiments in this chapter were 
performed with only the five NP amino acid changes. To determine if these mutations 
would confer a KPT-335-resistant phenotype, recombinant viruses harbouring the NP 
mutations were generated in a PR8 background. 293T cells were transfected with 8 
pDUAL plasmids (Wit et al., 2004), one for each segment of the IAV genome (Fig. 
4.1). pDUAL plasmids contain a RNA polymerase II promoter that drives production 
of mRNA for IAV protein translation and an opposed RNA polymerase I promoter 
that drives production of ‘vRNA-like’ RNA for genome replication (Hoffmann et al., 
2000). Plasmids containing the potential drug-resistant mutations were generated by 
site-directed mutagenesis and transfected in place of the WT segment 5 plasmid. Virus 
supernatant was harvested at 72 h post-transfection and termed the P0 stock. The P0 
stocks were then used to infect MDCK cells and the virus was propagated a further 48 
h to obtain a larger quantity and higher titre of infectious virus. These P1 stocks were 
harvested, clarified and the titre determined by plaque assay for use in subsequent 
experiments. A PR8-WT virus was generated as a positive control and a negative  
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Fig. 4.1. Schematic of the 8-plasmid reverse genetics system to generate IAV 
strains harbouring KPT-335 selected mutations. 293T cells were co-transfected 
with 8 pDUAL plasmids, one for each segment of the IAV genome. NP plasmids 
encoding the mutations of interest were generated by site-directed mutagenesis and 
were co-transfected instead of the WT NP plasmid. Reassortant viruses were 
harvested 72 h post-transfection and the infectious virus particles were propagated 
for a further 48 h in MDCK cells.
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control was also included which lacked a PB2 plasmid and therefore was unable to 
form infectious virus particles. Three independent rescues of the WT and the NP-
mutant viruses (hereafter denoted by the amino acid alteration e.g. Q311R, N309T, 
Y296H, P283S and C333S) were performed to determine the reproducibility of any 
phenotypes presented. Replicates within the experiments presented in this chapter 
come from (at a minimum), one experiment performed with each of the three 
independently generated stocks for each virus. All viruses were confirmed to contain 
the desired NP substitutions by Sanger sequencing analysis of the cDNA of the NP 
gene (data not shown).   
 
4.2.2 Replicative fitness of NP-mutant viruses  
To determine if the NP amino acid substitutions affected IAV replicative fitness, virus 
replication was assessed by multi-cycle growth assays. MDCK cells were infected 
with WT PR8 or the NP-mutant viruses at an MOI of 0.01. At 24 h p.i., viral 
supernatants were harvested and the titres were determined by plaque assay. WT virus 
replicated to (on average) >108 PFU/ml (Fig. 4.2), as expected for PR8 under multi-
cycle growth conditions. Q311R displayed a reduction in titre by ~2 log10 in 
comparison to the WT virus, down to ~105 PFU/ml. N309T, Y296H and P283S also 
presented slight reductions in replication by <1 log10 to ~107-8 PFU/ml. NP-mutant 
virus C333S showed little to no decrease in titre compared to the WT virus. However, 
due to the variability observed across the three independent experiments, none of the 
decreases were statistically different. Nevertheless, Q311R displayed a substantial 
reduction in replication in MDCK cells compared to the WT virus suggesting that the 




Fig. 4.2. Growth of NP-mutant viruses in MDCK cells. MDCK cells were infected 
with WT or mutant viruses at MOI 0.01. 24 h p.i. virus was harvested and titred. Data 
are the individual values and mean of three independently rescued viruses. 




































4.2.3 Susceptibility of NP-mutant viruses to KPT-335 
To determine if the NP amino acid substitutions allowed the virus to escape CRM1-
inhbition, the susceptibility of the mutant viruses to KPT-335 were examined by dose-
response assays as performed in chapter 2 (Fig. 2.1.D). A549 cells were infected with 
WT or the NP-mutant viruses at an MOI of 0.01 and treated with increasing 
concentrations of KPT-335, starting at 0.01 µM and increasing in 0.5 log10 increments 
to 1 µM. At 24 h p.i., virus supernatant was harvested and the titre determined by 
plaque assay. As expected, the WT virus was inhibited by KPT-335 in a dose-
dependent manner, resulting in an IC50 value of 0.04 µM (Fig. 4.3), which was identical 
to the IC50 value established in chapter 2 for PR8 multi-cycle dose-response inhibition 
(Table 2.1). Both Q311R and N309T viruses were considerably less susceptible to 
KPT-335, giving much higher IC50 values of 1.93 µM and 0.68 µM, respectively. 
However, the lack of an appropriate dose-response inhibition curve resulted in a poor 
R2 value of -0.1 for the curve fit used to estimate the IC50, thus, the estimated value for 
Q311R could not be considered accurate. The N309T dose-response data resulted in a 
more appropriate curve shape, giving a more desirable R2 value of 0.5. Here, the IC50 
value was 17-fold greater than that obtained for the WT virus. Y296H, P283S and 
C333S viruses were inhibited by KPT-335 in a dose-dependent manner resulting in 
IC50 values of 0.13 µM, 0.18 µM and 0.1 µM, respectively; figures that were slightly 
(3-4-fold) greater than the WT value. However, as well as the small increase in IC50 
value, the Y296H virus was noticeably less susceptible to 1 µM drug than WT, with 
titres decreased on average by less than 10-fold. The P283S virus was also less 
susceptible than WT to the highest drug concentration although the difference was less 
marked. In contrast, the C333S virus was apparently more sensitive than WT to higher 
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drug concentrations (0.3 µM and 1 µM). Overall, the dose response data revealed that 
Q311R and N309T were substantially less susceptible to KPT-335 than the WT virus 
with Q311R presenting the most drug-resistant phenotype. Data were less clear-cut for 
the other viruses but were suggestive of lesser degrees of resistance for Y296H and 
P283S, and an altered but not clearly resistant susceptibility profile for C333S.  
 
To further characterise the sensitivity of the NP mutant viruses to KPT-335, plaque 
reduction assays were performed as in chapter 3 (Fig. 3.3;3.4). MDCK cells were 
infected with WT or the NP-mutant viruses with 100 PFU per well in the presence of 
DMSO (0 µM) or KPT-335 (0.3 µM or 1 µM). AT 48 h p.i., cells were fixed and 
stained with toluidine blue to visualise plaque formation. As before, WT virus plaque 
formation was inhibited in the presence of 0.3 µM and 1µM of KPT-335. Both P283S 
and C333S viruses were also inhibited by KPT-335 at both drug concentrations 
(Fig.4.4). In contrast the Q311R, N309T and Y296H viruses presented plaques in the 
presence of 0.3 µM drug, although plaque formation was still mostly inhibited at 1 
µM. The N309T and Y296H viruses generally displayed a smaller plaque phenotype 
in the presence of the compound compared to the larger plaque phenotype present in 
the absence of compound, whereas Q311R presented a similar plaque size in both the 
absence and presence of compound. Notably, in the absence of compound, Q311R 
displayed a hazy plaque phenotype distinct from the larger and clearer plaques 
presented by the WT and the other mutant viruses. This phenotype was consistent with 
the plaque reduction data for the R1 pool of viruses (Fig. 2.3) in which the mutation 
Q311R was discovered, suggesting that this amino acid change was responsible for the 




Fig. 4.3. Efficacy of KPT-335 against NP-mutant viruses. (A) Dose response 
efficacy of KPT-335. A549 cells were infected with WT or mutant viruses at MOI 0.01 
and treated with increasing concentration of KPT-335. 24 h p.i. virus was titred by 
plaque assay. Data are the mean ± S.E.M of three independent experiments each 
performed with an independent virus rescue. (B) Table displaying IC50 values and 
95% confidence intervals (CI) for the WT and NP-mutant viruses with their 
corresponding goodness-of-fit R2 values. Values were determined by curve fitting with 
a non-linear regression model. The fold change of the mutant virus IC50 values is 
displayed in comparison to the WT IC50 value. Dotted line indicates the ~IC50 value 
on the graph
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Y296H viruses were less susceptible to KPT-335 inhibition at 0.3 µM compared to the 
WT virus, thus indicating that these NP mutations allowed the virus to partially escape 
CRM1-inhbition. However, all three viruses formed little to no plaques in the presence 
of the higher compound concentration suggesting the NP mutations did not allow the 
virus to fully escape CRM1 inhibition. In addition, the susceptibility of P283S and 
C333S to KPT-335 inhibition was similar to that of WT virus, indicating that these 
mutations did not elicit drug-resistance measurable by this assay. 
 
The plaque reduction data (Fig. 4.4) suggested a difference in the NP-mutant virus 
plaque size in the presence and absence of compound. To quantify the difference in 
cell-to-cell spread, the viruses were grown in the absence or presence of a sub-
inhibitory concentration of KPT-335 (0.15µM) and instead of relying on cell lysis and 
counterstaining of the cell monolayer with toluidine blue to detect gross CPE, 
immunostaining of viral NP was performed for increased sensitivity and accuracy of 
measuring plaque size. MDCK cells were infected with 100 PFU/well of WT or the 
mutant viruses in the absence (DMSO) or the presence of KPT-335 (0.15µM). At 48 
h p.i., cells were fixed, permeabilised and stained with anti-NP. Plaque diameter was 
quantified using ImageJ software and ~20 plaques were measured per well. 
 
In the absence of compound, the WT virus presented the largest plaque phenotype, 
with all NP-mutant viruses presenting significantly smaller plaques (Fig.4.5 A.B). In 
the presence of compound, a small plaque size was displayed by all viruses with no 
significant differences in size between the WT and the NP-mutant viruses (Fig.4.5. 
AB). The difference in plaque size in the presence and absence of compound was 
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Fig. 4.4. Plaque reduction assays with the NP-mutant viruses. MDCK cells were 
infected with WT or mutant viruses at 100 PFU/well in the presence (0.3 µM, 1 µM) or 
absence (0 µM) of KPT-335. 48 h p.i. cells were fixed and stained with toluidine blue 
and imaged.
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calculated and is presented in Fig.4.5.C as a fold change. By this metric, WT virus 
showed the largest reduction in plaque size after treatment with KPT-335 (Fig. 
4.5.BC). N309T, Y296H, P283S and C333S displayed smaller differences in virus 
spread after drug treatment; however, these changes in plaque size were not 
significantly different from that of WT virus (Fig. 4.5.C). Notably, Q311R spread was 
not affected by the presence of compound (in fact the average plaque size was 
marginally higher in the presence of drug), resulting in a significant difference in fold 
change compared to the WT (Fig.4.5.C). Overall these results showed that all NP-
mutant viruses were less able to spread in tissue culture than the WT virus in the 
absence of the drug. KPT-335 did not affect the plaque size of the NP-mutant viruses 
to the same magnitude as with WT which may correlate to the initial smaller plaque 
size presented by the NP-mutant viruses. The NP-mutant Q311R displayed a similar, 
if not slightly enhanced, plaque phenotype in the presence of the drug, which may 
indicate that this drug-resistant mutation came at a fitness cost to the virus.  
 
4.2.4 Immunofluorescent investigation of viral protein localisation during 
infection with NP-mutant viruses 
KPT-335 blocks the nuclear-cytoplasmic transport of vRNPs as shown previously by 
examination of NP intracellular localisation at late stages of infection. To determine if 
the NP-mutant viruses were inhibited by KPT-335 at the stage of nuclear export, IF 
analysis was performed as described in prior chapters. A549 cells were infected with 
WT or mutant viruses at an MOI of 3 in the absence (DMSO) or presence (0.3 µM or 




Fig. 4.5 Plaque size of NP-mutant viruses in the presence and absence of KPT-
335. (A) Immunostained plaque assays. MDCK cells were infected with 100 PFU/well 
of WT and the mutant viruses in the presence (0.15µM) or absence (DMSO) of KPT-
335. 48 h p.i. cells were fixed and stained with anti-NP to visualise virus spread (B) 
Quantification of plaque size. The diameters of infected foci were measured using 
ImageJ software. Around 20 plaques were measured per well from three independent 
experiments.  ****<0.0001 in one-way ANOVA.  (C) Fold change in plaque size in the 
presence and absence of drug.  Data are the mean ± S.E.M of three independent 
experiments *<0.01 in one-way ANOVA.
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stained for NP (green) and a nuclear stain (DAPI; blue). As expected, in the absence 
of compound, WT infected cells displayed cytoplasmic NP staining, indicating that 
nuclear export of the replicated viral genome had taken place (Fig. 4.6). A similar 
cytoplasmic NP pattern was observed for all the mutant viruses in the absence of 
compound. WT infected cells, in the presence of drug, displayed partial nuclear 
retention of NP at 0.3 µM and full nuclear NP retention at 1 µM, as shown previously 
for PR8 virus. In the presence of 0.3 µM compound, Q311R and N309T infected cells 
displayed noticeably more cytoplasmic NP than the WT virus, suggesting reduced 
susceptibility to KPT-335 inhibition. Y296H and P283S infected cells gave less 
cytoplasmic NP than Q311R and N309T but still more than the WT at 0.3 µM. C333S 
displayed a similar NP pattern to the WT at 0.3 µM, with no visible export. All mutant 
virus NPs were retained in the nucleus of cells in the presence of the higher 
concentration of 1 µM drug, suggesting that these mutations alone were not adequate 
for the virus to fully escape KPT-335-mediated inhibition of the nuclear export 
process. Overall these results suggest a variance in susceptibility of the NP-mutants, 
with Q311R and N309T showing the greatest drug-resistant phenotype, Y296H and 
P283S showing a partial drug-resistant phenotype and C333S displaying a similar 
phenotype as WT virus. 
To assess the reproducibility of the NP intracellular retention data in Fig. 4.6, analyses 
of multiple dose-response IF assays were carried out. Images were taken as single 
optical slices through the middle of the cell and areas of cells were chosen at random. 
Infected cells were scored for whether NP was predominantly and/or partially localised 
in the nucleus. As previously observed for the WT virus, NP was mostly cytoplasmic 































Fig. 4.6. Intracellular localisation of NP during infection with NP-mutant viruses 
in the presence of KPT-335. A549 cells were infected at MOI 3 with WT or NP-
mutant viruses in the presence (0.3µM or 1µM) or absence (DMSO) of KPT-335. 8 h 
p.i. cells were stained with anti-NP (green) and a nuclear stain (DAPI; blue) and 
imaged by confocal microscopy. Images shown were taken as single optical slices. 
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(Fig. 4.7.B). This was similar for all the NP-mutant viruses in the absence of 
compound. WT virus displayed ~40-50 % of cells with full or partial nuclear NP at 0.3 
µM. In comparison, Q311R and N309T infections gave only ~10-20 % of cells with 
NP nuclear retention, which was significantly lower than the values obtained for WT 
at this concentration (Fig. 4.7.B). Y296H, P283S and C333S viruses displayed similar 
NP retention patterns to WT virus. Although there was some evidence of reduced 
susceptibility for Y296H at 0.3 µM (~30 % retention), none of these viruses had 
showed a significant difference in the number of cells with RNP nuclear retention in 
comparison to the WT. All viruses displayed ~70-90 % NP nuclear retention at 1 µM 
drug with no significant differences between viruses. Notably, a ring-like formation of 
NP staining around the inner edge of the nucleus was observed for WT, Y296H, P283S 
and C333S infections in the presence of KPT-335 (Fig. 4.7.A), a similar phenotype 
observed in chapter 3 for PR8-WT (Fig. 3.8). However, this ring of NP was not evident 
in Q311R or N309T infected cells. Overall these results indicated that Q311R and 
N309T were least susceptible to CRM1-inhibiton.  In addition, the difference in 
intranuclear NP distribution presented by Q311R and N309T may suggest a change in 

































Fig. 4.7. Effect of KPT-335 on intracellular localisation and accumulation of NP 
in NP-mutant viruses. (A) A549 cells were infected at MOI 3 with WT or NP-mutant 
viruses in the presence (0.3µM or 1µM) or absence (DMSO) of KPT-335. 8 h p.i. cells 






Fig. 4.7. Quantification of the effect of KPT-335 on intracellular localisation of 
NP with NP-mutant viruses. Quantification of NP nuclear retention after KPT-335 
treatment. Cells with predominately nuclear NP were scored. Counts were taken from 
three images per drug concentration from two independent experiments and are 



























































Viral proteins M1 and NS2 are described as mediators involved in canonical CRM1-
mediated nuclear export of vRNPs (reviewed in Paterson et al., 2012). As previously 
shown in chapter 2, KPT-335 treatment did not alter the cytoplasmic localisation of 
M1 and NS2 during late stages of virus infection. To determine whether localisation 
of M1 and NS2 was altered during infection with the two most phenotypically drug-
resistant NP-mutant viruses Q311R and N309T, infected cells were treated with KPT-
335 and M1 and NS2 protein localisation examined by IF. As described previously for 
Fig. 4.6, A549 cells were infected with WT or the mutant viruses at an MOI of 3, in 
the absence (DMSO, ‘-’) or presence (0.3 µM, ‘+’) of KPT-335. At 8 h p.i., cells were 
permeabilised and immunofluorescently stained for NP (as a positive control for drug 
inhibition), M1 or NS2 (green) and a nuclear stain (DAPI; blue). As expected, mock 
infected cells showed little to no viral protein staining (Fig. 4.8). WT infected cells 
displayed punctate cytoplasmic NP in the absence of drug and nuclear NP in the 
presence of drug, indicating successful inhibition of nuclear export. Q311R and N309T 
infected cells displayed a similar cytoplasmic NP staining pattern to the WT in the 
absence of drug and some cytoplasmic staining in the presence of 0.3 µM as previously 
observed (Fig. 4.8), again suggesting that while hindered, RNP nuclear export was not 
blocked as effectively. However, M1 and NS2 localisation remained unchanged, in the 
absence and in the presence of KPT-335, displaying a mostly diffuse cytoplasmic 
localisation for all viruses analysed. Overall these results show that M1 and NS2 
localisation was unaffected by CRM1-inhibition (as shown previously) and that the 





Fig. 4.8. Effect of KPT-335 on localisation of M1 and NS2 during infection with 
NP-mutant viruses. A549 cells were infected with WT, Q311R or N309T viruses at 
MOI 3 in the presence 0.3µM (+) or absence (-) of KPT-335. 8 h p.i. cells were stained 
with anti-NP, anti-M1 and anti-NS2 (all green) and a nuclear stain (DAPI; blue) and 
imaged by confocal microscopy. Images taken as maximum intensity projections. 
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4.2.5 Susceptibility of NP-mutant viruses to LMB 
LMB is an irreversible inhibitor of CRM1 and therefore a more potent blocker of 
CRM1-mediated nuclear export than the SINEs. If the NP-mutant viruses escaped the 
permanent blockade of CRM1 by LMB, it could suggest that the viruses were utilising 
another cellular nuclear export pathway. A549 cells were infected with WT or the 
mutant viruses at an MOI of 0.01 and treated with increasing concentrations of LMB, 
starting at 3 nM and increasing in 0.5-log10 increments to 30 nM. At 24 h p.i., virus 
titre was determined by plaque assay. WT virus was inhibited by LMB in a dose-
dependent manner such that 3 nM compound reduced titre by >50 % and 10 nM by 
nearly 99 % (Fig. 4.9). Curve fitting to the data resulted in an estimated IC50 value of 
0.3 nM (R2 value = 0.5) (Fig.4.9). The multicycle LMB IC50 value determined in 
chapter 2 was 6 nM, indicating an inconsistency in antiviral activity of LMB between 
the two experiments, possibly due to different batches of compound. The Q311R and 
N309T viruses were also inhibited by LMB in a dose-dependent manner, resulting in 
IC50 values of 0.7 nM and 0.6 nM, respectively. These IC50 values were ~2-fold greater 
than the WT value however, due to low R2 values (0.5 and 0.4) it could not be 
confidently concluded that Q311R and N309T were significantly less susceptible to 
LMB than the WT virus. Y296H and C333S were also inhibited by LMB, although 
both viruses were more sensitive to low doses of the compound, resulting in ~100 and 
~600-fold smaller IC50 values than the WT, respectively. P283S was also more 
sensitive to LMB, especially at the lowest drug concentration tested. However, a 
suitable dose-response curve could not be fitted and subsequently an IC50 value could 
not be determined. Overall these data conclude that 
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the NP mutations did not allow the virus to fully escape LMB inhibition and that 
interestingly three of the mutant viruses (P283S, Y296H and C333S) were more 
susceptible to irreversible CRM1 inhibition.   
 
4.2.6 Effect of NP-mutants on viral gene expression  
The reduction in replicative fitness of the two most phenotypically KPT-335-resistant 
mutant viruses, Q311R and N309T (Fig 4.2), suggested that the escape mutations came 
at a cost to virus fitness. To determine if the reduced virus fitness correlated with a 
reduced ability of the NP-mutant polypeptides to support viral gene expression, their 
function in RNP reconstitution assays was assessed. This assay indirectly measures 
mRNA production from synthetic vRNA-like templates encoding a reporter gene by 
the viral polymerase (Huang et al., 1990). pDUAL plasmids for the protein 
components of the viral RNP (PB2, PB1, PA and NP; “3PNP”) are co-transfected. 
Transcription of these plasmids by cellular RNA polymerase II produce the viral 
polypeptides. A vRNA-like luciferase reporter gene construct is also co-transfected, 
which contains the UTRs of PR8 segment 8 flanking an antisense luciferase gene, all 
under the control of an RNA polymerase I promoter. This plasmid is transcribed by 
cellular RNA polymerase I to produce RNA that sufficiently resembles vRNA to the 
IAV components to be assembled into an RNP. The viral polymerase then transcribes 
it into mRNA which is translated to produce luciferase (Lutz et al., 2005). The 
luciferase output is therefore directly proportional to the activity of the viral 
polymerase, which (importantly for this experiment) is influenced by the support 




Fig. 4.9. Efficacy of LMB against NP-mutant viruses. (A) Dose response efficacy 
of LMB against NP-mutant viruses. A549 cells were infected with WT or NP-mutants 
at MOI 0.01 and treated with increasing concentrations of LMB. 24 h p.i. virus was 
titred by plaque assay. Data are the mean ± S.E.M of three independent experiments 
performed with three independent virus rescues. (B) Table displaying IC50 values and 
95% confidence intervals (CI) for the WT and NP-mutant viruses with their 
corresponding goodness-of-fit R2 values. Values were determined by a non-linear 
regression model. The fold change of the NP-mutant viruses IC50 values are displayed 
in comparison to the WT IC50 value. Dotted line indicates the ~IC50 value on the graph.
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Equal numbers of 293T cells were co-transfected in a 24-well plate alongside the 
pDUAL plasmids of each component of the PR8 RNP (3PNP) using WT segment 5 
(NP) or plasmids containing the mutations; Q311R, N309T, Y297H, P283S or C333S, 
along with the luciferase vRNA reporter plasmid. At 48 h post-transfection, all the 
cells from each well were lysed and luciferase activity was measured. A ‘minus PA’ 
negative control was included, therefore the full polymerase complex would not form 
and luciferase activity measured would be considered background (data not shown). 
NP-mutant RNP activity was normalised to the WT value (100 %) (minus background 
activity). Q311R and N309T NP plasmids gave a 10-30 % reduction in relative 
luminescence, which was statistically insignificant when compared to the WT (Fig. 
4.10). However, Y296H, P283S and C333S had significantly lower relative activity 
(by ~40-70 %) than WT NP. Interesting, the two least fit and most phenotypically 
drug-resistant mutants Q311R and N309T did not display a significant difference in 
gene expression in comparison to the WT as measured by this assay. Thus, KPT-335-
resistance and/or reduced replicative fitness did not necessarily correlate to with 
decreases in the viral gene expression.  
 
4.2.7 Viral gene expression during infection with NP-mutant viruses 
To determine if the NP-mutations affected viral gene expression during infection, 
western blot analyses were performed with infected cell lysates from a single cycle 
growth assay. MDCK cells were mock infected or infected with WT or the mutant 
viruses at an MOI of 3. 16 h p.i. cells were lysed and analysed by SDS-PAGE and 
western blotting for viral proteins PB1, HA, NP, M1, M2, NS1 and NS2 and cellular  
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Fig. 4.10. Transcriptional activity of NP-mutants. 293T cells were co-transfected 
with pDUAL PB1, PB2, PA and WT or mutant NP plasmids along with an RNA 
polymerase I firefly reporter vRNA plasmid. Luciferase activity was measured 48 h 
post transfection. Data are the means ± S.E.M of three independent experiments each 
carried out in triplicate. *p<0.05, ** p<0.01,***p<0.001 (one-way ANOVA with original 
data values).
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tubulin as a loading control. Mock infected samples did not contain any viral proteins, 
as expected (Fig. 4.11). Comparable amounts of the viral proteins PB1, HA, NP, M2 
and NS1 were present in all infected cell lysates. However, Q311R and N309T 
infections displayed increased accumulation of M1 and NS2, both of which are 
mediators thought to be involved in nuclear-cytoplasmic export of vRNPs via the 
CRM1 pathway (reviewed in Eisfeld et al., 2015). 
 
To determine the reproducibility of this apparent difference in M1 and NS2 expression, 
the amounts of these polypeptides were quantified from five independent experiments 
and normalised to the tubulin loading control. The Q311R and N309T infected cell 
lysates consistently presented around twice the amount of M1 in comparison to the 
WT infection. However, the increase in NS2 (as shown in Fig. 4.11.A) was less 
reproducible, leading to an average ~1.5-fold increase but with a high standard error. 
Consequently, the differences in NS2 abundance were not statistically significant 
when compared to the WT virus. Y296H, P283S and C333S NP-mutant viruses 
produced similar quantities of both M1 and NS2 relative to the WT virus. Overall the 
western blot analysis revealed significantly increased M1 expression during a single 




Fig. 4.11. Viral gene expression in a single cycle growth assay. (A) Western blot 
of infected cell lysates for viral proteins. MDCK cells were infected (or mock infected) 
with WT or mutant viruses at MOI 3. 16 h p.i. infection cells were lysed and analysed 
by SDS-PAGE and western blotting for viral proteins PB1, HA, NP, M1, NS1, and NS2 
and cellular alpha tubulin as a loading control. (B) M1 or (C) NS2 protein 
quantification. Protein bands were quantified using ImageStudio Li-cor software and 
normalised to tubulin and then the WT data. Data are the mean ± S.E.M of 5 
independent experiments. *p<0.05 in unpaired t-test. 
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4.2.8 Virion protein analysis of purified NP-mutant viruses  
As presented in the previous section, an increase M1 expression was observed during 
single cycle infections with the Q311R and N309T viruses (Fig. 4.11). To determine 
if the increase in the viral M1 protein was represented in released virus particles, 
purification of the WT and the five NP-mutants was performed to analyse virion 
composition. To obtain a large volume of virus for purification, viruses were grown in 
10-day old embryonated hens’ eggs before harvesting 2-days post infection. Allantoic 
fluid harvested from the mock infected and infected eggs was clarified and initially 
concentrated through a 60 % sucrose cushion. The pelleted virus was resuspended and 
purified further by banding on a 15 %-60 % sucrose gradient. Following re-
concentration by further ultracentrifugation, the purified viruses were resuspended 
again and aliquots were separated by SDS-PAGE and stained with Coomassie Brilliant 
Blue. Viral proteins were identified by their predicted molecular weight. The NP 
protein of the purified viruses was sequenced to confirm the presence of mutations 
after growth in eggs.  
 
As expected, the uninfected (mock) purified allantoic fluid did not contain substantial 
amounts of viral or cellular proteins (Fig. 4.12.A). The major structural polypeptides 
NP, HA1, M1 and HA2 were readily detected in the purified virus preparations. WT, 
Y296H, P283S and C333S samples contained similar quantities of the major viral 
proteins. Notably however, Q311R and N309T viruses displayed a slight increase in 
both the HA1 and HA2 proteins and (especially Q311R) a considerable increase in the 
M1 polypeptide. Western blotting analysis with the purified virus preparations was 
also performed (Fig. 4.12.B). The mock infected sample showed no NP or M1, as 
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expected (Fig. 4.12.B) and all viruses displayed similar amounts of NP. Q311R 
presented a clear increase in M1 in comparison to the other viruses. An increase in M1 
was not as evident in the N309T preparation as shown in the Coomassie analysis 
(Fig.4.12.A).  
 
To determine if these results were reproducible, an independent purification was 
carried out with the WT and Q311R and N309T mutant viruses (data not shown). The 
NP, M1 and HA protein bands were quantified using ImageJ from the two independent 
purifications. M1:NP and HA:NP ratios were then calculated for each mutant virus 
relative to the WT ratio (Fig. 4.12.A.B). Q311R and N309T both displayed a 
significant increase in relative M1 incorporation, of 3 and 2-fold, respectively (Fig. 
4.13.C). Additionally, significant differences in the HA1:NP ratio were observed for 
both the Q311R and N309T viruses, of ~1.5-2-fold compared to WT (Fig. 4.13.D). 
Y296H, P283S and C333S NP-mutant viruses displayed no significant difference in 
M1:NP or HA1/HA2:NP ratios compared to WT (Fig. 4.13.C.D). Overall these results 
indicated that Q311R and N309T virions contained significantly higher quantities of 
M1 and HA1 compared to the WT virus.  
 
4.2.9 Morphology of NP-mutant viruses   
The increase in M1:NP and HA:NP ratios in Q311R and N309T purified virus 
preparations (Fig. 4.12) suggested the hypothesis that these NP-mutations changed the 
morphology of these viruses, since filamentous influenza particles have been reported 
to contain a higher amount of M1 and HA relative to NP (Badham and Rossman, 
2016). Therefore, IF analysis was performed to examine the budding morphology of 
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Fig. 4.12. Analysis of purified virus preparations. (A) Proteins were separated on 
a 12 % polyacrylamide gel. Gel was fixed and stained with Coomassie Brilliant Blue. 
Viral proteins were identified by their predicted molecular weight. (B) Western blotting 
of viral NP and M1 proteins in purified virus preparations. Proteins were separated by 
SDS-PAGE and western blotting with anti-NP and anti-M1. (C, D) NP, M1, HA1 and 
HA2 bands were quantified using ImageStudio Li-cor software and normalised to NP. 
Data are the mean ± S.E.M of 2 independently purified virus preparations. **p<0.001 
***p<0.0005 in unpaired t-tests.
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the NP-mutant viruses. A549 cells were mock infected or infected with WT or -mutant 
viruses and 16  h p.i., cells were fixed, left unpermeabilised and immunofluorescently 
stained with anti-PR8 (green) to detect cell surface HA and a nuclear stain (DAPI; 
blue). Mock infected cells displayed some focal staining, indicative of some 
background noise from the PR8 antibody (Fig. 4.13). WT virus-infected cells 
displayed a stippled punctate array of surface HA, a pattern commonly seen for viruses 
that only produce spherical virus particles, consistent with previous reports that PR8 
is spherical in morphology (Mosely and Wyckoff, 1946, Elton et al., 2001). In contrast, 
Q311R and N309T viruses presented longer filamentous structures. Q311R displayed 
multiple, short filaments, while fewer but longer filaments were observed for N309T. 
Y296H and C333S displayed a slight increase in filament formation in comparison to 
WT virus but fewer than Q311R and N309T infected cells. P283S presented a similar 
HA surface staining pattern to the spherical WT virus. Overall these data show that the 
NP mutations Q311R and N309T altered the spherical budding morphology of the 
WT-PR8 virus towards a more filamentous phenotype. Thus, suggesting that the 
increase in structural proteins M1 and HA1 observed for Q311R and N309T did indeed 




Fig. 4.13. Cells surface staining for virus HA during infection with NP-mutant 
viruses. A549 cells were infected with WT or NP-mutant viruses at MOI 3. 16 h p.i. 
unpermeabilised cells were stained with anti-PR8 (green) and a nuclear stain (DAPI; 
blue). Z-stacks were taken by confocal microscopy. Images shown as maximum 




In this chapter, it was determined that amino acid substitutions within the NP gene 
allowed an H1N1 virus to partially escape CRM1-inhibition by the KPT-335 
compound. Generation of IAV harbouring potential drug-resistant mutations presented 
in chapter 3 was necessary to establish whether the amino acid changes contributed to 
a KPT-335-resistant phenotype. Utilising these recombinant NP-mutant viruses 
allowed determination of their susceptibility to KPT-335 by dose-response analyses 
and examination of the drug’s mechanism of action by IF. Additionally, further 
phenotypic assays gave an insight into the possible mechanism of escape from CRM1 
inhibition of the NP-mutant viruses.  
 
4.3.1 NP-mutant virus susceptibility to KPT-335 
The generated NP-mutant viruses’ susceptibility to KPT-335 was tested by multiple 
phenotypic assays which included plaque reduction assays, dose-response inhibition 
curves and analysis of NP intracellular localisation. The outcomes of these assays are 
summarised in Table 4.1. KPT-335 dose-response inhibition analysis revealed that 
viruses containing the NP amino acid changes Q311R and N309T were the least 
susceptible to the compound’s antiviral activity, with the most resistant phenotype 
displayed by Q311R (Fig. 4.2). The other NP-mutants Y296H, P283S and C333S were 
more susceptible to KPT-335; however, the estimated IC50 values were higher than the 
WT, suggesting a possible partial resistant phenotype (Fig. 4.2). The plaque reduction 
data determined that Q311R, N309T and Y296H were resistant to KPT-335 at 0.3 µM 
whereas P283S and C333S did not display a resistant phenotype at this concentration 
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(Fig. 4.3). The WT virus was more susceptible to KPT-335 inhibition when measured 
by plaque reduction assay compared to the dose-response test. This suggests that 
plaque reduction assays are a less sensitive method of measuring drug susceptibility, 
therefore explaining the variance in drug-resistant phenotypes between the two 
experiments. Examination of NP localisation during infection displayed a greater 
persistence of cytoplasmic NP in Q311R and N309T infected cells after treatment with 
0.3 µM, confirming the KPT-335-resistant phenotype previously observed for these 
viruses. Complementary to the plaque reduction data (Fig 4.4), nuclear retention of NP 
occurred at the higher concentration of compound (1 µM), indicating that Q311R and 
N309T were only partially resistant to KPT-335. Considering the plaque reduction 
data, dose response and IF analysis, it was concluded that NP amino acid substitutions 
Q311R, N309T and Y296H caused partial resistance to CRM1 inhibition, with P283S 
and C333S also displaying a questionable drug-resistant phenotype. Alongside these 
phenotypic tests, quantification of virus particles in presence of drug analysed by 
qPCR could be another method in which to assess the partial/questionable resistant 
phenotype of the NP variants. 
 
4.3.2 NP-mutant virus fitness  
The partial drug-resistance phenotype of Q311R, N309T and Y296H viruses suggests 
that additional mutations would be required to enhance and/or develop a fully resistant 
IAV strain. Compensatory mutations are likely to develop under serial passage of a 
pathogen under the selection of a drug and have been described to play an important 
role in the evolution of pathogens (reviewed in Handel et al., 2006). In this study, 
additional amino acid substitutions were discovered upon sequencing the serial  
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WT 	 	 	 
Q311R    
N309T    
Y296H  ? 	 
P283S 	 ? 	 
C333S 	 ? 	 
Key: 	 = not resistant, ? = questionable resistance,  = partial resistance 
 
Table 4.2 Summary of NP-mutant viral fitness 
 Multi-cycle 
replication 
Plaque size Transcriptional 
activity 
- drug +drug 
WT 	 	 	 	 
Q311R   	 
N309T ?  	 	 
Y296H ?  	  
P283S ?  	  
C333S   	  











passaged viruses described in the prior chapter. Mutations which possibly arose as an 
artefact of virus adapting to the A549 cells during the serial passage included: F551S 
(PB2), R363G (PB1) and A178T (NP). Generating recombinant viruses containing 
both the NP-mutations and the potential compensatory changes may enhance the drug-
resistant phenotype and/or increase virus fitness. However, testing a larger number of 
different mutant combinations was judged not be a valuable use of resources. 
Therefore, to simplify the phenotypic analysis, viruses were generated to contain 
single NP mutations only.  
 
The NP mutations, Q311R, N309T and Y296H allowed IAV to partially overcome 
inhibition by KPT-335. However, these amino acid substitutions came at a fitness cost 
to the virus. The differences in fitness were evident in some or all of multi-cycle 
replication assays, plaque size analysis and investigations into transcriptional activity 
(results summarised in Table 4.2). NP-mutant virus C333S replicated to a similar titre 
as WT whereas N309T, Y296H and P283S displayed a slight reduction in growth and 
Q311R presented a clear reduction in replicative fitness (Fig. 4.2). Further 
investigations into this loss of fitness by plaque reduction assay revealed that Q311R 
did not replicate efficiently in absence of drug, displaying small and hazy plaques (Fig. 
4.3); a similar phenotype that was seen in corresponding serial passage experiment 
(R1) (chapter 3, Fig. 3.3:3.4.). All NP-mutant viruses presented a significant reduction 
in plaque size compared to WT in the absence of compound (Fig. 4.5). Interestingly, 
Q311R plaque size remained unchanged in the presence of the compound whereas the 
plaque size of the other NP-mutant viruses and WT was restricted by KPT-335, 
indicating that Q311R replication fitness may increase in the presence of a sub-
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inhibitory compound concentration. Viral transcription was not affected by NP 
mutations Q311R and N309T (Fig. 4.10). However, NP-mutants Y296H, P283S, 
C333S showed a minor reduction in transcriptional activity in comparison to WT, 
although the corresponding titres suggested a limited loss of replicative fitness for 
these viruses. Thus, it was hypothesised that the loss of fitness and/or the resistant 
phenotype observed for Q311R and N309T amino acids substitutions did not correlate 
to a change in viral transcription.  
 
There are many factors by which amino acid changes could be detrimental to the virus. 
For example, amino acid substitutions can lead to a loss in enzyme activity, change in 
the structure/folding of a protein and/or reduction in a polypeptide stability (reviewed 
in Teng et al., 2010). The most drug-resistant mutant virus and also the least fit virus, 
Q311R had substitution of a hydrophilic, uncharged glutamine (Q) to a positively 
charged arginine (R). Arginine residues are abundant in protein active and/or binding 
sites and due to their positive charge, can pair with negatively charged amino acids to 
create a stable non-covalent bond. Therefore, an amino acid substitution to an arginine 
may suggest a modification in a protein-protein interaction which could change virus 
fitness and/or have implications for a mechanism of drug-resistance. Further 
mechanistic and structural analysis of the NP protein containing the mutations of 
interest would be required to confirm these suggestions.  
 
The two WHO-approved antiviral classes; adamantanes and NAIs, have had distinct 
levels of antiviral efficacy with respect to their resistance patterns. Adamantane 
resistance can occur with a single point mutation within the M2 gene (Bright et al, 
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2006; Deyde et al., 2007; Frederick and Hayden, 2006). These resistant strains, 
containing the S31N mutation, do not have a fitness disadvantage; thus they are 
transmissible and able to cause disease (Hayden et al., 1989, Mast et al., 1991), 
explaining the success of adamantane-resistance strains at taking hold within the 
population. In contrast, NAI escape mutations have been previously shown to 
significantly reduce viral replication (Burnham et al., 2014). Post-pandemic 2009, 
NAI resistance is not currently prevalent within the population, suggesting that the 
drug resistance mutations may hinder the ability of the virus to transmit and infect 
successfully. Considering the resistance patterns for current IAV antivirals, the single 
point NP mutations found in this study caused a viral fitness defect and therefore the 
potential of KPT-335 resistance to emerge and transmit efficiently would be predicted 
to be low.   
 
4.3.2 Effects of the NP mutations and possible mechanism of resistance  
Viral NP formed a ring-like pattern at the inner edge of the nucleus during WT 
infection in the presence of KPT-335 (Fig. 4.7.A). Elton et al., (2001, 2005), Ma et al., 
(2001) and Watanabe et al., (2001) previously described this specific NP staining 
pattern inside the nuclear envelope after treatment with LMB. In the absence of LMB, 
NP appeared more diffuse throughout the nucleus at 3.5 h p.i. which was unchanged 
by LMB treatment at 3.5 h p.i. However, at late times points of infection (9 h), LMB 
treatment caused NP to preferentially accumulate at the edge of the nucleus (Elton et 
al., 2001). In the present study, the NP peripheral ring formation was not noted during 
infection with Q311R and N309T viruses in the presence of KPT-335 and NP was 
more evenly distributed throughout the nucleoplasm, suggesting that these amino acid 
 165 
substitutions have disrupted ‘normal’ vRNP nuclear-cytoplasmic transport. Bui et al., 
(2000), have previously suggested that RNP export occurs in two stages. The first stage 
would involve the release of the vRNPs from cellular chromatin (data supported by 
Bukrinskaya et al., 1979, Chase et al., 2011, Takizawa et al., 2006), potentially 
causing the diffuse NP staining at early stages of infection and the second stage would 
involve translocation of the vRNPs across the nuclear pore. Considering the Elton and 
Bui data, it could be speculated that as Q311R and N309T NP did not form the ring-
like pattern as these substitutions could have slowed the nuclear export process prior 
to the second (late) stage of nuclear export.  
 
LMB covalently binds to cysteine-529 on CRM1, thus permanently blocking export 
of proteins that utilise the CRM1 nuclear export pathway. Dose-response inhibition 
with LMB indicated that the NP-mutant viruses were generally suppressed by the 
compound. This is consistent with the previous conclusion that the single amino acids 
changes did not allow the virus to fully escape KPT-335 inhibition and suggests that 
CRM1-function was most likely still essential for nuclear export of vRNPs. Unlike 
LMB, KPT-335 transiently binds to CRM1 for ~12 to 24 h (London et al., 2014). 
Therefore, the transient inhibition of nuclear export would allow for sufficient virus 
replication and thus the possible accumulation of genetic mutations necessary for 
resistance. During the serial passage experiments (chapter 3), one passage equated to 
48 h of replication in the presence of drug. In chapter 2, it was suggested that another 
reversible CRM1 inhibitor, KPT-185 had a half-life of <48 h (Fig. 2.7.) Thus, if KPT-
335 had a similar half-life, viral replication >24 h p.i may not have occurred in the 
presence of an active inhibitory concentration of compound, thus increasing the chance 
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of escape mutations. Consequently, it could be hypothesised that if a similar serial 
passage experiment was performed with LMB, due to its covalent nature, resistance 
may be difficult to select for. However, in terms of clinical relevance, LMB is too toxic 
to be used as an antiviral therapy and therefore, as with most cellular inhibitors, a 
balance between toxicity, effectiveness and potential for resistance emergence needs 
to be considered. 
 
A significant increase in M1 accumulation was observed in a single round of 
replication with Q311R and N309T viruses as analysed by western blot (Fig. 4.11). 
Analysis of purified viruses by SDS-PAGE established that Q311R and N309T 
incorporated a higher amount of M1 protein into the virion per NP molecule (Fig. 
4.12). The NP mutations Q311R and N309T may increase M1 expression by changing 
NP interactions with other proteins involved in the nuclear export process. Previous 
studies indicate that NS2 is responsible for vRNP interaction with CRM1 (O’Neill et 
al., 1998 Askarsu et al., 2003, Watanabe et al., 2011) for export of vRNP from the 
nucleus to the cytoplasm. Contradictorily Bui et al., 2000 suggested that vRNP nuclear 
export could occur in the absence of NS2 and highlighted that the presence of M1 was 
essential to the late stages of nuclear export. The M1 gene contains a leucine-rich NES 
domain which is critical for nuclear export of M1 (Cao et al., 2012). The last three 
residues of the NES motif are surface exposed, indicating a possible interaction with 
CRM1 and/or another protein involved in nuclear export. Previous studies have 
demonstrated that NP can directly interact with CRM1 via its NES motif and therefore 
it is reasonable to speculate that M1 could also interact with CRM1 and/or an adaptor 
protein via its NES domain. As mentioned previously, Cao and colleagues found that 
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a M1 NES fusion protein was not sensitive to LMB treatment. The function of most-
leucine rich NES can be inhibited by LMB (Kudo et al., 1999). However, there are a 
few reports that identify NES-containing proteins that are not inhibited by LMB, such 
as the N protein of canine distemper virus (CDV) and human receptor-interacting 
protein 3 (RIP3) (Sato et al., 2006, Yang et al., 2004). This may suggest that the M1 
NES domain is not sensitive to LMB because the compound does not block the 
interaction between CRM1 and M1 and/or M1 interacts with a different insensitive 
NES adapter protein. In this case, it could be hypothesised that if M1 was not sensitive 
to CRM1 inhibition, an increase in M1 concentration during infection may help the 
virus overcome CRM1-inhbition by KPT-335.  
 
M1 has been described to control influenza virion morphology (Bourmakina & Garcia-
Sastre, 2003. Elleman & Barclay, 2004). This was initially shown by changing a 
filamentous virus (A/Udorn/72) to a spherical form by a single point mutation in the 
M1 protein (Zebedee et al., 1988, Zebedee et al., 1989, Roberts et al, 1998). However, 
the exact mechanism by which M1 influences morphology is not well characterised. 
Investigations into the morphology of the NP-mutant viruses revealed that Q311R and 
N309T viruses displayed an increase in a filamentous budding phenotype compared to 
the PR8-WT virus, which usually forms exclusively spherical particles (Mosely & 
Wyckoff, 1946). The filamentous budding morphology of the NP-mutants could be 
further characterised by electron microscopy, which would allow for an alternative 
method of quantifying the differences in the filament size. 
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The correlation between the increase in M1 incorporation and filamentous virion 
formation was supported by the examination of the protein profile of a known 
filamentous virus (PR8 MUd), which contained an increase in M1 and HA structural 
proteins; similar to Q311R and N309T (data not shown). Bialas et al., (2014) have 
previously shown that NP amino acid substitutions can affect whether an influenza 
virus presents a spherical or filamentous budding morphology. The authors identified 
three NP residues: 214, 217 and 253 that play a role in determining virion morphology 
and suggested that the minor groove of helical vRNP is the site of interaction with the 
M1 layer during budding. The NP-M1 interactions have been described to induce a 
conformational change in M1, possibly by creating an angle between the layers 
beneath the viral envelope thus changing particle morphology (Bialas et al., 2014). 
These data suggest the possibility that the NP-mutants presented in this study have 
modified interactions between NP and M1, thereby creating a filamentous virus. 
Additionally, it has been previously demonstrated that filamentous viruses are less fit 
in vitro than spherical forms (Seladi-Schulam et al., 2013). Therefore, the smaller 
plaque phenotype and reduction in replicative fitness presented by Q311R and N309T 
viruses may in part be a result of their filamentous natures. 
 
The data described in this chapter showed that NP amino acid changes Q311R, N309T 
and Y296H allowed an H1N1 virus to partially escape KPT-335 CRM1-inhibition. 
The NP mutations did not select for a fully KPT-335-resistant virus strain, indicating 
the virus could not easily escape the consequences of CRM1 inhibition with a single 
point mutation. Additionally, drug-resistant mutations Q311R and N309T, came at a 
replicative fitness cost to the virus. This apparently higher genetic barrier for drug-
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resistance makes CRM1 a promising antiviral therapy target. The next chapter 
investigates the reduced fitness phenotype further and possible mechanisms of 



















Chapter 5 Investigating the sensitivity of KPT-335-
resistant NP-mutant influenza A viruses to the 
antiviral protein, MxA.  
 
5.1 Introduction  
 
In the previous chapter, individual single NP amino acid substitutions Q311R, N309T 
and Y296H were found to elicit a resistant phenotype to the drug KPT-335, which 
otherwise blocks the nuclear export of vRNPs by targeting the cellular protein, CRM1. 
A literature search for other studies that highlighted the same amino acid residues 
within NP that were altered upon serial passage of IAV in the presence of KPT-335 
(311, 309, 296, 283 and 333) was carried out. This search revealed a limited number 
of published studies which discussed the NP residues of interest (Table 5.1). However, 
three papers referenced an area on the surface of the NP protein (Fig. 5.1) that 
determined the sensitivity of IAV to the innate immune antiviral factor, myxovirus 
resistance gene A (MxA) (Ashenberg et al., 2017; Götz et al., 2016; Mänz et al., 2013), 
which correlated well with the KPT-335-resistant NP mutations found in this study.  
 
MxA is a human innate immune protein that’s expression is induced by the activation 
of the IFN response. MxA inhibits influenza replication by targeting the viral NP 
protein (Matzinger et al., 2013; Nigg & Pavlovic, 2015; Turan et al., 2004; 
Zimmermann et al., 2011; Verhelst et al., 2012; Xiao et al., 2013), however the exact 
mechanism of 
 





SUMMARY OF FINDINGS 
 
PAPER 
309 § Mutations were identified that facilitate growth of avian IAV in humans 
§ An influenza (dk/AB/76) (H1N1) virus was adapted to a high-growth phenotype (N309K)  
(Danzy et al., 
2014) 
296 § Phosphorylation of Y296 caused nuclear retention of NP by reducing the interaction between NP and CRM1 
§ Y296F ablated tyrosine phosphorylation of NP during the early stage of virus infection  
(Zheng et al., 
2015) 
283 § Deep mutational scanning identified surface exposed sites within the NP that affected viral inhibition by 
MxA (includes 283 and 309). Further information in table 5.2.  





(Götz et al., 
2016) 
 § Introduction of 100I/V, 283P, 313Y into the NP of an MxA-sensitive influenza virus (KAN-1)/04 (H5N1) 
resulted in a gain of MxA resistance and a decrease in viral replication fitness. 
(Mänz et al., 
2013) 
 § Reassortant viruses with the PB2, PA and NP of human influenza isolates were generated in the genetic 
background of an avian H5N1 virus to determine effect on pathogenicity in mice. 
§ 100I/V and 283P did not enhance pathogenicity in mice  
(Kim et al., 
2010) 
333 § Mutational analysis examined the roles of highly conserved amino acids within NP  
§ C333A had little to no effect on virus growth  




§ Identified 7 potential nuclear export signal (NES) motifs with striking similarity to leucine-rich NES motifs 
§ Potential motif [289-314] was not sufficient to a direct the fusion protein from the nucleus to cytoplasm and 
therefore was confirmed as a novel NES motif  
(Yu et al., 
2012) 171 
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the inhibitory interaction between NP and MxA is incompletely understood. Two 
strategies in which influenza viruses overcome MxA restriction have been described; 
blockage of the upregulation of the IFN response which drives the expression of MxA 
(Hale et al., 2010) and more specifically, by acquiring amino acid mutations within 
NP which can reduce sensitivity to MxA (Dittmann et al., 2008; Mänz et al., 2013). 
Manz et al, described human influenza viruses to be more resistant to MxA restriction 
than avian viruses and identified a small set of amino acid differences within NP that 
defined this sensitivity (100I/V, 283P and 313Y). Additionally, a deep mutational 
scanning study on the NP of an H3N2 virus identified amino acids clustered on the 
polypeptide surface that appeared to be important for MxA recognition (Ashenberg et 
al., 2017). 12 amino acid sites identified from the screen were confirmed to either 
increase or decrease the sensitivity of the virus to MxA restriction (Fig. 5.1.B). The 
MxA recognition amino acid positions from Mänz et al., (shown in blue) and 
Ashenberg et al., (shown in red) were mapped to the crystal structure of the NP protein 
(Fig. 5.1A). This illustrates that these amino acids lie in close proximity to the surface 
exposed NP mutations established in this study with two of the positions coinciding 
(N309T and P283S; shown in green). Therefore, it was hypothesised that the surface 
exposed NP mutations identified in this study (Q311R, N309T, Y296H, P283S) would 
influence IAV sensitivity to MxA restriction.  
 
The aim of this section was to determine whether the KPT-335-resistant NP-mutations 
altered the sensitivity of IAV to the innate immune antiviral protein, MxA. The 
mechanism by which MxA may restrict the NP-mutant viruses was investigated, as 
well as determining whether the NP-mutant viruses were suppressed by IFN-I 
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stimulation. Most of the work in the chapter was performed using an MxA over-
expressing cell line which was kindly gifted from Dr Dave Jackson’s laboratory, 
University of St. Andrews. (Xiao et al., 2013). 
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Fig. 5.1. NP amino acid residues involved in MxA recognition in relation to KPT-
335-resistant mutants. (A) Crystal structure of the NP monomer surface annotated 
with amino acids residues from Mänz et al., (shown in blue), Ashenberg et al., (shown 
in red) and overlapping mutations from this study and published work (shown in 
green). 311 (pink) and 296 (yellow). (B) Table indicating the amino acid changes 
required for KPT-335 and MxA resistance/susceptibility (Q4Y and Q12S not mapped).  
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5.2 Results  
 
5.2.1 Antiviral activity of MxA during NP-mutant virus infection 
The IFN-induced innate immune factor, MxA, can restrict IAV replication at early 
stages of infection (Xiao et al., 2013). As previously described, mutations within the 
NP protein can determine IAV sensitivity to MxA antiviral activity. To establish the 
effect MxA had on the NP-mutant viruses generated in chapter 4, virus replication was 
examined in a cell line which overexpressed the MxA protein (MxA-A549). Prior to 
infections in the MxA-A549 cells, the increased expression of MxA in the engineered 
cell line compared to normal A549s was confirmed by western blotting cellular lysates 
for MxA and tubulin as a loading control (Fig 5.2.B). In addition, an 
immunofluorescence assay was utilised to confirm that the majority of cells in the 
overexpressing cell line produced high levels of MxA (Fig 5.2.A). 
 
To determine if the NP-mutant viruses were susceptible or resistant to MxA restriction, 
multi-cycle growth infections were performed in naïve and MxA-A549 cells. Cells 
were infected with PR8 (WT) or the mutant viruses at an MOI of 0.01. At 24 h p.i., 
viral supernatant was harvested and the titre was determined by plaque assay. In naïve-
A549 cells, WT, Y296H, P283S and C333S viruses all replicated to ~107 PFU/ml, 
while Q311R and N309T grew to ~106 PFU/ml (Fig. 5.2.C), consistent with previous 
data (Fig. 5.3). The WT virus replicated to ~106 PFU/ml in the MxA-A549 cells. This 
1-log10 reduction in titre is comparable with previous reports that PR8 was partially 
resistant to MxA restriction (Manz et al., 2015). Y296H and P283S viruses also 
replicated to ~106 PFU/ml in the MxA cells, similar to the WT virus, suggesting that 
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they were also partially resistant to MxA. However, the two mutant viruses that had 
the strongest drug-resistant phenotypes, Q311R and N309T were notably more 
susceptible to MxA antiviral activity, resulting in a 3-log10 (to 103 PFU/ml) and 2-log10 
(to 104 PFU/ml) reductions in titre, respectively. Interestingly, the C333S virus was 
not affected by MxA restriction and replicated to a similar titre as in the naïve cells 
(107 PFU/ml). 
 
To give a clearer view of any differences in susceptibility, the fold changes in virus 
titre between naïve and MxA A549 cells were analysed (Fig. 5.2.D). These results 
displayed a greater fold decrease in titre for Q311R than the WT virus in all three 
independent experiments, indicating that the former virus was more sensitive to MxA 
restriction (Fig. 5.2.D). N309T also displayed a generally greater decrease in titre than 
the WT virus, however the spreads of individual data points from the two viruses 
overlapped suggesting this change may not be significantly different. Y296H and 
P283S viruses presented little difference in fold change, with the spread of values 
similar to that of the WT. Notably, C333S displayed a significantly smaller set of fold-
change values to the WT, indicating that this mutant virus was more resistant to MxA 
antiviral activity. Overall, these results indicated that NP amino acid changes Q311R, 
N309T and C333S altered the virus’ sensitivity to MxA restriction thus supporting the 





Fig. 5.2 Growth of NP-mutant viruses in an MxA over-expressing cell line. (A) 
Immunofluorescent staining of MxA. Naïve-A549 and MxA-A549 cells were fixed, 
permeabilised and stained with anti-MxA (green) and a nuclear stain (DAPI; blue). (B) 
Western blot detection of MxA. Cell lysates were analysed by SDS-PAGE and 
western blotting with anti-MxA and anti-tubulin as a loading control. (C) Virus 
replication in MxA cells. Naïve or MxA-A549 cells were infected with WT or NP-mutant 
viruses at MOI 0.01. Virus supernatant was harvested at 24 h and titred by plaque 
assay. Data are the mean ± S.E.M. of three independent experiments. (D) Fold 
change in virus titre (MxA cells vs naïve cells) ** p<0.05 in one way ANOVA. 
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5.2.2 Ability of NP-mutant viruses to infect MxA overexpressing cells  
To investigate further the difference in sensitivity of the NP mutant viruses Q311R 
and N309T to MxA, IF analysis of infection levels was performed in the 
overexpressing cell line to determine if the mutant viruses were able initiate viral 
infection (as measured by expression of the “early” class viral gene product NP) with 
similar efficiency to the WT virus.  Naïve and MxA-A549 cells were infected with 
WT or the mutant viruses at an MOI of 3. At 8 h p.i., cells were stained with anti-NP 
(red), anti-MxA (green) and a nuclear stain (DAPI; blue). The naïve cells expressed 
low levels of MxA, as expected (Fig. 5.3). All viruses displayed similar amounts of 
NP in the cytoplasm of the naïve cells, representing comparable infection levels 
between the viruses and also indicating that nuclear export of vRNPs had taken place 
(Fig. 5.3). The MxA-A549 cells displayed an abundance of MxA in the cytoplasm 
confirming that the cells overexpressed the protein. WT, Y296H, P283S and C333S 
displayed cytoplasmic NP in the MxA-overexpressing cell line, similarly to the 
infected naïve cells, indicating that these viruses were able to replicate in the presence 
of MxA. In contrast, Q311R infection gave very few NP-positive cells in the MxA cell 
line, indicating that the presence of the antiviral protein restricted the ability of the 
virus to establish infection. N309T infected MxA cells displayed a reduced number of 
NP-positive cells and interestingly, the NP was localised to the nucleus rather than the 
cytoplasm as observed for the WT and the other NP-mutants. Overall the IF analysis 
confirmed that Q311R was highly sensitive to MxA restriction during a single round 
of replication. The N309T virus was also less able to establish infection in the presence 
of high levels of MxA, but even in cells where viral gene expression was clearly 
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Fig. 5.3. Immunofluorescent staining of viral NP during infection in MxA-A549 
cells. Naive-A549 or MxA-A549 cells were infected with WT or NP-mutant viruses at 
MOI 3. 8 h p.i. cells were fixed, permeabilised and stained and with anti-NP (red), 




present, the presence of nuclear NP suggested that normal vRNP nuclear-cytoplasmic 
transport was disrupted in the presence of MxA.  
 
5.2.3 Investigation into mechanism of action of MxA sensitivity  
MxA is thought to inhibit IAV by acting upon two stages of the viral life cycle; 
preventing transcription by incoming vRNPs (primary transcription), most likely by 
blocking their transport into the nucleus (Matzinger et al., 2013, Xiao et al., 2013), as 
well as by inhibiting amplification of vRNA from cRNA copies (genome replication), 
possibly by sequestering newly synthesized NP and PB2 in the cytoplasm (Huang et 
al., 2012; Pavlovic et al., 1990; Verhelst et al., 2012). To determine if the NP-mutant 
viruses were blocked by MxA at the stage of RNP nuclear import, investigation into 
the ability of the viruses to transport vRNPs into the nucleus was determined utilising 
the MxA cell line. For this experiment, cells were infected in the presence of 
cycloheximide (a protein synthesis inhibitor) to allow immunofluorescent-tracking of 
incoming vRNP complexes into the nucleus.   
 
Naïve and MxA-A549 cells were infected with purified WT or NP-mutant viruses 
(Q311R and N309T) in the presence of CHX. 3.5 h p.i. cells were fixed and stained 
with anti-NP (green), anti-MxA (red) and a nuclear stain (DAPI; blue). Naïve cells 
infected with WT virus in the absence of CHX (-CHX) were used as a positive control 
for nuclear import of vRNPs and the efficacy of CHX treatment. Naïve cells treated 
with importazole and CHX (+IMP, +CHX) were used as a positive control for 
inhibition of vRNP import as IMP specifically targets the cellular importin-β pathway 
thus blocking their nuclear import (Soderholm et al., 2011). As expected, mock 
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infected naïve and MxA cells showed no NP staining (Fig. 5.4.A), and MxA was 
abundant in the overexpressing cell line (Fig. 5.4.A.B). WT virus in the absence of 
CHX displayed bright staining of nuclear and cytoplasmic NP, indicating normal 
infection had taken place (Fig. 5.4.A). WT virus treated with IMP (+CHX) presented 
much fainter NP-staining largely in the form of cytoplasmic puncta, indicating that 
nuclear import of vRNPs had been blocked by the compound (Fig. 5.4.A). Infections 
with WT, Q311R and N309T in naïve cells (+CHX) gave NP staining predominantly 
in the nucleus demonstrating typical import of vRNPs (Fig. 5.4.B). In the MxA cells, 
WT RNP was still localised to the nucleus, indicating nuclear import had occurred 
even in the presence of MxA. However, in the MxA cells, NP staining from Q311R 
and N309T viruses was mostly cytoplasmic with little to no evidence of RNPs in the 
nucleus of the cells. Thus, both Q311R and N309T NP-mutant viruses were blocked 
at the stage of nuclear import during infection of a MxA overexpressing cell line. 
Therefore, the MxA restriction observed in the multi-cycle replication assay (Fig. 5.2) 
and IF analysis (Fig. 5.3) for Q311R and N309T was, at least in part, from MxA 
antiviral activity acting at the stage of RNP nuclear import. 
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Fig. 5.4. Import of viral NP into the nucleus during infection in MxA-A549 cells. 
Naïve or MxA-A549 cells were infected with purified WT or NP-mutant viruses. 3.5 h 
p.i. cells were stained with anti-NP (green), anti-MxA (red) and a nuclear stain (DAPI; 
blue). (A) Mock and WT infected naïve and MxA-A549 cells. WT infected cells in the 
absence of cycloheximide (-CHX) were used as a positive control for import of NP. 
Cells were treated with 100µM of importazole (+IMP/+CHX) as a positive control for 
blocking import of NP. (B) Infections were carried out in the presence of CHX (+CHX) 
to stop translation of newly synthesised proteins. 
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5.2.4 Expression of innate immune factors during infection with NP-
mutant viruses 
During IAV infection, the virus typically modulates the innate responses, restricting 
upregulation of antiviral factors such as MxA (Pauli et al., 2008). To determine if the 
NP-mutant viruses could suppress upregulation of MxA, its expression was analysed 
after a single round of virus replication. Naïve and MxA-A549 cells were uninfected 
(mock) or infected with WT or the NP-mutant viruses at an MOI of 3. 16 h p.i. cellular 
lysates were analysed by SDS-PAGE and western blotting with anti-MxA and anti-
tubulin as a loading control. Mock infected naïve-A549 cells did not contain MxA 
indicating the protein was not intrinsically present at detectable levels in uninfected 
A549 cells (Fig. 5.5). As expected, MxA was expressed to high levels in the MxA-
A549 cells, with no visible difference MxA abundance between the viruses analysed. 
All viruses induced a low level of MxA expression in the naïve cells, excluding Q311R 
where a prominent band was observed. This suggested that the Q311R virus could 
possibly upregulate MxA expression and/or lacked the capability to suppress the IFN-
I signalling pathway thus upregulating interferon stimulated genes (ISGs).  
 
To determine if the increase in MxA expression present during infection with Q311R 
was specific, two other ISGs; protein kinase R (PKR) and ISG-15 were analysed by 
western blotting. Like MxA, PKR and ISG-15 are both IFN-induced anti-viral proteins 
that are normally suppressed during IAV infection (reviewed in Iwasaki & Pillai, 
2014). A549 cells were left uninfected (mock) or infected with WT and the NP-mutant 
viruses at an MOI of 3. Samples of mock and WT infected cells were also pre-treated 
with IFN-I (100 U/ml) for 16 h pre-infection as a positive control for upregulation of 
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ISG expression. At 16 h p.i., cellular lysates were analysed by SDS-PAGE and western 
blotting for anti-MxA, anti-PKR, anti-ISG-15 and anti-tubulin as a loading control. As 
expected, IFN-I-stimulated uninfected and cells infected with WT virus to express 
high levels of all three ISGs examined, with slightly increased ISG expression in the 
infected cells (Fig. 5.6). As previously observed in Fig 5.5, infected cells displayed 
low levels of MxA in the absence of exogenous IFN-I, apart from those infected with 
Q311R. Similarly, PKR and ISG-15 levels were also elevated in Q311R infected cells. 
Thus, the western blot data suggested that the Q311R NP-mutant virus may have a 
wider influence on the IFN signalling pathway.  
 
5.2.5 Quantification of secreted IFN-I during infection with NP-mutant 
viruses  
To determine if the increase in ISG expression during Q311R infection was a result of 
greater triggering of the IFN-I response, levels of active IFN-I secreted during virus 
infection were examined using a bioassay. The reporter cell line HEK-blue IFN- α/β 
has been transfected with human STAT1 and IRF8 genes to obtain a fully active IFN-
I signalling pathway and also engineered to express secreted alkaline phosphatase 
(SEAP) under the control of an ISG54 promoter (Ahmed et al., 2016). Thus, 
stimulation of the HEK blue cell line with IFN-I activates the JAK-STAT/ISGF3 
pathway and induces the production of SEAP which can be measured by colorimetry 
following the addition of substrate.  
 
A549 cells were mock infected or infected with WT or the NP-mutant viruses at an 








Fig. 5.5. ISG expression during infection with NP-mutant viruses (A) MxA 
expression during virus infection. Naïve or MxA-A549 cells were infected at MOI 3. At 
16 h p.i., cellular lysates were analysed by SDS-PAGE and western blotting for MxA 
and tubulin. (B) ISG expression during virus infection. A549 cells were infected with 
WT or mutant viruses at MOI 3. Cells were pre-treated with IFN (100 U/ml) for 16 h 
pre-infection as a positive control for ISG expression (+) or left untreated (-). 16 h p.i. 
cellular lysates were analysed by SDS-PAGE and western blotting for MxA, PKR, 




K41A) which is deficient in IFN-antagonism was included as a positive control for the 
detection of secreted IFN-I (Talon et al., 2000; Newby et al., 2007). At 24 h p.i., viral 
supernatants were quantified for the presence of IFN-I using the HEK-Blue reporter 
assay. A standard curve of recombinant human IFN-I was also incubated on the HEK-
Blue cells, starting at a concentration of 7.8 U/ml and increasing in 2-fold increments 
to 1000 U/ml. Media and cells only samples were also included as negative controls 
to determine the background level of the assay. SEAP activity from the HEK-Blue 
cells increased with increasing concentrations of exogenous IFN-I treatment, as 
expected. The media and cells only controls indicated that the limit of detection of the 
assay was ~80 U/ml of IFN-I, as determined by the standard curve (Fig. 5.6). Mock 
infected cells displayed similar amounts of SEAP activity as the media and cells only 
controls. The positive control NS1 mutant virus infection resulted in high levels of 
IFN secretion, equivalent to at least 1000 U/ml of IFN-I. WT, N309T, Y296H, P283S 
and C333S viruses induced comparable amounts of SEAP activity to the mock infected 
and negative controls, suggesting that these viruses efficiently supressed the IFN-I 
response. Notably, the Q311R virus displayed a significant increase in SEAP activity 
which equated to ~200 U/ml of IFN-I. These results demonstrated that Q311R either 
lacked the ability to suppress IFN-I secretion during infection and/or the virus 




Fig. 5.6. HEK-Blue reporter assay to quantify IFN-I upregulation during infection 
with NP-mutant viruses. A549 cells were infected at MOI 3 for 24 h. Cell 
supernatants were quantified for IFN-I using a HEK-Blue cell reporter assay 
(absorbance read at 680 nm). The black line indicates the limit of detection. Data are 
the mean ± S.E.M from three independent experiments. *p<0.05 in unpaired t-test
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5.2.6. Effect of NP-mutant viruses on the global IFN response 
Following detection of the virus by the host innate immune system via pathogen-
associated molecular patterns (PAMPs), IFN-I is secreted which upregulates hundreds 
of different ISGs (reviewed in Iwasaki & Pillai, 2014). Therefore, it could be 
hypothesised that the MxA sensitive mutation, Q311R, may also be more sensitive to 
global IFN-I antiviral activity. Prior to testing the effect IFN-I induction had on NP-
mutant virus replication, a IFN-I dose response assay was performed to determine an 
optimal IFN-I concentration to inhibit virus replication. A549 cells were left untreated 
or pre-treated with increasing concentrations of IFN-I starting at 10 U/ml and 
increasing in 0.5-log10 increments to 1000 U/ml. At 16 h post-treatment, cells were 
infected with PR8-WT at an MOI of 0.01. 24 h p.i. virus supernatant was harvested 
and titre was determined by plaque assay. As expected, pre-treatment with IFN-I 
inhibited virus replication in a dose-dependent manner (Fig. 5.7.A). From the dose-
response curve, it was determined that 100 U/ml was optimal as inhibition of the virus 
plateaued at concentrations somewhere between 100-300 U/ml suggesting saturation 
of IFN-I antiviral activity.  
 
To determine the effect of IFN-I stimulation on NP-mutant virus replication, A549 
cells were pre-treated with IFN-I (100 U/ml) or left untreated. 16 h post-treatment, 
cells were infected with WT or the NP-mutant viruses at an MOI of 0.01. 24 h p.i. 
virus supernatant was harvested and titre was determined by plaque assay (Fig. 5.7.B). 
The fold change in virus replication was determined by calculating the difference in 
titre from cells untreated and treated with IFN-I (Fig. 5.7.C). In untreated A549 cells,  
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Fig. 5.7 Effect of IFN-I pre-treatment on virus growth. (A) IFN-I dose inhibition 
curve. A549 cells were pre-treated with increasing concentrations of IFN-I. 16 h post-
treatment, cells were infected with PR8 virus at MOI 0.01. Virus supernatant was 
harvested at 24h and titre determined by plaque assay. Data are the mean and range 
of two independent experiments. (B) Virus replication in IFN-I stimulated cells. A549 
cells were pre-treated with 100 U/ml of IFN-I (+IFN) or left untreated (-IFN). 16 h post-
treatment, cells were infected with WT or NP-mutant viruses at MOI 0.01. Virus 
supernatant was harvested at 24 h and titred by plaque assay. Data are the mean ± 
S.E.M of three independent experiments. (C) Fold change in virus titre 




WT, Y296H, P283S and C333S viruses all replicated to ~107 PFU/ml and as expected, 
Q311R and N309T displayed a 1-log10 reduction in replication ( to ~106 PFU/ml). As 
determined by the dose-response inhibition curve in Fig. 5.7.A, 100 U/ml of IFN-I pre-
treatment inhibited WT virus by ~2-log10 to ~105 PFU/ml (Fig. 5.7.B). This reduction 
in titre was similar for N309T, Y296H, P283S and C333S viruses after IFN pre-
treatment. Notably, the NP-mutant virus that had the strongest drug-resistant 
phenotype, Q311R, was also the most susceptible to IFN induction, resulting in a 3-
log10 decrease down to only 103 PFU/ml. A greater fold decrease in titre by Q311R 
was observed when compared to the WT virus and the other NP-mutant viruses, 
indicating that this mutant virus was more sensitive to IFN pre-treatment (Fig. 5.7.D). 
Overall, these results indicated that the NP amino acid change Q311R increased IAV 
sensitivity to IFN-I inhibition and suggests the susceptibility of this virus to MxA 















5.3 Discussion  
 
In this chapter, it was discovered that the nuclear export inhibitor escape mutant 
viruses Q311R and N309T were more sensitive to MxA restriction compared to the 
partially MxA-resistant PR8-WT virus. Previous studies have demonstrated that amino 
acid substitutions within the NP gene can greatly influence the antiviral activity of 
MxA. Surface exposed amino acid residues on the NP protein, defined by Manz et al., 
(2015) and Ashenberg et al., (2017) clustered in the same region as the amino acid 
changes isolated in this study (Fig. 5.1).   
 
KPT-335 escape NP-mutant viruses, Q311R and N309T, displayed an increase in 
susceptibility to MxA restriction as determined by multi-cycle replication assays and 
measurement of infection levels in an MxA-A549 overexpressing cell line (Fig. 
5.2;5.3). An NP N309R mutation has been shown previously to produce a MxA 
sensitive strain (Ashenberg et al., 2017). In this study, N309 mutated to a threonine 
(T) also altered the virus’ susceptibility to MxA, thus supporting the previous data that 
the 309 side chain is involved in MxA recognition. While N309T did not cause a 
significant reduction in virus replication in the MxA cells (Fig. 5.2), analysis of 
infection levels by IF showed that NP remained localised predominately in the nucleus 
(Fig. 5.3), suggesting that the N309T substitution may have somehow slowed nuclear 
export of vRNPs. A proline (P) at amino acid position 283 within NP has been 
described to help the virus escape MxA restriction (Mänz et al., 2015). P283 is 
naturally present in the PR8 (H1N1) strain and as shown in Fig. 5.2., WT virus was 




not change the PR8 partial resistance phenotype (Fig. 5.2, 5.3). Q311R appeared the 
most susceptible to MxA restriction (Fig. 5.2, 5.3). NP amino acid residue 311 has not 
been previously identified as a MxA recognition site, thus adding a novel NP residue 
to the list if those that can affect the virus’ sensitivity to MxA. The altered sensitivity 
to MxA caused by Q311R and N309T mutations further supports the current published 
studies that this region on the surface of NP may specifically interact with MxA and/or 
an adaptor protein involved in MxA’s mechanism of action.  
 
The amino acid residues involved in NP and MxA interaction and the mechanism by 
which this interaction restricts IAV is currently unknown. Previous studies regarding 
other viruses show a relation between MxA and nucleoproteins. MxA can inhibit 
thogotovirus (THOV) infection via interaction with THOV nucleocapsids and thereby 
blocking their cytoplasmic-nuclear import (Kochs and Haller, 1999). Additionally, it 
has been demonstrated that MxA and NP directly interact during La Crosse virus 
infection (Kochs et al., 2002). Recently, Gao et al., (2016) solved the crystal structure 
of MxA which revealed that it oligomerizes into ring-like structures and have been 
suggested to assemble around incoming vRNPs. It was hypothesised that these MxA 
rings would interfere with RNP nuclear import and/or primary transcription. The 
authors found that attenuated MxA escape viruses disturbed intracellular trafficking of 
incoming vRNPs, thus supporting one of their hypotheses. Here, it was determined 
that MxA sensitive viruses Q311R and N309T were blocked at the stage of RNP 
nuclear import in an MxA-overexpressing cell line (Fig. 5.4). This outcome is 




blocking vRNPs at the stage of nuclear import, however the exact details of MxA 
antiviral mechanism of action are still not fully elucidated.  
  
Q311R infected cell lysates contained an increased amount of in MxA and two other 
ISGs; ISG-15 and PKR (Fig. 5.5), indicating upregulation of these antiviral proteins 
and/or the incapability of the virus to control the IFN-response. Quantification of IFN-
I secretion indicated that Q311R increased IFN-I levels (Fig. 5.6). This may suggest 
that the Q311R mutation has enhanced IFN induction, for example by allowing vRNA 
to be more exposed to PRRs (as discussed below) or that the mutation has reduced the 
ability of the virus to suppress the IFN-I response. Additionally, it was discovered that 
Q311R was significantly more susceptible to the IFN-I innate immune response (Fig. 
5.7), indicating that Q311R may not be exclusively restricted by MxA. The viral NS1 
protein is a potent virulence factor that helps ‘mask’ the virus from the innate immune 
response by multiple mechanisms (Tisoncik et al., 2011). It is the most important IFN-
antagonist protein encoded by the virus. The Ortin and Fodor laboratories, 
demonstrated that NS1 can interact with NP within the RNP complex (Marion et al., 
1997; Robb et al., 2010) which suggests the hypothesis that NP surface mutation 
Q311R may affect NS1 IFN-antagonism by altering the interaction between NP and 
NS1. However, there is limited knowledge on the interaction of these two proteins. It 
could be speculated that the mechanism by which the NP-mutant virus, Q311R has 
overcome inhibition of nuclear-cytoplasmic transport of vRNPs has somehow altered 
NS1’s ability to shuttle between the nucleus and cytoplasm; possibly necessary for a 




nuclear-cytoplasmic transport may potentially have limited the ability of NS1 to 
prevent an efficient IFN response and expression of ISGs.  
 
The main PRR that recognises IAV is the cytoplasmic retinoic acid-inducible gene I 
(RIG-I) (Kato et al., 2006). RIG-I responds to strongly to dsRNA and binds 
immediately after RNPs are released from the endosomes into the cytoplasm (Li et al., 
2014), resulting in antiviral signalling. Therefore, it could be speculated that Q311R 
triggered a greater IFN response (Fig. 5.6) because of an enhanced detection of the 
RNPs via RIG-I. As suggested previously, MxA may restrict IAV by forming ring-
like structures around the vRNPs, thus if a virus was more sensitive to MxA restriction, 
expression of MxA could potentially ‘hold’ RNPs in the cytoplasm for easier 
recognition by RIG-I. Thus, in turn RIG-I would upregulate expression of IFNs and 
ISGs.   
 
As determined in chapter 4, the MxA sensitive viruses, Q311R and N309T, contained 
a higher relative amount of the viral M1 protein in the virion (Fig. 4.11). Presently, 
there is limited evidence to suggest an interaction between MxA and M1. However, 
one study demonstrated that MxA inhibition of IAV replication did not affect the 
synthesis of PA, PB1, PB2, HA, NA and NP primary transcripts but increased M1 and 
NS2 primary transcripts by 2-3-fold (Pavlovic et al., 1992). Additionally, despite the 
higher abundance of M1 and NS2 transcripts, these proteins were still efficiently 
exported and translated. Therefore, it could be hypothesised that the increase in M1 
expression in Q311R and N309T NP-mutants may somehow relate to the mechanism 





MxA can also interfere with the function of cellular host proteins. Wisskirchen et al., 
(2011) demonstrated that UAP56, a cellular ATP-dependent RNA helicase protein, co-
immunoprecipitated with human MxA. UAP56 is a nuclear-cytoplasmic shuttling 
protein which plays an important role during assembly of the spliceosome and nuclear 
export of both spliced and unspliced mRNAs into the cytoplasm (Thomas et al., 2011). 
A direct interaction between NP and MxA has yet to be described (Turan et al., 2004) 
therefore, Wisskirchen et al., suggested that the cellular protein UAP56 was the 
missing link between NP and MxA; a hypothesis which was suggested by previous 
studies showing that UAP56 can bind directly to free NP and vRNPs (Momose et al., 
2001; Mayer et al., 2007). UAP56 is also required during influenza infection to prevent 
accumulation of dsRNA in the cytoplasm of cells and therefore assists the virus to 
overcome evasion of the IFN-I response (Wisskirchen et al., 2011). In the context of 
this study, if the possible linker nuclear-cytoplasmic protein UAP56 was involved in 
the NP-MxA interactions it may be hypothesised that surface exposed NP-mutation 
Q311R has altered NP’s interaction with UAP56 and therefore has disrupted the 
transport of dsRNA, increasing dsRNA accumulation in the cytoplasm thus increasing 
IFN-I expression and upregulation of ISGs.    
 
NP amino acids substitutions Q311R and N309T confer a resistant phenotype to the 
selective nuclear export inhibitor, KPT-335 but at a replication fitness cost to the virus. 
In this chapter, it was discovered that the Q311R and N309T mutations limit the ability 
of the virus to escape the IFN-induced innate immune restriction factor MxA and 




ISG-15 expression. The increased sensitivity of the KPT-335-resistant NP-mutant 
viruses to MxA suggested that there could be an evolutionary trade-off if KPT-335 
resistance virus variants emerged. MxA may pose a barrier during human IAV 
infection if the virus obtained CRM1-inhibition escape mutations and therefore, in a 
clinical environment, it may be difficult for the virus to overcome both drug selection 






















Chapter 6 Discussion   
 
6.1 Conclusion  
 
The aim of this project was to investigate the potential of two cellular nuclear export 
inhibitors; KPT-335 (verdinexor) and KPT-185 as novel therapeutic agents against 
IAV infection. The data described in this thesis provided pre-clinical evidence of 
efficacy for both compounds. KPT-335 and KPT-185 inhibited an H1N1 virus in a 
dose-dependent manner by blocking CRM1-mediated RNP nuclear export, with 
limited cytotoxic effects in vitro. Additionally, KPT-335 was effective against a wide 
range of both human and animal IAV strains suggesting that the host protein, CRM1 
is utilised by all influenza viruses. Investigations into the potential for drug-resistance 
revealed the emergence of apparently resistant virus variants after 9-10 passages in the 
presence of KPT-335. Sequencing analysis of independently derived resistant virus 
clones showed that IAV acquired four surface mutations within the NP protein 
(Q311R, N309T, Y296H, P282S). The NP amino acid changes: Q311R and N309T 
presented the strongest drug resistant phenotype. However, they came at a fitness cost 
to virus replication. Interestingly, both mutations caused an increase in M1 levels 
during infection, increased M1:NP ratios in the virion and also induced a filamentous 
budding morphology at the final stage of virus replication. Furthermore, the NP 
surface mutations were found to cluster in a region reported to have a role in 
interactions with the cellular antiviral protein MxA. The Q311R and N309T viruses 




Q311R also induced higher levels of IFN-I during infection. Taken together with 
Karyopharm’s promising data on KPT-335 
(https://www.karyopharm.com/pipeline/oralverdinexor-kpt-335), this thesis confirms 
the potential of KPT-335 as a therapeutic agent against IAV infection in humans. 
Additionally, if KPT-335 drug-resistance was to emerge within the population it could 
be hypothesised that the virus may not be able to overcome both the drug selection 
pressures and the increased innate immune response faced by escape mutations. Thus, 
KPT-335 could be a successful novel antiviral to overcome the resistance problem as 
seen with current anti-influenza therapies.   
 
6.2 Future directions  
 
6.2.1 Advancing KPT-335 as a therapeutic anti-influenza agent   
Preclinical efficacy guidance for the development of a novel antiviral compound are 
shown in Table 6.1. These guidelines have been taken and adapted from the FDA 
recommendations for “Guidance for Industry - Antiviral Product Development” 
(https://www.fda.gov/ohrms/dockets/98fr/05d-0183-gdl0002-01.pdf). Each aim is 
outlined and the relevant preceding studies with KPT-335 as well as the work 
presented in the thesis are summarised. Brief suggestions of future work related to 







Table 6.1. Summary of the pre-clinical efficacy of KPT-335  




Demonstrate the compounds 
ability to specifically inhibit viral 
replication by establishing the site 
of the products action  
 
The compound blocked nuclear 
export of vRNPs by disrupting 
CRM1-NS2 binding (Perwitasari et 
al., 2014) 
vRNPs were retained in the 
nucleus of the cell after 
treatment with the compound. A 
known CRM1 inhibitor, LMB was 
used as positive control for 
blockade of nuclear export 
 
Determine if there are any 
possible off target effects 
 
Investigate the in vitro half-life 




Assess the antiviral activity of the 
compound against a broad range 
of clinical and laboratory viral 
isolates in vitro 
 
The compound inhibited 
replication of both influenza A and 
B viruses including a pandemic 
H1N1 virus and an H5N1 avian 
influenza virus (Perwitasari et al., 
2014)  
 
The compound was effective 
against a wide range of both 
human and animal strains 
including swine, avian and 
equine IAVs 
Investigate the antiviral activity 
of the compound against other 
viruses that also utilise the 
CRM1 pathway such as HSV-
1 and HCMV 
Measure the viral titres after 
treatment in animal model 
systems to assess the antiviral 
activity of compound in vivo   
Prophylactically and 
therapeutically protected mice 
against disease pathology  
(Perwitasari et al., 2014) 
 
Virus shedding and pro- 
inflammatory cytokine expression 
were reduced in both mouse and 
ferret models after treatment with 
compound (Perwitasari et al., 
2016) 
 
- In vivo efficacy established  
Cytotoxicity 
and 
Cytotoxicity tests using increasing 
concentrations of antiviral 
compound to determine the 
A CC50 value of 26.8 µM was 
determined in A549 cells 
(Perwitasari et al., 2014) 
CC50 values of 2.6 µM (A549 
cells) and 9.8 µM (MDCK cells) 
were determined 










concentration that results in death 
of 50% of the host cells (CC50) 
 
  
Determine the relative 
effectiveness of the compound in 
inhibiting viral replication 
compared to inducing cell death -
selective index (SI) (CC50/IC50) 
 
SI range = 64-2680 
(Perwitasari et al., 2014) 
 





Evaluate the antiviral activity of 
the compound in two-drug 
combinations with other approved 
antivirals 
 
In vivo efficacy was enhanced 
with a combination of oseltamivir 
and KPT-335 compared to KPT-
335 alone (Perwitasari et al., 
2016) 
- Further evaluation of 
combination efficacy with 
current antivirals/experimental 
agents (in vitro and in vivo) 
Resistance 
 
Select for drug-resistant virus 
variants in vitro  
 
 
Serial passage with 0.2 µM of 
KPT-335 was performed for 10 
passages however drug-
resistance viral variants did not 
emerge (Perwitasari et al., 2016) 
 
Resistant virus variants emerged 
after 9-10 passages in the 
presence of 0.15 µM and 0.3 µM 
of compound 
Characterise resistance in 
several genetic backgrounds 
(i.e., strains, subtypes) to 
determine if the same or 
different patterns of resistance 
mutations would develop 
Genotypic analysis of resistant 
viruses selected in vitro to 
determine if mutations contribute 
to a reduced susceptibility to the 
compound 
 
- Five mutations found within the 




mutations were also found in 
PB2, PB1 and NP  
 
Next generation sequencing of 
passaged viruses and host 
cells 
Phenotypic analysis to determine 
if mutant viruses have reduced 
susceptibility to the compound  
 
- NP mutations Q311R and 
N309T elicited a drug resistant 
phenotype. Y296H and P283S a 
partial drug-resistant phenotype  
Generate viruses containing 
multiple drug-mutations to 
determine if there would be an 






6.2.2 Investigations into the molecular mechanism of drug-resistance to 
a CRM1 inhibitor  
 
The mechanism by which IAV escaped inhibition of the CRM1 pathway was unclear. 
Possible mechanisms of resistance to KPT-335 are presented in Fig 6.1. Evidence to 
support each hypothesised mechanism and future experiments to explore the 
possibility of each are discussed below. Information on how the virus overcomes 
CRM1-inhibition would enhance the ability to troubleshoot if resistance was to occur 
in humans; i.e. target another cellular pathway that the virus has adapted to use and/or 
a novel cellular/viral mediator protein involved in the nuclear export process. This 
would potentially allow for the use of a combination therapy and/or allow the selection 
of alternative therapies based on knowledge of the mechanism of resistance. 
 
Figure 6.1. Possible mechanisms of KPT-335 resistance. (A) Enhanced binding 
and/or recruitment of M1. (B) Direct binding of NP to CRM1. (C) Nuclear export 





A. Enhanced canonical nuclear export  
The current ‘daisy chain’ model for nuclear export of vRNPs suggests that NP within 
the vRNP complex binds to M1 which in turn binds to NS2. The NS2 protein contains 
the NES domain which then interacts with CRM1. KPT-335 disrupts the binding 
between NS2 and CRM1 thus blocking nuclear export. Work presented in chapter 4 
showed that viruses harbouring the KPT-335-resistant NP mutations Q311R and 
N309T produced increased levels of M1 during infection as well as yielding virus 
particles containing an increase in the M1:NP ratio. Thus, it may be hypothesised that 
the amino acid changes within NP caused an alteration in NP-M1 interaction which 
could increase M1 recruitment and/or binding for enhanced daisy chain export (as 
shown in Fig. 6.1A). It could also be speculated that the increase in M1 incorporation 
into the virion was an artefact of resistance to CRM1 inhibition, in which the NP 
mutations caused a change in the interaction with M1 and thereby changed the 
morphology of the virus to form to filaments. Subsequently, more membrane-
associated structural proteins such as M1 would be incorporated into the virion. To 
determine if there was an alternation in the interaction between the NP-mutants the 
WT virus, the in vitro binding could be analysed between NP and CRM1 and/or NP 
and NS2/M1. Radiolabelling of CRM1, M1 and NS2 plasmids and subsequently 
incubating them with WT NP and mutant NP plasmids alongside Sepharose beads 
would reveal the bound material as analysed by SDS-PAGE and autoradiography. The 
co-immunoprecipitation between NP (WT and mutants) with the virus proteins and 
host protein would reveal if there was an increased interaction with the mutant NP and 





B. Viral NP binds directly to CRM1  
As KPT-335 disrupts the interaction between NS2 and CRM1, it could be hypothesised 
that the NP surface mutations have allowed the RNP to bind directly to CRM1, thereby 
overcoming the inhibition of this interaction (Fig 6.1.B). As discussed in chapter 3, 
published studies have shown that that NP can directly bind to CRM1 (Elton et al., 
2001, Chutiwitoonchai et al., 2014; Kakisaka et al., 2015), however whether this is 
essential for CRM1-mediated export of RNPs has yet to be determined. To establish 
if the mutations within the NP protein caused the virus to directly interact with CRM1, 
biochemical assays could be performed to compare binding efficacy of the NP-mutants 
with CRM1 to the WT NP. Additionally, investigation into the effect of CRM1 
overexpression on mutant vs WT NP localisation may determine an increase in binding 
to  CRM1. For example, if there was an increase in cytoplasmic accumulation of NP 
after CRM1 overexpression, this would support the hypothesis that NP interacts with 
CRM1 nuclear export in absence of other viral proteins.  
 
C. Involvement of an unknown mediator and/or pathway   
Another mechanism by which the virus may have overcome CRM1 inhibition could 
be that it has adapted to utilise another nuclear export pathway (Fig 6.1.C). To date 
there is limited evidence to suggest that nuclear export of vRNPs is CRM1-
independent. However, there are a wide range of cellular export pathways that are 
utilised by other viruses for the export of several different types of RNA. For example, 
Mason-Pfizer monkey virus (MPMV) RNA nuclear export involves the human Tap 
protein (Kang and Cullen, 1999) Thus, it could be speculated that the virus has 




interacted with an unknown host protein, a pull-down assay could be carried out and 
mass spectrometry performed to determine which cellular proteins bound to the NP 
mutants.  
 
Additionally, a paper by Mulhbauer et al., (2015), described that influenza viruses can 
CRM1-independently passively transport their RNPs across the nuclear pore at later 
stages of infection by inducing caspase activation. The authors describe that during 
infection caspases can enlarge the cellular nuclear pores, which in turn can facilitate 
the translocation of large protein complexes such as vRNPs across the nuclear 
membrane. Therefore, suggesting that vRNP nuclear export could occur via a CRM1-























7.1.1 Plasmids  
Table 7.1 Plasmids  
Name Description  Source  
pDUAL Reverse genetics 8-plasmid system for 
A/Puerto Rico/8/1934 (H1N1). RNA pol I 
and pol II bidirectional promoters at either 
side of insert to allow for mRNA and vRNA-
like RNA synthesis  





















Reverse genetics 12-plasmid system for 
A/Udorn/1971 (H3N2) 









pHH21 Pol I promoter leads to vRNA-like RNA 
synthesis  
Prof. Robert Lamb 









pcDNA3.1 CMV pol II promoter upstream of insert 
allows for constitutively high protein 
expression 
Prof. Robert Lamb 





pPol I Luc Reporter for minireplicon assay. Contains 
firefly luciferase reporter gene in reverse 
orientation. Flanked by UTRs of PR8 
segment 8 under the control of a pol I 
promotor.  











7.1.2.1 Sequencing primers  
Table 7.2 Sequencing primers  
Primer Sequence (5’ to 3’) 
Uni 12 AGCAAAAGCAGG 
pDUAL forward   ATGTCGTAACAACTCCGCCC 
pDUAL reverse   TTTTTGGGGACAGGTGTCCG 
PR8 PB2 internal forward TCAAGGAACATGCTGGGAACA 
PR8 PB2 internal reverse CCTCCTCGGGAGACAGTAGT 
PR8 PB1 internal forward GGGAAGCTAAAACGGAGAGCA 
PR8 PB1 internal reverse TGTCACCTCTATGGCATCGG 
PR8 PA internal forward GCAGAACTGCAGGACATTGA 
PR8 PA internal reverse AGTTGTGGAGATGCATACAAGC 
 
 
7.1.2.2 Mutagenesis primers  
Table 7.3 Mutagenesis primers  




































7.1.3 Antibodies  
 
7.1.3.1 Primary antibodies to IAV proteins 
Table 7.4 Primary antibodies and antisera raised against IAV proteins 
Antibody Application Source 
Rabbit polyclonal anti-MBP-
NP (2915) 
WB (1:500), Plaque 
immunostaining (1:1000) 
(Noton et al., 2007) 
Rabbit polyclonal anti-PR8 M1 WB (1:500) (Amorim et al., 2007) 
Rabbit polyclonal anti-
PB1(V19) 
WB (1:500) (Digard et al., 1989) 
Rabbit polyclonal anti-PB2 
(2N580) 
WB (1:500) (Carrasco et al., 
2004) 
Rabbit polyclonal anti-PR8 IF 1:1000 (Amorim et al., 2007) 
Rabbit polyclonal anti-PR8 
NS1 
WB (1:500), IF (1:1000) (Carrasco et al., 
2004) 
Mouse monoclonal anti-NP 
(AA5H) 
IF (1:1000) Abcam (ab20343) 
Mouse monoclonal anti-M2 
(14C2) 
WB (1:1000) Abcam (ab5416) 
Mouse monoclonal anti-M1 
(GA2B) 
IF (1:500) Abcam (ab22396) 





7.1.3.2 Primary antibodies to cellular proteins 
 
Table 7.5 Primary antibodies against cellular proteins 
Antibody Application Source 
Goat polyclonal anti-MxA WB (1:1000), IF (1:500) R&D Systems 
(AF7946) 
Rat monoclonal anti-tubulin  WB (1:1000) Serotec (MCA77G) 
Rabbit monoclonal anti-PKR WB (1:500) Millipore (07-886) 




7.1.3.3 Secondary antibodies  
 
Table 7.6 Secondary antibodies 
Antibody Application Source 
Donkey anti-mouse IgG (H+L) 
Secondary antibody, Alexa Fluor® 
488 conjugate  
IF (1:1000) ThermoFisher  
(A-21202) 
Donkey anti-rabbit IgG (H+L) 
Secondary antibody, Alexa Fluor® 
488 conjugate 
IF (1:1000) ThermoFisher  
(A-21206) 
Donkey anti-mouse IgG (H+L) 
Secondary antibody, Alexa Fluor® 
595 conjugate 
IF (1:1000) ThermoFisher  
(A-21202) 
IRDye® 800CW Donkey anti-Mouse 
IgG (H+L) 
WB (1:10000) LiCor (925-32212) 
IRDye® 800CW Donkey anti-Rabbit 
IgG (H+L) 
WB (1:10000) LiCor (925-32213) 
IRDye® 800CW Donkey anti-Goat 
IgG (H+L) 




IRDye® 680CW Donkey anti-Rabbit 
IgG (H+L) 
WB (1:10000) LiCor (926-68071) 
IRDye® 680CW Donkey anti-Rat 
IgG (H+L) 
WB (1:10000) LiCor (926-68029) 








7.1.3.4 Fluorescent dyes  
 
Table 7.7 Fluorescent dyes 
Dye Application Source 
Prolong Gold Antifade Mountant 
with DAPI 
IF (neat) Thermo Fisher 




7.1.4 Eukaryotic cells 
 
Table 7.8 Eukaryotic cell lines 
Cell Description Source 
MDCK Madin-Darby Canine Kidney cells Sigma 
A549 Human Adenocarcinomic Alveolar 
Basal Epithelial cells 
Sigma 
293T Human Embryonic Kidney cells  Sigma 
HEK-Blue HEK293-Blue IFN-α/β cells InvivoGen  
MxA-A549 A549 cells constitutively expressing 
MxA 
Dr Dave Jackson 





Naïve-A549 A549 cells  Dr Dave Jackson 






Table 7.9 IAV virus strains 
Strain Subtype Source 
A/PR/8/34 H1N1 Reverse genetics virus (de Wit 
et al., 2004) 
A/Udorn/72 H3N2 Reverse genetics virus (Chen 
et al., 2007) 
PR8 MUd H1N1 (PR8 
containing seg7 
from Udorn) 
Reverse genetics virus 
A/swine/England/453/06 H1N1 Prof. James Wood, University 
of Cambridge  
A/duck/England/62 H4N6 Prof. Wendy Barclay, Imperial 
College London  
A/duck/Singapore/5/97 H5N3 Prof. Wendy Barclay (Imperial 
College London, UK) 
A/equine/Miami/53 N3N8 Animal Health Trust (AHT)  
PR8-NP-Q311R mutant H1N1 This study 
PR8-NP-N309T mutant H1N1 
PR8-NP-Y296H mutant H1N1 
PR8-NP-P283S mutant H1N1 










7.1.6 Drugs  
 
Table 7.10 Compounds  
Drug Mechanism  Source 
KPT-335 Selective inhibitor of nuclear export  Karyopharm 
Therapeutics  
KPT-185 Selective inhibitor of nuclear export Karyopharm 
Therapeutics 
KPT-301 Enantiomer of KPT-185  Karyopharm 
Therapeutics 
Leptomycin B  Cytotoxic inhibitor of nuclear export Cambridge Bioscience 
(1814-025) 
Importazole Selective inhibitor of nuclear import Sigma-Aldrich 
(SML0341) 
















7.2.1 Cell culture  
7.2.1.1 Eukaryotic cell culture  
MDCK cells, 293T cells, A549 cells and Naïve-A549 cells were grown in complete 
Dulbecco’s Modified Eagle Medium (D-MEM) (D-MEM supplemented with 10 % 
(v/v) foetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 U/ml 
streptomycin) at 37 ˚C in 5 % CO2. HEK-Blue cells were cultured in complete D-
MEM with 30 µg/ml blasticidin and 100 µg/ml Zeocin. MxA-A549 cells were cultured 
in complete D-MEM with 2 µg/ml puromycin. Cells were typically passaged twice 
weekly by washing cells 2 x PBS and detached using 0.25 % trypsin-EDTA solution 
(ThermoFisher, cat# 25200056) or without trypsin for HEK-Blue cells. Cells were 
resuspended in complete D-MEM and typically split 1 in 10.  
 
7.2.1.2 Cell counting 
Cells were counted using a Neubauer chamber which consists of 4 x 4 grids which was 
visualised using the 10X objective lens in a light microscope. Cell suspension was 
added to the chamber under a glass coverslip. The number of cells was counted in a 4 









7.2.2 Virus work  
7.2.2.1 Generation of P0 stocks 
Reverse genetics pDUAL 8-plasmid sets were transfected into 75-90 % confluent 
293T cells in 6-well plates. Media from 293T cells was replaced with 1 ml of Opti-
MEM (reduced serum media) 1 h before transfection. Reverse genetics plasmids (250 
ng/µl of each plasmid) were diluted in 100 µl Opti-MEM. 4 µl Lipofectamine2000 
(Invitrogen, cat# 11668) per 100 µl Opti-MEM was incubated for 5 min at room 
temperature then mixed with the diluted DNA for 30 min. The transfection mix was 
slowly dropped over the 293T cells. Media was replaced 5-6 h post-transfection with 
2.5 ml of D-MEM supplemented with 0.3 % BSA, 2 mM glutamine, 100 U/ml 
penicillin and 100 U/ml streptomycin and incubated at 37 ˚C in 5 % CO2. Trypsin-
TPCK (Sigma, cat# 4352157) was added to the cells 2 days post-transfection at 1 
µg/ml in 500 µl D-MEM with 0.3 % BSA, 2 mM glutamine, 100 U/ml penicillin and 
100 U/ml streptomycin. Cell supernatant was harvested 3 days post-transfection and 
spun at 1200 rpm for 5 min to clarify the supernatant. P0 stocks were aliquoted and 
stored at -80 ˚C to be used to make P1 virus stocks. 
 
7.2.2.2 Generation of P1 stocks  
MDCK cells were grown to 90 % confluency in T75 flasks. Cells were washed 2 x 10 
ml serum-free D-MEM (D-MEM containing 2 mM glutamine, 100 U/ml penicillin and 
100 U/ml streptomycin) before adding 300 µl of P0 stock with 3 ml of virus growth 
media (D-MEM supplemented with 0.14 % BSA, 2 mM glutamine, 100 U/ml 
penicillin, 100 U/ml streptomycin and 1 µg/ml TPCK trypsin) for 1 h. After the 




at 37 ˚C in 5 % CO2. Supernatants were harvested and cells clarified at 3000 rpm for 
5 min. P1 stocks were aliquoted and stored at -80 ˚C.  
 
7.2.2.3 Egg grown virus stocks 
Embryonated hen eggs (Henry Stewart & Co.) were incubated at 37 ˚C in 40-50 % 
humidity for 10 days. Prior to infection, eggs were candled to check viability of the 
embryo. The shell was sterilised with 70 % ethanol (v/v) and two small holes were 
punctured in the egg shell, one just below the line of the air sac and one at the top of 
the egg. Virus was diluted to 100 PFU/ml in serum-free D-MEM and using a 1 ml 
syringe and 25 G needle 100 µl of diluted virus stock was inoculated into the allantoic 
cavity. The two punctures were sealed with Scotch Magic Tape and eggs were 
incubated for a further 48 h at 37 ˚C in 40-50 % humidity. Before harvesting the 
allantoic fluid, the eggs were chilled overnight at 4 ˚C. The top of the shell was 
removed using curved forceps and the air sac membrane was punctured. Allantoic fluid 
was collected using a P1000 Gilson, clarified at 4000 rpm for 10 min and stored at -
80 ˚C. 
 
7.2.2.4. Virus purification by ultracentrifugation 
Eggs were infected as described above 7.2.2.3 Egg grown virus stocks. 4 eggs were 
infected with 100 PFU of virus per egg to obtain ~20-50 ml of allantoic fluid for 
purification. The allantoic fluid was clarified twice at 2,100 x g for 10 min then 23 ml 
of allantoic fluid was loaded onto a 30 % sucrose/PBS cushion and spun at 30,000 rpm 
for 90 min at 4 ˚C using a SW28Ti rotor (Beckman). The resulting pellet was washed 




purified by loading 200 µl of 30 % sucrose purified virus sample onto a 15-60 % 
sucrose/PBS gradient and spun for 38,000 rpm for 40 min at 4 ˚C, without a brake 
using a SA41Ti rotor (Beckman). The virus band was extracted from the gradient using 
a 1 ml syringe and 19 G needle. The extracted virus was loaded on to PBS and spun at 
30,000 rpm for 9 min at 4 ˚C. The resulting pellet was resuspended in 100 µl of PBS 
overnight at 4 ˚C. Purified virus sample was stored at 4 ˚C for up to 10 days.  
 
7.2.2.5 Infections 
Cells were grown to ~90 % confluency in 24-well plates. Cells were washed 2 x 1 ml 
serum-free D-MEM and 200 µl of virus diluted in serum free D-MEM was added for 
1 h at 37 ˚C in 5 % CO2. For a multi-cycle infection, cells were infected with virus at 
an MOI of 0.01 and overlaid with virus growth media. For a single cycle infection, 
cells were infected with virus at an MOI of 3, virus inoculum was removed and an acid 
wash buffer (10 mM HCL, 150 mM NaCl (pH 3.0)) was applied for 1 min to inactive 
non-internalised virus particles. Cells were then washed 3 x 1 ml PBS and overlaid 
with complete DMEM. Supernatants were harvested at various time points post-
infection and stored at -80 ˚C for downstream analyses. 
 
7.2.2.6 Plaque assays  
MDCK cells were seeded in 6-well plates and grown to 100 % confluency. Prior to 
infection cells were washed 1 x 2 ml serum D-MEM. Virus samples were serially 
diluted 10-fold in serum free D-MEM. Virus dilutions (400 µl per well) were added to 
the cells and incubated for 1 h at 37 ˚C in 5 % CO2. After incubation, 2 ml of Avicel 




BioPolymer, cat# 9004-34-6) was added to each well and incubated a further 48 h at 
37 ˚C in 5 % CO2. Cells were then fixed with 2 ml 10 % neutral buffered formalin per 
well and incubated for 20 min – 24 h. After fixation, the formalin/overlay was removed 
and cells were stained with 0.1 % (w/v) toluidine blue for 20 min – 1 h. Toluidine blue 
stain was then removed and cells were washed with water before counting the number 
of plaques per well (PFU/ml).  
 
 
7.2.3 Drug analyses 
7.2.3.1 Cytotoxicity assays  
Drug cytotoxicity analyses were performed using the CellTiter-Glo viability assay 
(Promega, cat# G7570), which quantifies the ATP content of cells. A549 cells were 
seeded at 1 x104 cells/well in a 96-well flat clear bottom, opaque-walled plate 
(Corning, cat# 07-200-587). The following day, cells were incubated with 2-fold 
increasing concentrations of drug and/or DMSO in serum-free DMEM at 37 ˚C in 5 % 
CO2 for 24 h. Equal volumes of the CellTiter-Glo reagent were added to each well and 
mixed for 2 min on an orbital shaker to induce cell lysis. The plate was incubated at 
room-temperature for 10 min to stabilise the luminescent signal before imaging with 









7.2.3.2 Drug-dose inhibition assays 
After a 1 h incubation with virus (as described in section 7.2.2.5 Infections), inoculum 
was removed and 1 ml of media was added containing concentration of drug of 
interest. Drugs were typically diluted in 0.5-log10 increments. For multi-cycle dose 
response curves, compound was added to virus growth media and incubated for 24 h. 
For single cycle dose response curves, compound was added to complete media and 
incubated for 16 h. Virus supernatants were then harvested and titre was determined 
by plaque assay. To determine the IC50 values, data was converted to a % of the 
untreated control and plotted against a log10 inhibitor concentration. Dose-response 
curves were then fitted by a non-linear regression using the program GraphPad Prism. 
 
7.2.3.3 Time of drug addition assays 
A549 cells were seeded at 2 x105 cells/well in a 24-well plate and at 1x105 cells/well 
on to 13 mm round coverslips. The following day, cells were washed 1 x 1 ml serum-
free D-MEM and incubated with virus at an MOI of 3 for 1 h at 37 ˚C in 5 % CO2. 
Cells were incubated with either DMSO or with KPT-335 (0.3 µM) an hour prior to 
infection, at time of infection or 2, 4, 6 and 8 h post-infection (p.i.). For infections 
carried out on coverslips, cells were fixed at 8 h p.i. and immunofluorescence analysis 
was performed as described in 7.2.6.3. Immunofluorescence staining. For infections 
carried out in the 24-well plates, viral supernatant was harvested at 16 h p.i. and virus 







7.2.3.4 Plaque reduction assays  
MDCK cells were seeded at 1x106 cells/well in 6-well plates. The following day, cells 
were washed 1 x 2 ml serum-free D-MEM and incubated with ~100-1000 PFU of virus 
for 1 h at 37 ˚C in 5 % CO2. Virus inoculum was removed and cells were incubated 
with Avicel overlay containing either DMSO or KPT-335 (0.3 µM or 1 µM) for 48 h 
at 37 ˚C in 5 % CO2. After incubation, the plaque reduction assays were processed and 
analysed as described for 7.2.2.6 Plaque assays. 
 
7.2.3.5 Serial passage  
A549 cells were seeded at 1x106 cells/well in a 6-well plate. The following day, cells 
were washed with 1 x 2 ml serum-free D-MEM and incubated with 200 µl of virus at 
an MOI of 0.001 for 1 h at 37˚C in 5% CO2. Virus inoculum was removed and cells 
were overlaid with virus growth media containing DMSO, KPT-335 (0.15 µM or 0.3 
µM) or amantadine (30 µM). 48 h p.i., virus supernatant was harvested and titre was 
determined by plaque assay as described above 7.2.2.6 Plaque assays. After titre 
determination, the harvested viral supernatant was subject to further rounds of 
replication under the same conditions as described above. This was performed for 9-
10 passages.  
 
7.2.3.6 Plaque isolation 
Plaque assays with serial passaged viruses were performed similarly as described 
above 6.2.2.5 Plaque assays using an agarose overlay in place of the Avicel overlay. 
For agarose plaque assays, 7.5 ml of 2 % (w/v) boiled agar was mixed with 17.5 ml of 




sodium bicarbonate, 10 mM HEPES, 0.007 % (w/v) Dextran, 3 mM L-glutamine, 140 
U/ml penicillin, 140 µg/ml streptomycin and 1.4 µg/ml N-acetylated trypsin (NAT) 
and was incubated for 1 h at 37 ˚C in 5 % CO2. Virus inoculum was removed and 2 ml 
of agarose overlay was added per well. Once agarose had set, plates were inverted and 
incubated at 37 ˚C in 5 % CO2 for 48 h. Single plaques were then picked from the live 
cells using a cut P1000 tip and the isolated plaque was then ejected onto fresh MDCK 
cells in 24-well plate in 0.5 ml of virus growth media. Cells were incubated at 37 ˚C 
in 5 % CO2 for 24 h to allow for virus propagation.    
 
 
7.2.4 Molecular techniques  
7.2.4.1 RNA extraction from viral supernatant 
Extraction of viral RNA (vRNA) from virus supernatant was performed using a 
QIAamp viral RNA Mini Kit (Qiagen, cat# 52906), as per manufacture’s instructions. 
Isolated vRNA was eluted in 30 µl of nuclease-free water and stored at -20 ˚C. 
 
7.2.4.2 Reverse Transcription (RT) 
vRNA was transcribed into complementarily DNA (cDNA) using a Verso cDNA 
Synthesis Kit (Thermo Scientific, cat# AB1453A) and a universal oligonucleotide 
primer (Uni12, 5′-AGCAAAAGCAGG-3′), which binds to the 12 conserved nucleotides 
at the 3’ end of influenza segments. 1 ng vRNA and 0.5 µM Uni12 primer were added 
to nuclease free water to make up a reaction volume of 10 µl. The vRNA/primer mix 
was incubated at 65 ˚C for 10 min and then a Verso reaction mix containing 20 % (v/v) 




final reaction volume of 20 µl. The mix was further incubated for 1 h at 65 ˚C. RT 
reactions were stored at -20 ˚C.  
 
7.2.4.3 Polymerase chain reaction (PCR) 
Amplification of IAV gene segments was carried out using Taq DNA polymerase 
(Invitrogen, cat# 18038042). Forward and reverse oligonucleotide primers were 
designed to complement ends of the coding regions for segments 1, 2, 3, 5, 7 and 8 of 
A/PR/8/34 (Table 7.1.2.1) and sets of internal primers for segments 1, 2 and 3 were 
designed to amplify the middle regions of these larger genes (Table 7.1.2.1). Each 
reaction contained: 1 mM of each dNTP, 1.5 mM MgCl2, 0.2 µM of each primer and 
0.05 % buffer W1. Thermocycling condition were as follows: 94 ˚C for 2 min, 
followed by 94 ˚C for 1 min, 55 ˚C for 1 min and 72 ˚C for 3 min for 30 cycles and a 
final incubation at 72 ˚C for 10 min.  PCR reactions were stored at 4 ˚C.  
 
7.2.4.4 PCR purification 
Before sequencing, the PCR product was purified using a QIAquick PCR purification 
kit (Qiagen, cat# 28104) as per manufacturer’s instructions. PCR product was eluted 
in 30 µl of nuclease-free water and stored at -20 ˚C.  
 
7.2.4.5 Site-directed mutagenesis of plasmid DNA 
To generate DNA plasmids containing nucleotide changes of interest, mutagenesis 
was performed using a QuikChange Lightning Site-Directed Mutagenesis kit (Agilent, 
cat# 210518). Two complementary oligonucleotides were synthesised containing the 




Sample reactions were prepared as follows; 5 µl 10 x reaction buffer, 10-100 ng 
dsDNA template, 125 ng primer 1, 124 ng primer 2, 1 µl dNTP mix, 1.5 µl 
QuikSolution reagent and nuclease free water to a final volume of 50 µl. 1 µl of 
QuikChange lightning enzyme was added per reaction. Reactions were then cycled 
using the following conditions; first step, 95 ˚C for 2 min then 95 ˚C for 20 sec, 60 ˚C 
for 10 sec and 68 ˚C for 30 sec/kb of plasmid length for 18 cycles, followed by a final 
step at 68 ˚C for 5 min. 2 µl of Dpn I restriction enzyme was added directly to each 
amplification reaction and incubated at 37 ˚C for 5 min. Dpn I-treated DNA was then 
transformed as below; 7.2.4.6 Transformation of competent DH5a. 
 
 7.2.4.6 Transformation of competent DH5a 
Plasmid DNA (250 ng) or 2 µl of Dpn I-treated DNA (for mutagenesis reactions) was 
added to 10 µl of competent DH5a cells and was gently mixed and incubated 5-15 
min on ice. The plasmid and cell mixture was incubated for 45 sec at 42 ˚C and 
immediately placed back on ice for 2 min. 900 µl of LB broth (15 g/l agar, 10 g/l 
tryptone, 5 g/l yeast extract, and 10 g/l sodium chloride (pH 7)) was added to the cells 
and placed in a shaker (200 rpm) for 1 h at 37 ˚C. Cells were pelleted using 
centrifugation (13,000 rpm for 1 min) and ~800 µl of supernatant was removed. The 
remaining cells were resuspended in the remaining supernatant and then spread on an 
agar plate with the appropriate antibiotic using a sterile spreader in the presence of a 
Bunsen burner flame to prevent contamination. Transformation plates were incubated 






7.2.4.7 DNA gel electrophoresis  
1 % (w/v) agarose was boiled in 1 x TAE running buffer (40 mM Tris, 20 mM acetic 
acid and 1mM EDTA) and 1:10,000 dilution of SYBR Safe DNA gel stain 
(ThermoFisher, cat# S33102) was added. DNA samples were mixed with 1 x DNA 
loading dye (6 x, 10 mM Tris-HCl (pH7.6), 0.15 % (w/v) Orange G dye, 0.03 % (w/v) 
xylene cyanol FF, 60 % (v/v) glycerol and 60 mM EDTA) and loaded into the set 
agarose gel alongside a 1kb DNA ladder (Promega, cat#G5711). Gels were run at 100 
V for 45-60 min in TAE running buffer.  
 
7.2.4.8 Sequencing of DNA  
5 µl of template DNA (100 ng/ml plasmid DNA or 20-80 ng/ml of PCR reaction) was 
added to 5 µl of appropriate primer (5 µM) (Table 7.1.2.1). The sequencing mix was 
sent for Sanger sequencing performed by GATC Biotech (Germany). Sequencing 
results were analysed using the DNASTAR Lasergene 9 core suite.   
 
 
7.2.5 Protein analyses 
7.2.5.1 SDS-PAGE 
Proteins were separated by molecular weight using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE apparatus and reagents 
were supplied by Bio-Rad (Mini-Protean tetra system). Generally, 2 x 105 cells/well 
in a 24-well plate were lysed with 200 µl of Laemmli buffer (20 % (v/v) glycerol, 2 % 
(w/v) SDS, 100 mM DTT, 24 mM Tris and 0.016 % (v/v) xylene cyanol solution). 




centrifuged for 1 min. 8-30 µl of sample was loaded per lane and separated on a 4-20 
% gradient Protean TGX gel (Bio-Rad). For virion analysis, 2-10 µl of gradient 
purified virus was loaded per lane and separated on a 12 % Protean TGX gel (Rio-
Rad). Gels were run at a constant voltage of 100 V for ~2 h in Tris-Glycine running 
buffer (25 mM Tris, 192 mM glycine and 0.1 % (w/v) SDS). Proteins were identified 
using a Precision Plus Protein dual colour molecular marker (Bio-Rad, cat#1610374). 
Proteins were visualised by Coomassie Brilliant Blue staining or western blot analysis 
(see below). 
 
7.2.5.2 Coomassie blue protein staining  
Protein samples separated by SDS-PAGE were fixed using a fixing solution (50 % 
(v/v) methanol, 10 % (v/v) acetic acid in deionised water). Gels were washed 3 x 15 
min in fixing solution and were then stained using 0.2 % (w/v) Coomassie Brilliant 
Blue (R-250) in fixing solution for 30 min. Gels were then de-stained using a 
destaining solution (25 % (v/v) methanol, 5 % (v/v) acetic acid in deionised water) for 
6 – 24 h before imaging on the LiCor Odyssey imaging platform. 
 
7.2.5.3. Western Blotting   
Proteins separated by SDS-PAGE were blotted onto 0.2 µM nitrocellulose membrane 
by semi-dry transfer using the Trans-Blot Turbo TM Transfer System (Bio-Rad). The 
transfer membrane and stacks were immersed in ~100 ml of transfer buffer for 2-3 
min. The nitrocellulose membrane was placed on the polyacrylamide gel (positive 
cathode side) and placed between two ion reservoir stacks (Bio-Rad) in the cassette. 




skimmed milk/0.1 % Tween20/PBS for 20 min. Blocked membranes were washed 3 
x 0.1 % Tween20/PBS (v/v) then incubated with the appropriate primary antibody 
diluted in 0.1 % Tween20/PBS (v/v) for 1 h at room temperature or 4 ˚C overnight. 
Membranes were washed as above and incubated at room temperature for 45 min with 
the appropriate secondary antibodies conjugated with near-infrared dye. Membranes 
were washed as above and analysed on the LiCor Odyssey imaging platform. 
 
 
7.2.6 Immunofluorescent microscopy  
7.2.6.1 High MOI infection 
A549 cells were seeded onto 13 mm round coverslips at 1 x 105 cells/coverslip. The 
following day, cells were washed 1 x 1 ml serum free D-MEM and incubated with 200 
µl of virus at an MOI of 3 for 1 h at 37 ˚C in 5 % CO2. Virus inoculum was then 
removed and cells were overlaid with 1 ml complete media. 8 h p.i., cells were washed 
3 x PBS and then fixed with 4 % (v/v) formaldehyde in PBS. Fixed cells were stained 
and analysed as described in 7.2.6.3. Immunofluorescent staining.  
 
7.2.6.2 Import assay  
A549 cells were seeded onto coverslips (as described above) and washed 1 x 1 ml 
serum free D-MEM. Cells were then incubated with 2-10 µl of gradient purified virus 
(nominal MOI) for 1 h at 37 ˚C in 5 % CO2. Infections were performed in the presence 
or absence of 100 µg/ml cycloheximide (CHX) to inhibit protein synthesis and 100 
µM importazole (IMP) to inhibit nuclear import. Virus inoculum was then removed 




1ml PBS and then fixed with 4 % (v/v) formaldehyde in PBS. Fixed cells were stained 
and analysed as below 7.2.6.3. Immunofluorescent staining. 
 
7.2.6.3 Immunofluorescent staining  
After infection, cells were washed 1 x 1 ml PBS (pre-warmed) and fixed using 250 µl 
4% formaldehyde/PBS (v/v) for 20 min. Fixed cells were washed 3 x 1 ml 0.1% 
FBS/PBS (v/v) and permeabilised using 250 µl 0.2% Triton X-100 (v/v) for 5 min. 
Permeabilised cells were washed 3 x 1 ml 0.1% FBS/PBS (v/v) and stained with the 
appropriate primary antibody diluted in 0.1% FBS/PBS (v/v) for 1 h at room 
temperature. Cells were washed as above and incubated with appropriate fluorescent-
labelled secondary antibody for 45 min at room temperature covered in foil to protect 
fluorophores from photobleaching. Cells were washed as before and stained with 
nuclei dye DAPI for 5 min at room temperature. Coverslips were mounted on a glass 
microscopy slide using ~3 µl ProLong Gold Antifade reagent (ThermoFisher, 
cat#P36934). Slides were cured at room temperature for at least 24 h before imaging.  
 
7.2.6.4 Microscopy  
Images were taken on either Leica DMLB microscope (x20 or x40 objective lens) or 
on a Zeiss LSM 710 confocal microscope (x63 objective lens). Fluorescence settings 







7.2.7 Molecular assays 
7.2.7.1. Minireplicon 
293T cells were seeded at 1 x 105 cells/well in a 24-well plate. The following day, 
50ng pDUAL plasmids (PB2, PB1, PA and NP) and 20 ng firefly reporter plasmid 
(pPol I Luciferase) were diluted in 50 µl Opti-MEM for transfection. 1 µl 
lipofectamine2000 was mixed with 50 µl Opti-MEM and incubated for 5-10 min at 
room temperature.  The lipofectamine2000 mixture was added to the plasmid mix and 
incubated for 30 min. Medium on the 293T cells was removed and 500 µl of Opti-
MEM was added per well. 100 µl of transfection mix was added dropwise into each 
well and cells were incubated for 48 h at 37 ˚C in 5 % CO2. The medium was then 
removed and cells were lysed with 100 µl of 1 x Reporter Lysis Buffer (Promega, cat# 
E4030). Cells were scraped and plates were centrifuged at 12000 x g for 2 min at 4 ˚C. 
60 µl of cell lysate was added to an opaque 96-well plate (Corning, cat# CLS3362). 
25 µl of 0.6 mM beetle luciferin (Promega, cat# E1601) was injected per well using a 
GloMax luciferase reader (GloMax, Promega) to measure luciferase activity (200 
µl/sec injection speed, 0.5 sec gap and 5 sec integration time).  
 
 
7.2.8 Interferon assays  
7.2.8.1 IFN-type I dose inhibition experiments 
A549 cells were seeded at 1 x 105 cells/well in a 24-well plate for 12 h. Cells were 
then treated with varying concentrations of exogenous universal Type I IFN (PBL 
Assay Science, cat# 11200) diluted in complete media. 24 h after treatment, cells were 




µl of serum free D-MEM for 1 h at 37 ˚C in 5 % CO2. 24 h p.i., virus supernatant was 
harvested for titre determine and cell lysates were generated for western blot analysis.  
 
7.2.8.2 IFN-I HEK-blue assays   
A549 cells were seeded in 24-well plates at 2 x 105 cells/well. The following day, cells 
were infected with virus at an MOI of 3 as described in 7.2.2.5 Infections. 24 h p.i. 
virus supernatant was harvested, clarified (3000 rpm, 5 min) and stored at -80 ˚C prior 
to assaying. To determine the IFN-I levels in the supernatant of infected cells, 20 µl of 
sample was incubated with 180 µl of HEK-Blue cell suspension (2.5 x 105 cells/ml) in 
a 96-well plate for 24 h at 37 ˚C in 5 % CO2. 20 µl of HEK Blue cell supernatant was 
then incubated with 180 µl of Quanti-Blue substrate in a 96-well plate for 2 h at 37 ˚C. 
Absorbance (630 nm) was read using a microplate reader (GloMax, Promega) as a 
read-out for bioactive IFN-I levels in the samples. An IFN-I standard curve was 




7.2.9 Statistical analyses  
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